Improved Detection of Kratom Alkaloids in Forensic Toxicology by Basiliere, Stephanie Pauline






The Faculty of the Department of Forensic Science 




In Partial Fulfillment 
of the Requirements for the Degree of 





Stephanie Pauline Basiliere 
December, 2019 
IMPROVED DETECTION OF KRATOM ALKALOIDS IN FORENSIC 
TOXICOLOGY 
by 





















Phillip Lyons, PhD 




“If you have faith as small as a mustard seed, nothing will be impossible for you.” 
-Matthew 17:20 
 
To my Advisor, Dr. Sarah Kerrigan, I could not have done this without your faith, 
guidance, and support. Even when frustrations were high, we always pushed through and 
were able to complete this beautiful project. In addition, I wouldn’t have experienced as 
much personal growth in terms of maturity and skill, had it not been for your influence. 
Thank you.  
 
To my committee members, whom I’ve also had as professors during my 
undergraduate and graduate years, thank you for your time and guidance. Without you, I 
would not have gained the foundational knowledge necessary to complete this project. In 
addition, I also value the perspectives you bring to different subjects. 
 
To my PhD cohorts, thank you for your support and encouragement. I especially 
want to thank Dr. Skillman, Polston (soon), and Winborn who have more than once 
uplifted me when I was at a low point in this journey. 
 
To my parents, Elaine and Wayne Basiliere, thank you for your constant support 
and faith in me. We’ve come a long way from the days when I wanted to be a 
paleontologist at age 5. It’s nice to see you helped keep my love for science alive. I hope 
I’ve made you proud. 
 
To my family and friends, of whom there are too many to name, thank you for 
your support and all the laughs. Whether it’s sending me memes or having a heart to 
heart conversation at 2 AM, you all have contributed to this journey and I couldn’t have 
completed it without you. Although there are too many of you to name, I want to 
highlight Jackson, Hayden, Holly, Denise, Michael, Jordan, Erin, and Cathryn who have 






Basiliere, Stephanie P., Improved detection of kratom alkaloids in forensic toxicology. 
Doctor of Philosophy (Forensic Science), December, 2019, Sam Houston State 
University, Huntsville, Texas. 
 
Kratom is a botanical drug with psychoactive properties that produces both 
stimulant and opiate effects depending on the dosage. Its major psychoactive components 
are mitragynine and 7-hydroxymitragynine. The drug may not be included as part of 
routine toxicological screening and as such, its use may be underreported. This research 
seeks to improve the analysis of kratom alkaloids in toxicological specimens, and increase 
overall understanding related to their properties and drug metabolism.  
Five Mitragyna alkaloids including speciociliatine (SC), mitragynine (MG), 
paynantheine (PY), speciogynine (SG), and 7-hydroxymitragynine (7-MG-OH) were 
analyzed in blood and urine using liquid chromatography quadrupole time-of-flight mass 
spectrometry (LC-Q/TOF-MS). Each method was validated in accordance with published 
guidelines for forensic use. LC-Q/TOF-MS was used throughout the study due to its 
selectivity and sensitivity. 
Recombinant human cytochrome P450 isoenzymes (rCYPs) were used to 
investigate the biotransformational pathways involved during drug metabolism. Phase I 
metabolism was attributed to four rCYPS (CYP3A4, CYP2D6, CYP2C19, and CYP2C18) 
producing a total of four metabolites (9-O-demethylmitragynine, 16-carboxymitragynine, 
9-O-demethyl-16-carboxymitragynine, and 7-hydroxymitragynine). The pH and 
temperature dependent stability of MG, SC, SG, PY, and 7-MG-OH were also investigated. 
All five alkaloids were acid labile, with 7-MG-OH being the most unstable. However, SC, 
 
v 
SG, and PY were more stable than MG and 7-MG-OH. In addition, two degradation 
products of mitragynine were identified. 
Chemical and enzymatic hydrolysis of conjugated metabolites of mitragynine were 
investigated using postmortem urine specimens. Acid and base hydrolysis, in addition to 
nine enzyme systems (β-glucuronidase:  Escherichia coli, Patella vulgata, Helix pomatia; 
sulfatase: abalone entrails, Aerobacter aerogenes. Patella vulgata, Helix pomatia; 
recombinant systems; BGTurbo™, BGS™, ASPC™, IMCSzyme) were evaluated. 
Ultimately, hydrolysis did not improve the analysis of 9-O-demethylmitragynine and 7-
hydroxymitragynine, but did improve the detection of 16-carboxymitragynine.  
Postmortem blood (n=40), urine (n=16), and tissue (n=20) specimens from 20 
fatalities were also evaluated. Speciociliatine and speciogynine were shown to be 
biomarkers of kratom use, with concentrations higher than mitragynine in the majority of 
specimens. In addition, the majority of blood and urine specimens contained several 
metabolites of mitragynine, with 9-O-demethylmitragynine and 7-hydroxymitragynine 
being the most prominent. 
KEY WORDS:  Kratom, LC-Q/TOF-MS, Mitragynine, 7-Hydroxymitragynine, 
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In an effort to circumvent legislation, many drug users will seek drugs that 
can produce similar effects to illegal drugs, but are not yet regulated by law (1). 
There is also a preconceived notion that herbal or botanical drugs are a “safer” 
alternative to synthetic drugs, because they are naturally derived (2). One herbal 
drug that currently fits the criteria for a botanical “legal high” is kratom.  
Kratom is traditionally used as an herbal medicine by the natives of Thailand 
and South East Asia due to its unique characteristic of being both a psychostimulant 
and a depressant, although the effects are dependent on dose (3). Kratom’s dominant 
alkaloid is mitragynine, but it has many minor psychoactive alkaloids, most notably 
7-hydroxymitragynine, which is a more potent analgesic than mitragynine (4). 
Recently, kratom usage has been increasing in the United States and Europe, as the 
plant is now widely available online and in retail outlets where it is being marketed 
as a safe, natural, and a legal alternative to opiates (2). The lack of legislation, wide 
availability, and the low cost of the drug when compared to other illicit substances 
has also increased the popularity of this drug.  
History 
Kratom, also known as Ketum or Baik-Baik, comes from the leaves of the 
Korth (Mitragyna speciosa) tree (5). The Korth tree is a large arboreal tree that can 
reach a height of 50 feet and a spread of 15 feet. The leaves of the tree are oval 
shaped and dark green in color. The veins of the leaves are either greenish-white or 
red, with red veins considered to be more potent (6). The tree is a member of the 
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Rubiaceae family which also includes the coffee plant (7). M. speciosa flourishes in 
hot, warm, and wet environments and grows in swamps, rubber plantations, rice 
fields, fruit gardens, ditches, and fishing ponds (8). The tree is indigenous to South 
East Asia, the Philippines, and Papua New Guinea, but is commonly seen in 
Thailand, Malaysia, and Myanmar (7). However, the plants can be cultivated in other 
regions of the world (8, 9). 
Kratom usage was first recorded in the early twentieth century and it is a 
known herbal drug in Southeast Asia (10). Traditionally, kratom leaves have been 
chewed by the natives of Thailand to relieve pain and as an energy stimulant (10). It 
was also known to be used as an opium substitute (11). However, it has many other 
reported uses and is considered a cultural practice in Thailand and in some rural 
villages its use is even considered to be ritualistic (7). Since kratom is widely 
available for sale on the internet, marketed as a natural alternative herbal remedy for 
many conditions, and lacks strict legal restrictions, usage has increased dramatically 
in Western Europe and the United States (8). This use has further increased due to 
its opioid like properties, largely due to the growing opiate crisis in the United States 
(12). Kratom, and its major pharmacologically active component, mitragynine, have 
also been found in herbal blends sold in retail outlets (13). Although kratom usage 
has been reported for over 100 years, research on kratom is still ongoing and its 
chemistry and pharmacology are not well understood. 
Scheduling 
Kratom is illegal in Australia, Malaysia, Myanmar (Burma), and Thailand. 
It is also a regulated or a controlled substance in Finland, Denmark, Romania, 
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Germany, and New Zealand, but is still unregulated in most countries (6). Kratom 
was outlawed in Thailand by the Kratom Act in 1943, but it has not decreased usage 
(8). Kratom is one of the most widely abused illicit substances in Thailand and the 
use of the drug has been difficult to regulate due to the consumption of the drug 
being a culturally acceptable practice and because the plant grows naturally in the 
region with no human interference (14, 15). The plant is also easily cultivated which 
has led to it being grown in other regions of the world (9, 10). Although illegal in 
many countries in Southeast Asia, in Indonesia kratom is able to be grown legally 
and is shipped worldwide, making regulation even more difficult (8).  
The legal status of kratom in the United States is somewhat controversial and 
has sparked much debate. At the federal level, the Drug Enforcement Administration 
(DEA) identified kratom as a “drug of concern” several years ago (16, 17). 
Following a recommendation from the US Department of Health and Human 
Services, in 2016 the DEA announced its intention to place kratom (and its primary 
psychoactive components, mitragynine and 7-hydroxymitragynine) into Schedule I 
of the Controlled Substances Act (17, 18). However this legislation was withdrawn 
in October 2016 due to intense public outcry from lobbyists, users, and medical 
professionals. Currently, the federal status of kratom regulation is uncertain pending 
additional research regarding its abuse potential, medical use, and overall health 
concerns (3). However, at the time of this study, the drug does not have any 
legitimate medical usage in the United States (16). 
Regulation in the states is even more complicated with legislation varying 
by state (Figure 1.1). Kratom is illegal in Wisconsin, Indiana, Arkansas, Alabama, 
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and Vermont (19). There is currently pending legislation in Michigan, Louisiana, 
North Carolina, Ohio, New York, and Rhode Island. Kratom use is still legal in 39 
states and Washington D.C., even though 8 of those states have attempted to pass 
(or had) legislation banning or regulating the drug. Interestingly, in 8 of the 39 states 
where kratom use is legal, the drug is regulated, usually by age. Three states 
(Arizona, Utah, and Georgia) have even passed legislation referred to as “The 
Kratom Consumer Protection Act” (20). This legislation is designed to protect 
consumer’s access to the drug, but allow for the ban of adulterated products. It 
essentially requires vendors, creators, and sellers to properly label their products, 
prohibits the sale of certain products, creates specific penalties for violations of the 
act, mandates registration for kratom producers and creates standards for kratom 
production and sale. To summarize, kratom’s legal status at both the state and federal 
level is still being defined and it is likely that it will be in a state of flux and 
uncertainty for many years to come. 
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Figure 1.1: Map of kratom legality in the United States. 
 
Chemistry 
Forty-four compounds (Figure 1.2) have been isolated from the leaves of M. 
speciosa (3, 9). Although the alkaloid content varies due to geographical region and 
season, the total alkaloid content ranges from 0.5%-1.5% (8). The alkaloids in the 
leaves are a mixture of indole and oxindole alkaloids. Of these two types of 
alkaloids, the terpenoid indole alkaloid content remains the most stable in the leaves 
with little variation (7). The alkaloid content also varies with the age of the plant, 
with younger plants containing more of the mitragynine diastereoisomers, 
speciociliatine, and the paynantheine diastereomer, isopaynantheine than older 
leaves (8, 9). The alkaloid content also varies depending on several other factors 
including species, region of the plant, environmental factors and geographical 
location (9). Some specimens grown in the west have even reportedly contained 
alkaloids not seen in the specimens grown in Southeast Asia (21).  
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Figure 1.2: Indole alkaloids in Mitragyna speciosa. 
 
Major Psychoactive Alkaloids 
 
Diastereoisomers of Mitragynine 
 




Mitragynine is the principal pharmacologically active compound in kratom, 
accounting for 60-66% of the total alkaloids present (5, 9, 22). The alkaloid content  
as described above, varies considerably, with one study by Takayama et al. reporting 
that speciogynine, speciociliatine, and paynanthenine account for 6.6%, 8.6%, and 
0.8% of the total alkaloid content, respectively (5). Speciociliatine and speciogynine 
are both diastereoisomers of mitragynine while paynantheine is an alkaloid in 
kratom that is a dehydro analog of mitragynine.  However, neither of these three 
compounds are thought to be significantly psychoactive (23). There is research that 
suggests that speciociliatine and speciogynine play a minor role in kratom’s effects, 
but more research is needed to better understand these alkaloids. 7-
Hydroxymitragynine is another prominent psychoactive compound present in 
kratom plant materials (2%) (5, 22). Remaining alkaloids such as mitraciliatine, 
mitraphylline, and isomitraphylline account for less than 1% collectively (8, 9). The 
primary target analyte for kratom in forensic toxicological analysis is mitragynine, 
although 7-hydroxymitragynine is sometimes targeted (Table 1.1). Other 
compounds in kratom such as, speciociliatine, speciogynine, and paynantheine are 
occasionally targeted, but published analytical methods for these compounds in 
biological specimens are uncommon and methods that target these compounds are 





























Urine 0.2 mL LLE - 1 1-500 MG, 7-MG-OH Mitraphylline LC-MS/MS (27) 
Urine 3 mL SPE 100 - - MG, PY, SC, SG - GC-MS (28) 







1 mL or  
1 g 
LLE 0.25 1 1-10 MG Proadifen LC-MS/MS (30) 





























1 mL SPE 30 50 50-1000 MG MG-D3 GC-MS (33) 
Plasma 0.1 mL LLE 2 10 10-4000 7-MG-OH Tryptoline LC-MS (34) 
Blood 0.5 mL LLE 0.16 - 5-500 MG MG-D3 LC-MS/MS (35) 
Plasma 0.5 mL LLE 0.2 0.2 0.2-1000 MG Amitriptyline LC-MS/MS (36) 







2 mL or  
2g 
LLE 0.25 1 1-100 MG Proadifen LC-MS/MS (30) 
BAµE, bar adsorptive microextraction; GC-MS, gas chromatography-mass spectrometry; LC-DAD, liquid chromatography-diode 
array detector; LC-MS, liquid chromatography-mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; 
LC-Q/TOF-MS, liquid chromatography-quadrupole time-of-flight-mass spectrometry; LC-DAD, liquid chromatography-UV-vis-
diode array detector; LLE, liquid-liquid extraction; MG, mitragynine; MG-D3, mitragynine-D3: 7-MG-OH, 7-hydroxymitragynine; 
MG-OH-D3, 7-hydroxymitragynine-D3; PY, paynantheine; SC, speciociliatine; SG, speciogynine; SPE, solid phase extraction. 
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Mitragynine’s structure was defined in 1963 and was later confirmed through 
crystallographic studies in 1965 (38, 39). It is a corynanthe-like alkaloid structurally similar 
to yohimbine (Figure 1.3) (40). Corynanthe-type alkaloids are known to be classified into 
four groups (normal, pseudo, allo, and epi-allo) based on chemical structure (9). 
Mitragynine belongs to the allo group, while its distereoisomers belong to the normal 
(speciogynine) and epi-allo (speciociliatine) groups. These differences in orientation on the 
chemical structure are thought play a major role in terms of its psychoactive effects (41).  
Mitragynine’s chemical name is 9-methoxy-corynantheidine and its chemical structure is 
composed of an indole aromatic ring attached to two piperidine rings. Conformational 
studies suggest that the exocyclic groups have free rotation, but Rings A and B are thought 
to be planar due to being aromatic (42). Ring C is a piperidine derivative and the nitrogen 
is thought to be essential to mitragynine’s ability to bind to opioid receptors (3). The 
methoxy-moiety at the positions C16 and the C9 have an open ring with substitution (42).   
Mitragynine has an empirical formula of C23H30N2O4 with a corresponding molecular 
weight of 398.50. Its pKa is 8.1 and the melting point is 104°C (7, 43).  





7-Hydroxymitragynine’s structure (Figure 1.2) was identified relatively recently in 
1993 (22). It is structurally similar to mitragynine with a hydroxyl group in the C7 position 
between rings 2 and 3. 7-Hydroxymitragynine’s empirical formula is C23H30N2O5 with a 
corresponding molecular weight of 414.50, and a pKa of 12.20 (4). Speciociliatine and 
speciogynine share identical structures with mitragynine, differing only in spatial 
arrangement, and paynantheine has an unsaturated carbon at C18. Research on these three 
compounds is limited as much of the focus has been on 7-hydroxymitragynine and 
mitragynine. The structures of SC, SG and PY were confirmed between 1967 and 1975 (9, 
44, 45). The molecular weights for these compounds are 396.5 (PY) and 398.5 (SC and 
SG) with corresponding molecular formulas of C23H28N2O4 (PY) and C23H30N2O4 (SC and 
SG). 
Pharmacology 
M. speciosa is a psychoactive plant, which means that it contains phytochemical 
compounds that affect the central nervous system and induce changes in behavior and/or 
mental activity (46). Kratom is not only known to be psychoactive, but it is also known to 
have several physiological effects (4, 5, 8, 9, 17, 40, 43, 47). Since kratom was recently 
introduced to western users, its pharmacological properties are not as well understood as 
many other illicit drugs. However, because of its increased popularity, comprehensive 
peer-reviewed studies on its unique properties are being further investigated. 
Pharmacokinetics 
Kratom is composed of more than 25 alkaloids, so the pharmacokinetics associated 
with the drug are complex. The drug is usually obtained as whole or crushed leaves, 
concentrated  extracts, resin, or a loose or encapsulated powder that is typically consumed 
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orally (directly or prepared as a tea) (1, 8, 10). There are no studies that discus differences 
between doses of the more concentrated drug mediums such as the resin extract or the 
powder form. Also, although several internet forums do discuss what doses will give the 
desired effects, there are no published studies describing the relationship between dosage 
and the desired effect in humans (48, 49). Although there are many alkaloids in kratom, 
the primary alkaloid that has been the focus of the majority of pharmacokinetic studies is 
mitragynine. There have been several studies involving rats to determine its 
pharmacokinetic properties. After a 12 hour fasting period, 96 rats (8 rats per time interval) 
received a single oral dose of 20 mg/kg of mitragynine. Peak mitragynine concentrations 
of 424 ng/mL were reported at 1.3 hours in plasma (36). Another study involved 6 rats 
administered 1.5 mg/kg of mitragynine intravenously and 50 mg/kg orally. The 
mitragynine concentration in plasma peaked at 700 ng/mL at 4.5 hours following oral 
administration and 2,300 ng/mL at 1.2 hours following intravenous administration (37). 
Although pharmacokinetic studies involving humans are limited, Trakulsrichai et al. 
reported that mitragynine concentrations in ten male individuals peaked between 18.5-105 
ng/mL with an average of 0.83 ± 0.35 hours (50). 
The solubility of mitragynine has been reported to be 18.7 ± 0.4 μg/mL in buffer at 
pH 9, to 64.6 ± 1.2 μg/mL in water, 88.9 ± 1.6 μg/mL in buffer pH 7, and 3.5 ± 0.01 mg/mL 
in buffer at pH 4 (43). Since mitragynine is a weakly basic compound, it is not surprising 
that it is highly soluble at acidic pH since it is predominantly in its ionized form. In that 
same study, mitragynine was found to have an intermediate lipophilicity (logP value of 
1.70). This intermediate lipophilicity indicates that mitragynine favors high blood-brain 
barrier penetration which could explain the psychotropic properties of the compound, but 
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there is currently no study that confirms this. In fact, since both mitragynine and 7-
hydroxymitragynine are reported to be highly protein bound (>90%) they might actually 
have restricted passage across the blood-brain barrier (51). Information on postmortem 
redistribution (PMR) is limited at this time to two case reports. McIntyre et al. described 
PMR in a fatality caused by kratom (n=1). The central blood to peripheral blood (C/P) ratio 
was 0.83 and the liver to peripheral blood (L/P) ratio was 1.9  (33). Another study by Holler 
et al. described PMR from another fatality linked to kratom use and reported C/P and L/Ps 
of 0.39 and 0.12, respectively (30). These ratios indicate little to no propensity toward 
postmortem redistribution. However, due to the very limited sample size, inferences 
regarding PMR should not be made (52, 53). 
The half-life following oral administration of mitragynine was reported to be 
between 3.9 and 6.6 hours in rats (36, 37). Half-lives in humans following oral 
administration of kratom tea was 23.24 ± 16.07 hours (50), highlighting important 
differences between species. The half-life following intravenous administration of 
mitragynine was reported to be 2.9 hours (37). That same study also found the oral 
bioavailability to be 3.03 ± 1.47%. The volume of distribution for mitragynine is widely 
variable in the literature and reported to be 38 L/kg (36) and 90 L/kg (54). However, the 
wide range might also be explained by the overestimation of mitragynine concentrations 
due to the lack of sensitivity of ultraviolet (UV) detection used by Janchachee et al. 
compared to the high sensitivity of liquid chromatography-tandem mass spectrometry 
(LC–MS/MS) used in the study by de Moraes et al. (36, 54). In another study by 
Trakusrichai et al. the estimated volume of distribution was 38.04 ± 16.07 L/kg. In that 
same study, the total clearance was 98.1 ± 51.34 L/h kg and the estimated half-life was 23 
14 
 
hours. Overall, only 0.14% of the drug was eliminated unchanged in urine (50). It is 
suspected from this study, along with the other pharmacokinetic studies, that mitragynine 
has a large volume of distribution and is mainly distributed outside of the circulation (36, 
50, 54). The reported volumes of distribution in these three studies might suggest that the 
drug is a candidate for PMR, but limited reports to date have not confirmed this (30, 33).  
With regard to the other Mitragyna alkaloids, the literature is much more limited in 
terms of their pharmacokinetic activity. 7-Hydroxymitragynine was reported to have a half-
life of 23 mins and a much lower volume of distribution (1.5 L/kg) relative to mitragynine 
(34). Given the compounds increased polarity when compared to mitragynine, this is not 
surprising, but it is important to note that studies have only been performed using animal 
and in-vitro models. 
Kratom is widely considered a “safe drug” by many users and one study suggests 
that it may be less toxic compared to similar drugs of abuse. Sabetghadam et al. found that 
using kratom extracts, the median effective dose (ED50) was 22 mg/kg and the median 
lethal dose (LD50) was 477 mg/kg in mice (55). The authors suggest that this high 
therapeutic index supports the contention that the drug is “safe” because it is unlikely to 
result in a fatal overdose from overconsumption of the drug alone (55). However, numerous 
fatalities have been reported (33, 56-58), albeit most frequently in combination with other 
drugs. 
Pharmacodynamics 
The pharmacodynamic behavior of kratom can be characterized by both 
physiological and psychological effects. Kratom has dual stimulating and sedative effects 
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that are dose-dependent (40). Low doses of kratom are reported to produce a stimulant 
effect similar to cocaine and high doses are reported to produce opiate-like effects (8). 
There are numerous studies detailing the positive and negative effects of kratom, including 
alertness, euphoria, and impaired memory (59). Acute usage may induce nausea and 
headaches and chronic usage has been shown to cause hepatic problems, 
hyperpigmentation, reduced mental prowess, and an induction of indolence that is usually 
associated with opiate use (47). Other side effects include seizures, coma, hypothyroidism, 
weight loss, pulmonary edema and congestion, increased blood pressure, increased heart 
rate, distended bladder, tremors, anxiety, irritability, aggression, constipation, itching, 
psychosis, weight gain, and insomnia (4, 8, 17, 30, 50, 55, 56, 60-64). 
Kratom has various physiological effects depending on dosage. Muscle relaxation 
is a physiological effect often associated with opiate use, and is also widely reported in 
kratom users (40). A study by Watanabe et al indicates that mitragynine causes a decrease 
in muscle contractions by inhibiting the neurotransmitter release from the nerve endings 
by blocking the neuronal Ca 2+ (65). This study indicates that mitragynine and other kratom 
alkaloids may act on the neuromuscular junction in a similar function to other opiates. 
However, the anecdotal and experimental evidence for  muscle relaxation is contradicted 
by an earlier study, which states that mitragynine consumption may result in light tremors 
and tenseness in the hands and feet (64). This contradiction could be explained by the 
unique dose-dependent relationship that mitragyine has where studies have shown that low 
doses commonly cause stimulant like effects, such as tremors and muscle contractions (5, 
27, 40). However, two case studies suggest that kratom usage may actually encourage 
seizures in some users which further supports the stimulant-like effects of mitragynine (61, 
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66). It should be noted that in the case studies, it is not known if a combination of drugs 
with kratom or the individual’s health circumstances could have also helped instigated the 
seizure activity. However, seizures linked to kratom quadrupled in Thailand from 2005 to 
2011 (67) further supporting the reports of kratom causing seizure activity.  
Another physiological symptom commonly associated with kratom usage is 
constipation. In Thailand, natives often used kratom for gastrointestinal illness (40). A 
study by Chittrakarn et al. suggests that kratom has an inhibitory effect on the 
gastrointestinal tract (68). The study maintains that the effect is similar to a mu opioid 
receptor agonist (loperamide) used to treat diarrhea by decreasing potassium and sodium 
permeability giving more indication that kratom behaves like an opiate in certain doses 
(68).  The study also showed that gastric acid secretion is inhibited by the same interactions 
with the opioid receptors in the gastrointestinal tract and leads to decreased motility (68). 
These interactions with the gastrointestinal tract may explain the anorexic effects users of 
kratom often experience (4, 8). However, there are conflicting reports on its anorexic 
effects, including a case study that suggests kratom may in fact cause weight gain (62). 
This suggests that the anorexic effect may depend on the individual and other mitigating 
factors and not solely the usage of kratom. 
Kratom has been reported to cause a slight nystagmus and dilation of the blood 
vessels (64). A toxicity study by Harizal et al. indicated that high doses of over 1000 mg/kg 
in rats increased blood pressure and caused severe hepatotoxicity and nephrotoxicity (69). 
Another toxicity study reported that rats exposed to kratom at doses of 100 mg/kg, 200 
mg/kg, and 500 mg/kg, showed a decreased body weight, toxicity in the kidneys, lungs, 
and liver, behavioral changes, and changes in blood chemistry. The authors noted that 
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adverse effects were more likely to be seen in the rats exposed to 200 mg/kg and 500 mg/kg 
(70). The hepatotoxicity seems to be supported by a case study where kratom usage caused 
intrahepatic cholestasis, although this effect may be dose dependent or dependent on the 
individual’s health situation (71). However in an recent case study, cholestatic hepatitis 
was solely linked to kratom usage (72). However, Dorman et al. stated that hepatoxicity is 
only reported in western countries indicating that the hepatoxicity is potentially caused by 
contamination or as a result of an error in plant identification (72).   
Kratom products have also been shown to be cytotoxic to both human neuronal and 
intestinal cells, as well as genotoxic in intestinal cells, but this is likely due to kratom 
products being mixed with other psychoactive substances (73). Glucose transport may also 
be affected by kratom usage. A study by Purintrapiban et al.  indicated that kratom 
increases post-transcriptional expression of the glucose transporter 1 (GLUT1) gene, which 
increases glucose transport, suggesting that kratom has an anti-diabetic effect (74). 
Kratom’s effect on glucose transport could explain why the plant is commonly used in 
traditional Thailand folk medicine for the treatment of diabetes (14).  
In a case study involving a fatal overdose, an autopsy showed pulmonary 
congestion, edema, and a distended bladder thought to be caused by solely by kratom usage 
(56). Another study involving the multiple autopsies of deaths caused by kratom showed 
brain and lung edema and congestion in multiple organs (75). While these cases may 
suggest that kratom has a toxic effect on lung tissue, there is no existing toxicity study that 
confirms pulmonary tissue toxicity. Another study by Utar et al. showed that mitragynine 
decreases cyclooxygenase-2 (COX-2), which might explain the anecdotal descriptions of 
hot flashes, edema, and anti-inflammation effects of kratom (76).  
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Kratom also has several psychological effects that are unique to the mixture of 
compounds, primarily mitragynine, found in the plant.  A study conducted by Boyer et al. 
reported that mitragynine inhibits radioligand binding at the central nervous system 
receptors including the adrenergic, dopamine, and opioid receptors (66). In that same study, 
mitragynine had an affinity for all opioid receptors, but had a high affinity μ-opioid 
receptor which could indicate why many users report its ability to reduce opiate withdrawal 
symptoms (66). In fact it has been reported that mitragynine has one fourth of the potency 
of morphine (5). 7-Hydroxymitragynine is reported to be 13-fold more potent than 
morphine and 46-fold more potent than mitragynine (3, 77).  It has a high affinity for the 
mu opioid receptor, especially when kratom is consumed orally. 7-Hydroxymitragynine 
has reportedly been found to be more 46-fold more potent then morphine (77). In addition, 
a recent study by Kruegel et al. also reported that mitragynine and 7-hydroxymitragynine 
are partial agonists on the human opioid receptors, however other prominent alkaloids in 
kratom such as paynantheine, speciogynine, and speciociliatine, have no agonist activity 
and may in fact have partial antagonistic activity (78).  Another study conducted by 
Matsumoto et al. showed that mitragynine at high doses inhibited the contraction of the 
vas deferens in mice, which indicates that mitragynine may be weakly agonistic towards 
the delta-opioid receptors (79). There is also evidence that crude extracts of kratom which 
contain large amounts of various alkaloids may both excite and inhibit the hippocampus 
through short term potentiation with a decrease of the intracellular calcium ion 
concentration (46).  
It has frequently been reported that mitragynine has anxiolytic effects (80). A study 
conducted by Khor et al. indicated that mitragynine attenuated morphine withdrawal in 
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zebra fish by decreasing the production of G-protein coupled receptors that are associated 
with endocrine and behavioral responses to stress (81). The decrease in production led to a 
decrease in stress-induced behaviors (81). A similar study by Yusoff et al. showed that 
mitragynine’s opiate like quality for reducing stress has a potential for addiction and abuse 
when given to mice in acute quantities (82). Mitragynine also has been shown to suppress 
the head twitch response in mice associated with the stimulation of serotonergic and 
adrenergic receptors, which adds more credibility to the idea that mitragynine also binds 
to these receptors (83). One study also indicates that mitragynine has an antidepressant 
effect in which the compound restores the monoamine neurotransmitter levels, specifically 
the serotonin, norepinephrine, and dopamine receptors (84). Studies in rats indicate that 
mitragynine may also cause neuropathological changes including local vacuolation, 
necrosis, an increase in lactate dehydrogenase, and the degeneration of neurons at high 
doses (63).  
Both 7-hydroxymitragynine and mitragynine have been shown to have a similar 
response to morphine and cocaine when discriminative stimulus tests were performed on 
rats, further indicating the drugs stimulant and opiate like effects (85). Another study by 
Carpenter et al. showed behavior and biological activity in rats on par with oxycodone after 
mitragynine consumption (86). One study by Sufka et al. indicated that rats who were given 
mitragynine often showed place preference when consuming the drug (87). Another study 
involving human cancer cells and in vivo methods indicated that neuronal cells were highly 
sensitive to the cytotoxic effects of kratom (73).   A study by Apryani et al. indicated that 
low doses of mitragynine may impair working memory (88) while another study indicated 
that it improved memory and learning behaviors (70). Finally, a study by Ismail et al. 
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disputed that claim by reporting that mitragynine can increase exploration activity, enhance 
punishment resistance, and impair learning behavior in mice exposed to it frequently (89). 
Kratom has unique psychological effects when used with other drugs. A study by 
Fakurazi et al. showed that the combination of mitragynine and morphine increased the 
analgesic effects, but reduced the development of morphine tolerance (90). This indicates 
that the anecdotal reports on kratom being used for the treatment of opiate addiction may 
have some validity. Another study by Cheaha et al. reported that mitragynine extracts may 
also help with ethanol withdrawal symptom (91). Kratom also has been shown to be 
addictive and produces physiological and psychological withdrawal symptoms similar to 
opiate withdrawal (92). Withdrawal symptoms commonly reported are insomnia, anorexia, 
nausea, vomiting, muscle spasms, sweating, fever, diarrhea, hot flashes, watery eyes and 
nose, body aches, depression, restlessness, moodiness, coughing, fatigue, lack of 
motivation, anxiety, cravings, and sleepiness (60, 92, 93).  At this time, one case study has 
been published describing a case of kratom addiction and withdrawal in the United States 
(94). While several surveys from Asia have reported addiction and withdrawal, this is the 
first case study of addiction and withdrawal from the United States.  There have also been 
several case studies of neonatal abstinence syndrome on infants whose mothers consumed 
kratom frequently during pregnancy (95-98). These infants primarily displayed symptoms 
associated with opiate withdrawal. Although there are several reports of kratom being used 
to treat opiate addiction and discussions surrounding its potential for supervised medical 





At present, information regarding the stability of Mitragyna alkaloids is limited to 
only mitragynine and 7-hydroxymitragynine. Mitragynine has been reported to be stable 
in several processed samples and during freeze-thaw cycles (37, 50, 54, 99). Currently, 
only two studies have focused on the stability of mitragynine outside of method 
development and validation. A study by Manda et al. found that when incubated for two 
hours in simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8), 
mitragynine degraded by 26% and 3.6% indicating that mitragynine is acid labile (51). 
Another study by Ramanathan et al. reported that the percentage of mitragynine recovered 
at 0.5 h, 6 h, and 24 h in multiple buffer systems were 100.6 ± 0.3%, 91.8 ± 1.0% and 88.8 
± 1.4% for pH 4 buffer; 99.2 ± 0.4%, 96.1 ± 1.9% and 101.9 ± 0.9% for pH 7 buffer; and 
101.3 ± 2.6%, 97.8 ± 0.3% and 95.5 ± 2.5% for pH 9 buffer (43). In that same study, 
mitragynine was incubated in simulated gastric fluid (pH 1.2) and simulated intestinal fluid 
(pH 6.8). Mitragynine was stable for 3 hours in the simulated intestinal fluid with less than 
5% deviation from the original drug content. In contrast, mitragynine was highly unstable 
in the simulated gastric fluid, with over 20% deviation from the original drug content at 20 
minutes after incubation (43).  
In contrast to mitragynine, 7-hydroxymitragynine is known to be extremely 
unstable. Currently, methanolic 7-hydroxymitragynine certified accredited reference 
materials require special handling and must be stored in highly alkaline conditions at sub-
freezing temperatures (-60 to -80°C) (100). Stability studies for 7-hydroxymitragynine are 
more limited than mitragynine, but Manda et al. determined that when incubated for two 
hours in simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8), 7-
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hydroxymitragynine degraded by 27% and 6%, respectively (51). However, 7-
hydroxymitragynine has been reported to be stable in rat plasma for 12 hours at room 
temperature and for 30 days at -20°C (34), showing that 7-hydroxymitragynine may be 
stable in the short term under certain conditions.  
Metabolism 
The metabolism of the Mitragyna alkaloids is not fully understood. An early study 
by Zarembo et al. used Helmin-thosporum sp. to determine that oxidation and 
hydroxylation pathways are the primary mechanism for mitragynine metabolism (101). It 
is also thought that mitragynine is mainly metabolized by hepatic metabolism and that 
metabolism is linear on a two-compartment model (50). Although studies involving 
microbial transformations are useful, these studies are limited because they cannot fully 
mimic metabolism in humans in which case human and animal studies are important for 
identifying phase I and II metabolism. In phase I metabolism the primary mechanism is the 
hydrolysis of the methylester groups (C16) and the demethylation of the methoxy groups 
(C9 and C17) (102). The phase I metabolites of mitragynine found in studies involving 
human urine include 9-O-demthylmitragynine, 9-O-demethyl-17-carboxy-16, 17-
dihydromitragynine, 9-O-demethyl-16-carboxymitragynine, 16-carboxymitragynine, 17-
dihydromitragynine, 17-O-demethyl-16, 17-carboxy-16, 7-hydroxymitragynine, and 17-
dihydromitragynine (102). While phase II metabolism has not been studied as thoroughly 
as phase I, one study by Philipp et al. has shown that mitragynine is heavily conjugated by 
both glucuronides and sulfates in human urine samples (102). The same study found that 
the phase II metabolites include 9-O-demethylmitragynine sulfate, 9-O-
demthylmitragynine glucuronide, 9-O-demethyl-16-carboxymitragynine glucuronide, 9-
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O-demethyl-16-carboxymitragynine sulfate, 9,17-O-demethyl-16,17-dihydromitragynine 
glucuronide, 16-carboxymitragynine glucuronide, 9,17-O-bisdemethyl-16,17-
dihydromitragynine sulfate, and 17-O-bisdemethyl-16,17-dihydromitragynine glucuronide 
(102). During the course of this study, 7-hydroxymitragynine was reported to be a 
metabolite of mitragynine (103, 104). This finding is highly significant due to the increased 
potency of 7-hydroxymitragynine.  
There are currently no studies that identifying the phase I metabolites of 7-
hydroxymitragynine.  Manda et al. reported that 7-hydroxymitragynine converted to 
mitragynine in the presence of human live microsomes (HLM) and in alkaline intestinal 
fluid (pH 6.8) (51). Although this is the first report of the metabolic conversion of 7-
hydroxymitragynine into mitragynine, future studies are needed to evaluate this 
conclusion.  In addition, a study by Kruegel et al. reported that 7-hydroxymitragynine may 
not be present in all plant samples but seems to be found more in dry leaf materials that 
have been exposed to air and sun for long periods of time (78). In conclusion, while 7-
hydroxymitragynine is present in some plant samples and is psychoactive, very little is 
known about the compound. The phase I and II metabolites of speciogynine, speciociliatine 
and paynantheine have been identified (105-107) and they metabolize in a manner 
analogous to mitragynine, with many metabolites sharing identical structures.  
Although several metabolites of mitragynine have been identified, there is little 
information regarding the cytochrome P450 isoforms (CYPs) responsible for metabolism. 
This is concerning, because understanding the isoforms involved is important from the 
standpoint of drug-drug interactions and potential adverse reactions due to genetic 
polymorphisms. A recent study  identified CYP3A4 as the primary contributor to 
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metabolism with minor contributions from CYP2D6, CYP2C9, and CYP2C19 (104).  
Mitragynine and 7-hydroxymitragynine were also shown to inhibit P-glycoprotein. This 
indicates  the possibility of a drug interaction if mitragynine and 7-hydroxymitragynine are 
coadministered with drugs that are P-glycoprotein substrates (51). Mitragynine has also 
been shown to have toxicokinetic interactions with permethrin by inhibiting hydrolysis, 
increasing the risk of developing neurotoxicity (108). The compound has also been found 
to inhibit hERG (human ether-à-go-go-related gene) and GIRK (G protein-coupled 
inwardly-rectifying) potassium channels which can cause a risk of cardiotoxicity (109). In 
addition, 7-hydroxymitragynine has also been reported to negatively interact with drugs 
that are metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGTs) 2B7 and 
1A1 (77).  
Administration and Use 
Kratom has been traditionally used by chewing on the leaves and brewing into a tea 
(10). In modern times, the leaves are also smoked, swallowed in a “gum” like substance, 
or taken by capsule (3). A typical user in Thailand will often consume ten leaves per day 
(110). Western users typically obtain the drug through vendors online or in retail outlets in 
herbal blends (40). However, several of these products are known to contain not only 
kratom, but several other psychoactive drugs (2, 75, 111). 
Users claim that kratom has a variety of therapeutic uses. In Thailand, kratom was 
used by natives who performed manual labor because of its stimulant properties and its 
ability to treat chronic pain (3). It is also important to note that kratom usage in Thailand 
does not interfere with the social functioning of kratom users in Thailand and its usage is 
not seen as a negative (112). The only exception is the negative social stigma towards 
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female addicts and users which might explain why more male users are self-reported (112). 
Kratom usage in the United States and Western Europe is more recent and is often 
recreational because of its euphoric effects (3).  However, a growing number of drug users 
are beginning to use kratom as an opioid alternative for the treatment of chronic pain and 
to treat opioid addiction (11). Other uses include treating intestinal infections, as an 
antidepressant, to reduce coughing, as an antidiarrheal, treatment for alcohol withdrawal, 
insomnia, diabetes, and to improve sexual performance (113). It also has been reportedly 
used as an analgesic, antidiabetic, antipyretic, to treat hypertension, and as an anxiolytic 
(8, 92, 93). Because of its recent introduction to Western society, there are few 
comprehensive studies on its potential medical uses and as of this time there are no official 
medical uses in the United States (16, 114). 
Analytical Methods 
There are few analytical methods for the detection of kratom in toxicological 
samples (Table 1.1).  Most of the published methods for multiple Mitragyna alkaloids 
describe the analysis of the compounds directly from plant materials. In contrast, many of 
the methods for analysis of biological specimens only target mitragynine, and occasionally, 
7-hydroxymitragynine. Current analysis methods are mostly centered on gas 
chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass 
spectrometry (LC-MS), but several other identification methods like thin layer 
chromatography (TLC) and ultraviolet-visible spectrometry (UV-VIS) have been reported.  
As the drug is relatively new to the Western world, very few methods have been 
developed using toxicological specimens. Based upon the limited number of published case 
reports (Table 1.2) analytical methods must have a wide range of detection for 
26 
 
concentrations of these alkaloids in biological specimens. In a study involving urine from 
fifty recreational kratom users, mitragynine concentrations ranged from 1 to 50,000 ng/mL 
(27). Concentrations of mitragynine following overdose or fatalities have been reported in 
the range 10-3,470 ng/mL (Table 1.2). In another study, mitragynine concentrations in 
femoral blood (n=8) were 20-180 ng/mL (75). Another case detailing a fatality from kratom 
use reported mitragynine concentrations at 0.23 mg/L in peripheral blood, 0.19 mg/L in 
central blood, 0.43 mg/kg in liver, <0.05 mg/L in vitreous fluid, and 0.37 mg/L in urine 
(33). It is important to note that these studies (and most published analytical methods) 
focused only on the detection of mitragynine. It is also possible that kratom cases may be 







Table 1.2: Concentrations of Mitragynine in blood and urine specimens. 
Investigation Matrix Internal Standard Concentration (ng/mL) Reference 
Antemortem samples (n=50) Urine Mitraphylline 1.2  - >50,000  (27) 
Intoxication (n=1) Urine Not described 167  (61) 
Fatality (n=1) Femoral Blood Not described 600 (56) 
Fatality (n=9) Femoral Blood LSD-D3 20-180 (µg/g) (75) 
Fatality (n=1) Heart Blood Proadifen 390 (30) 
Fatality (n=1) 
Femoral Blood    
Heart Blood 
Mitragynine-D3 




Femoral Blood    
Urine 
Amphetamine-D3 
1,060 ng/mL (Femoral)             
3,470 ng/mL (Urine) 
(116) 
Fatality (n=2) 
Femoral Blood   
Urine 
 MPPH 
10-780 (Femoral)                           
10 - >400 (Urine)         
(57) 
Fatality (n=31) 
Femoral Blood          
Iliac Blood    
Subclavian Blood 
Mitragynine-D3 
11-3,300 (Femoral)                       







Most of the published methods for the analysis of Mitragyna alkaloids have utilized 
LC-MS, while only three methods used GC-MS. Although GC-MS is the most commonly 
used analytical instrument in forensic laboratories, several issues with these alkaloids have 
made GC-MS methods undesirable. Phillip et al. developed a GC-MS method for 
toxicological samples using conventional electron ionization and full scan acquisition (28). 
Although the method was able to detect mitragynine, speciociliatine, paynantheine, and 
speciogynine, it lacked overall sensitivity (limit of detection; 100 ng/mL), was unable to 
quantify the alkaloids, and required derivatization due to the polarity of mitragynine (28).  
Analytical methods that utilize LC-MS do not require derivatization for Mitragyna 
alkaloids and is also a more appropriate technique for the analysis of polar analytes. A 
study by de Moraes et al. used LC-MS/MS to detect mitragynine in rat plasma (36). This 
method used a mobile phase gradient of a 70:30 (v/v) solution of ammonium acetate and 
acetonitrile containing 0.5% formic acid coupled to a MS operating in positive electrospray 
ionization mode (36). This method was shown to be precise, accurate, and sensitive with a 
reported limit of quantitation (LOQ) of 0.2 ng/mL although the limit of detection (LOD) 
was not reported (36). Another study by Lu et al. developed a quantitative method for the 
analysis of mitragynine in urine using LC-MS/MS (31). This method used a mobile phase 
gradient of ammonium acetate with 0.1% formic acid (mobile phase A) and acetonitrile 
(mobile phase B) and methanol coupled to a MS operating in positive electrospray 
ionization mode and was able to detect and quantitate mitragynine with a limit of detection 
at 0.02 ng/mL and a limit of quantitation at 0.1 ng/mL.  Several metabolism studies on 
multiple Mitragyna alkaloids have also used liquid chromatography-linear ion trap-mass 




Some analytical methods have focused on detecting and quantifying 7-
hydroxymitragynine is biological matrices. Vuppala et al. described an LC-MS/MS 
method for the detection and quantitation of 7-hydroxymitragynine in rat plasma with a 
LOQ of 10 ng/mL and a concentration range of 10-4,000 ng/mL (34). Le et al. also 
described an analytical method for 7-hydroxymitragynine in urine using LC-MS/MS. 
Although only a qualitative study, they reported that all specimens with mitragynine also 
contained 7-hydroxymitragynine (27). Studies involving the analysis of paynantheine, 
speciogynine, and speciociliatine in biological specimens are limited, but qualitative assays 
utilizing LIT/MS/MS were used to structurally identify potential metabolites of 
speciociliatine, paynantheine and speciogynine (105-107). Philipp et al. also described a 
quantitative GC-MS method that was able to detect speciociliatine, speciogynine, and 
paynantheine in human urine specimens (28). In addition, a study by Arndt et al. was able 
to qualitatively identify speciocilatine, speciogynine, and paynantheine using an LC-
MS/MS method (111). 
Recently a notable study for Mitragyna alkaloids by Avula examined kratom leaf 
extracts using liquid chromatography quadruple time-of-flight mass spectrometry (LC-
Q/TOF-MS) and was able to successfully predict the characteristic fragmentation patterns 
of mitragynine and 7-hydroxymitragynine (25). While the method was effective, sensitive, 
selective, rapid, and allowed the identification of the indole group and other functional 
groups in kratom, this method was developed using plant extracts and has not been used in 




Mitragyna Alkaloids in Forensic Toxicology 
Kratom is new to the western world and is still legal in most of the United States.  
However, increased recreational use, interest in therapeutic use and the growing number of 
case reports involving fatal overdose and other serious side effects (58, 117) are a cause 
for concern. Between 2009-2013, over 14 exposures of kratom requiring hospitalization 
were reported in Texas (117). In fact, according to NFLIS (National Forensic Laboratory 
Information System), cases involving mitragynine were not reported until 2010. By 
December 2011, only 42 cases had been reported to NFLIS for that year and in 2013, 173 
cases were reported. In total, over 745 cases were reported to NFLIS by June 2018 (118-
120).  In a recent report from Anwar et al. the number of poison control center calls related 
to kratom use in the US increased ten-fold from 2010 to 2015 (121). A more recent report 
by the Centers for Disease Control and Prevention (CDC), identified 152 kratom positive 
deaths in 27 states from July 2016-December 2017 (115). Of these fatalities, 91 of these 
deaths involved kratom, but it was the only drug present in just 7 cases. The majority of 
decedents (80%) had a history of substance abuse and the most frequently co-administered 
drugs were fentanyl (or its analogs), heroin or benzodiazepines. Overall, the majority of 
literature concedes that kratom use is growing in the United States. 
As it relates to forensic analysis of kratom samples, there are many challenges. 
Most methods for kratom only focus on mitragynine, while literature suggests that other 
alkaloids might also be present (28, 111). The analysis itself is not trivial due to the need 
to separate structural isomers. Information on phase II metabolites and deconjugation is 
also limited. Lee et al. reported that sulfated conjugates of some of the metabolites were 




to be biomarkers of kratom use in order to improve analytical methods has not been fully 
investigated and with kratom use increasing, the ability to better detect the use of this drug 
is needed. 
Statement of Problem 
Kratom is a drug that is not readily detected using common toxicological screening, 
and as a consequence its use may be underreported in forensic laboratories (115). 
Previously published methods in biological fluids may not separate the structural isomers 
and other alkaloids present in the plant. In addition, some analytical methods lack the 
requisite sensitivity to identify the drug.  
 Another challenge involves knowledge gaps regarding metabolism and stability. 
As many kratom users are known to be poly drug users, this is a concern for both medical 
and forensic toxicology. When it comes to phase II metabolites, the efficiency of methods 
to deconjugate metabolites are relatively unknown and the benefits have not been explored. 
The limited information on stability is also an issue because this is critical in terms of 
sample preservation, storage, disposition and ultimately, interpretation.   
To improve the detection of Mitragyna alkaloids in forensic toxicology, a 
comprehensive study of five prominent alkaloids (Figure 1.4) (speciociliatine, 
speciogynine, paynantheine, 7-hydroxymitragynine, and mitragynine) was undertaken. 
Analytical methods were developed, optimized, and validated in accordance with 
published guidelines (123). Simultaneous identification of the five alkaloids in urine and 
blood was achieved using LC-Q/TOF-MS. This is a highly sensitive technique that shows 
promise for these challenging analytes. Recombinant CYPs were also used to investigate 




pathways. The stability of the target compounds under variable conditions of temperature 
and pH was also investigated in order improve sample preservation, sample collection, and 
toxicological interpretation. Finally, postmortem case samples were evaluated in order to 
identify potential biomarkers for kratom use, determine the efficiency and necessity for 





Figure 1.4: Targeted Mitragyna alkaloids and their deuterated analogs. 
Targeted Analytes 
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Mitragyna speciosa (Kratom) is a psychoactive plant that has recently emerged as a 
recreational drug. Mitragyna alkaloids are not within the scope of traditional forensic 
toxicology screening methods, which may contribute to under-reporting.  Solid phase 
extraction (SPE) and liquid chromatography-quadrupole/time of flight mass spectrometry 
(LC-Q/TOF-MS) were used to identify five alkaloids in urine. Target analytes included the 
two known psychoactive compounds, mitragynine and 7-hydroxymitragynine, in addition 
to speciociliatine, speciogynine, and paynantheine. Two deuterated internal standards 
(mitragynine-D3 and 7-hydroxymitragynine-D3) were employed. Using traditional 
reversed phase chromatography all compounds and isomers were separated in 10 mins. The 
procedure was validated in accordance with the Scientific Working Group for Forensic 
Toxicology (SWGTOX) Standard Practices for Method Validation. Extraction efficiencies 
were 63-96% and limits of quantitation were 0.5–1 ng/mL. Precision, bias and matrix effect 
were all within acceptable thresholds, with the exception of 7-hydroxymitragynine, which 
is notably unstable and unsuitable for quantitative analysis. In this paper we present a 
simultaneous quantitative analytical method for mitragynine, speciociliatine, speciogynine 
and paynantheine, and a qualitative assay for 7-hydroxymitragynine in urine using high 
resolution mass spectrometry (HRMS). 
 
Keywords:   Mitragynine, Kratom, Urine, LC-Q/TOF-MS, HRMS 
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Identification of Five Mitragyna Alkaloids in Urine using Liquid Chromatography-
Quadrupole/Time of Flight Mass Spectrometry 
Introduction 
Kratom, also known as Ketum, Thang, Thom and Biak, comes from the leaves of 
Mitragyna speciosa, a tropical evergreen tree of the Rubiaceae family (1). The tree is 
indigenous to South East Asia, but is commonly seen in Thailand, Malaysia, and Myanmar 
(2). Forty-four compounds have been isolated from the leaves of M. speciosa (3), many of 
which include both indole and oxindole alkaloids. Mitragynine is the principal 
pharmacologically active compound in kratom, accounting for 66% of the total alkaloids 
present (4). Speciogynine, speciociliatine, and paynanthenine are estimated to account for 
6.6%, 8.6%, and 0.8% of the total alkaloid content (1). Speciociliatine and speciogynine 
are both stereoisomers of mitragynine while paynantheine is a dehydro analog of 
mitragynine (Figure 2.1). Although these compounds are not believed to be 











Figure 2.1: Target analytes included in this study. 
 
Mitragynine is known to undergo hepatic metabolism (5). Hydrolysis of the 
methylester group (C16) and demethylation of the methoxy groups (C9 and 17) have been 
reported in humans (4). Hydroxylated and carboxylic acid metabolites are subsequently 
conjugated by both glucuronides and sulfates (4). Speciogynine, speciocilliatine, and 
paynantheine are reported to undergo similar biotransformations (6-8). The metabolic fate 
of 7-hydroxymitragynine has not been reported and may be complicated by the inherent 
instability of this compound. 7-Hydroxymitragynine is extremely labile, requiring storage 
at subzero temperatures under alkaline conditions (9). Metabolites of mitragynine are not 
yet commercially available, so the identification of kratom use in forensic toxicology 
specimens is currently limited to the parent drug and related alkaloids.   
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Kratom elicits both stimulating and sedative effects in a dose-dependent manner 
(10). Low doses of kratom are reported to produce a stimulant effect similar to cocaine, 
and high doses are reported to produce opiate-like effects (11). When used in a traditional 
setting as a mild stimulant, fresh or dried leaves of kratom are most commonly chewed or 
brewed into a tea. In the United States and Western Europe however, the drugs is used 
recreationally for its euphoric effects (3).  However, a growing number of individuals also 
use kratom as an opioid alternative for the treatment of chronic pain, or to treat opioid 
addiction (12). Although mitragynine has an affinity for both mu and kappa opioid 
receptors, Boyer suggested that additional receptor affinities might augment its 
effectiveness, mitigating unpleasant effects associated with opioid withdrawal (13). More 
recent studies have indeed confirmed that Mitragyna alkaloids exhibit receptor binding 
activities distinct from classical opioids (14). Both mitragynine and 7-hydroxymitragynine 
act as partial agonists at mu opioid receptors and competitive antagonists at kappa and delta 
opioid receptors (15). Since both are G protein-based agonists at the mu receptor, their 
tendency to produce respiratory depression may be somewhat reduced. 7-
Hydroxymitragynine is reported to be more potent than mitragynine, and has a high affinity 
for the mu opioid receptor, especially when kratom is consumed orally (3). Kratom is also 
reported to have adrenergic, serotonergic and dopaminergic effects, which may explain the 
relatively complex pharmacological profile of plant-based extracts (15). Given the current 
epidemic of opioid abuse in the United States, non-medical use of kratom is of growing 
concern (16). Although the Drug Enforcement Administration has identified kratom as a 
drug of concern, it is not currently scheduled at the Federal level (17). 
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The dose-dependent effects of kratom have been well documented throughout the 
literature (5, 11, 18-25). These range from increased energy and alertness, sociability and 
heightened libido at low dose, to drowsiness, confusion, seizures, loss of consciousness, 
coma and death at high doses. Regular kratom use is associated with drug dependency and 
withdrawal (26). In a series of 293 habitual kratom users estimated to use 276 mg/day, 
physical withdrawal effects included difficulty sleeping, muscle spasms, fever, watery eyes 
or nose and diarrhea (27). Psychological symptoms associated with withdrawal include 
restlessness, tension, anger, sadness and nervousness.  
Since kratom is widely available and lacks strict control, usage has increased 
dramatically in Western Europe and the United States (11). The online marketplace has 
fueled the recreational use of novel or emerging psychoactive drugs. Using business-to-
business and business-to-consumer marketing, the Internet and dark web make new 
psychoactive substances readily accessible (28).  According to the National Forensic 
Laboratory Information System (NFLIS), mitragynine seizures in the U.S. have been on 
the rise since 2010 (29, 30). Kratom is illegal in Australia, Malaysia, Myanmar (Burma), 
and Thailand. It is also a regulated or a controlled substance in Finland, Denmark, 
Romania, Germany, and New Zealand, but is still unregulated in most countries (31). In 
August 2016, the DEA announced its intention to add kratom to Schedule I of the Federal 
Controlled Substances Act (32). However, the DEA promptly withdrew the request 
following significant public outcry by users, commercial vendors and researchers, citing 




Animal studies show that peak plasma concentrations following oral dosing (20 and 
50 mg/kg) were reached at 1.3 (424 ng/mL) and 4.5 hours (700 ng/mL) (33, 34). In case 
studies following overdose or fatalities, concentrations of mitragynine in blood have been 
reported in the range 20-600 ng/mL (18, 19, 23). The distribution of mitragynine following 
a fatality involving kratom indicated concentrations of 0.23 mg/L in peripheral blood, 0.19 
mg/L in central blood, <0.05 mg/L in vitreous fluid, and 0.37 mg/L in urine (35).  
The vast majority of published reports describe the identification of mitragynine 
from plant material rather than biological fluids using either gas chromatographic (GC) or 
liquid chromatographic (LC) based techniques (36). Phillip was the first to describe the 
identification of kratom and its metabolites in urine using gas chromatography-mass 
spectrometry (GC-MS). However, due to the polar nature of the drug and its metabolites, 
derivatization was required and the limit of detection of the method was relatively high (50 
ng/mL) (37). Lu was the first to describe the use of LC tandem mass spectrometry (LC-
MS-MS) for the identification of mitragynine in urine, with enhanced sensitivity (38). 
Although LC-MS-MS procedures have been the most widely reported to date, none of the 
LC-based methods have utilized isotopically labelled internal standards or validated 
methods for forensic use (39). 
In a study involving urine from fifty recreational kratom users, mitragynine 
concentrations ranged from 1 to 50,000 ng/mL (40). A subsequent controlled dosing study 
in humans indicated that elimination of unchanged drug in urine was relatively limited, 
accounting for only 0.14% of the total dose (5). For this reason, analytical methods capable 
of detecting low ng/mL concentrations are desirable in forensic investigations, because 
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specimen collection is sometimes delayed. Additionally, the identification of other 
Mitragyna alkaloids in a biological sample could potentially identify kratom usage.  
In this report, we describe the simultaneous identification of mitragynine (MG), 7-
hydroxymitraginine (7-MG-OH), speciogynine (SG), speciocilliatine (SC), and 
paynantheine (PY) in urine using liquid chromatography-quadrupole/time of flight mass 
spectrometry (LC-Q/TOF MS). Following careful optimization to eliminate problematic 
adduct ions and separate regioisomers, the method was validated in accordance with 
generally accepted guidelines in forensic toxicology (39). 
Experimental 
Chemicals and reagents 
Reference standards for mitragynine, 7-hydroxymitragynine, mitragynine-D3, and 
7-hydroxymitragynine-D3 were purchased from Cerilliant (Round Rock, TX USA). 
Reference standards for paynantheine and speciociliatine were purchased from Chromadex 
(Irvine, CA, USA) and speciogynine was provided by the National Center for Natural 
Products Research (NCNPR) at the University of Mississippi, (University, MS, USA). 
Reference standards were purchased as methanolic standards with the exception of 
paynantheine, speciociliatine and speciogynine (solids). 7-Hydroxymitragynine, which is 
known to be unstable, was purchased in ammoniated methanol (1% concentrated 
ammonium hydroxide in methanol, v/v) and stored at -80oC. All working standards or 
mixtures containing 7-MG-OH (or its deuterated analog) were also prepared and stored 
accordingly, prior to use. Pooled drug-free urine was preserved with 1% preserved with 
sodium fluoride (w/v). Unless otherwise stated, solvents and inorganic reagents were LC 
or ACS grade, respectively. Concentrated ammonium hydroxide, ethyl acetate, hexane, 
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concentrated hydrochloric acid, and methanol (LCMS grade) were obtained from J.T. 
Baker (Center Valley, MA, USA).  Acetonitrile (LCMS grade) was obtained from Fisher 
Scientific (Fair Lawn, NJ, USA). Glacial acetic acid was obtained from Mallinckrodt 
Chemicals (St. Louis, MO, USA) and ammonium acetate (LCMS grade) was obtained from 
Sigma-Aldrich (St. Louis, MO, USA Deionized water was purified using a Millipore 
Direct-Q®UV Water Purification system (Billerica, MA, USA). PolyChrom ClinII 3 cc 
(35 mg) solid phase extraction (SPE) columns were obtained from SPEware (Baldwin Park, 
CA, USA). 
Instrumentation 
Nitrogen was generated using a Genius 3040 nitrogen generator (Peak Scientific, 
Billerica, MA, USA). SPE was performed using a J. T. Baker vacuum manifold and 
extracts were evaporated to dryness under nitrogen using a TurboVap LV®concentration 
workstation (Caliper Life Sciences, Hopkinton, MA, USA). After the samples were 
reconstituted, they were centrifuged using an Allegra™ X-22 Centrifuge (Beckman 
Coulter, Indianapolis, IN, USA). An Agilent Technologies 6530 LC-Q/TOF-MS (Agilent 
Technologies, Santa Clara, CA, USA) equipped with an Agilent 1290 Infinity autosampler 
was used to analyze samples. Separation was achieved using an Agilent Technologies 
Series 1200 LC system equipped with an Agilent Poroshell 120 EC-C18 column (2.1 × 100 
mm, 2.7 µm) and an Agilent Poroshell 120 EC-C18 guard column (2.1 × 5 mm, 2.7 µm) 
in a thermostatically controlled column compartment (35oC). 
The optimum mobile phase consisted of 5 mM ammonium acetate solution (A) and 
acetonitrile (B). A flow rate of 0.4 mL/min was maintained using the gradient elution 
profile as follows: 47% B (0–0.5 min), to 90% B (0.5–10 min), followed by re-
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equilibration. The total acquisition time was 12 min and the target compounds eluted 
between 1.9 mins and 6 mins. The LC-Q/TOF-MS was equipped with an ESI source 
(positive mode) with Jet Stream technology under the following conditions: drying gas 
(N2), 13 L/min; drying gas temperature, 350
oC; nebulizer, 45 psi; sheath gas temperature, 
400oC; nitrogen sheath gas flow, 12 L/min; capillary voltage, 4000 V; nozzle voltage, 0 V; 
fragmentor, 150 V; skimmer, 65 V. Agilent MassHunter software was used for acquisition, 
qualitative and quantitative analysis. Following optimization of collision induced 
dissociation (CID) voltages, a minimum of two transition ions were selected using targeted 
MS/MS acquisition. Precursor and product ions, collision energies, retention times and the 
internal standard for each drug are summarized in Table 2.1. Precursor ions were selected 
in the quadrupole using a 1 Da window. Data was acquired using a mass range of 100–
1000 Da, with a MS scan rate of 8 spectra/s and a MS/MS Scan rate of 3 spectra/s. During 
the selection of product ions, fragments were structurally identified and significant 





















Table 2.1: Transition ions, collision energies (CE), retention time (RT), and internal 
standard (IS) selection. Quantitation ions are underlined and ion ratios (relative to the 
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Preparation of standards and reagents 
Working standards containing all five target compounds were prepared in 
ammoniated methanol at 5, 0.5, and 0.05 µg/mL for the fortification of urine. The combined 
internal standard solution consisted of MG-D3 and 7-MG-OH-D3 in ammoniated methanol 
at 2 µg/mL. Ammoniated methanol was routinely prepared from concentrated ammonium 
hydroxide in methanol (1%, v/v). The elution solvent which was prepared daily, consisted 
of concentrated ammonium hydroxide in ethyl acetate (2%, v/v). 
Urine extraction 
Internal standard solution (50 µL) was added to 1.0 mL urine to achieve a final 
concentration of 100 ng/mL. Urine was acidified with 2 mL of 1 M hydrochloric acid and 
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briefly vortexed. Samples were transferred to SPE columns and allowed to flow through 
under gravity or sufficient vacuum to maintain constant flow (approximately 1 mL/min). 
Columns were rinsed with 1 mL deionized water followed by 1 mL of 1 M acetic acid. 
After drying columns for five minutes at full vacuum, samples were washed using 1 mL 
aliquots of hexane, ethyl acetate and methanol. MG, 7-MG-OH, PY, SC, and SG were 
eluted using 1 mL of elution solvent. Samples were then evaporated to dryness under 
nitrogen at 50oC. Extracts were reconstituted in 25 µL of a 50:50 mixture of Mobile Phase 
A/B, briefly vortexed, and then centrifuged at 2500 rpm for 20 mins. After centrifugation, 
1 µL was injected onto the LC-Q/TOF-MS for analysis.  
Assay validation 
Assay performance was evaluated in terms of extraction efficiency, calibration 
model, precision, bias, limit of detection (LOD), limit of quantification (LOQ), matrix 
effects, interference, ion suppression, and carryover in accordance with published 
recommendations (39). The extraction efficiency in urine was determined at 250 ng/mL by 
direct comparison of extracted and non-extracted samples. Samples containing internal 
standard were extracted in the presence and absence of the target compounds. Samples 
extracted without target compounds were fortified with equivalent drug post-extraction 
(prior to evaporation and reconstitution). Analytical recovery was calculated by comparing 
the relative peak area (drug/IS) for extracted samples (n = 6) with the mean relative peak 
area for the non-extracted samples (n = 6).  
Limits of detection and quantitation were established using drug-free urine fortified 
with target analytes. Three sources of drug-free matrix were analyzed in duplicate over 
three independent runs. The LOD was the lowest concentration of drug that produced a 
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reportable result (signal to noise (S/N) ratio of 3:1 or more; retention time ± 2% of the 
standard; ion ratios ± 20%). The LOQ was determined contemporaneously and was defined 
as the lowest concentration of drug to produce a quantitative value within 20% of the 
expected value, a S/N ratio of 10:1 or more, retention time ± 2 % of the standard, ion ratios 
within 20%, and acceptable precision and bias. Precision and bias was evaluated at 5, 200 
and 400 ng/mL using pooled fortified matrix (in triplicate), at three concentrations (low, 
medium,high), over five runs. Within-run precision was calculated for each concentration 
(n = 3) over each of the five assays. Between-run precision was calculated for each 
concentration over all five days (n = 15). Bias was evaluated contemporaneously with 
precision using the same concentrations over five days. Tolerance for bias and precision 
was ± 20%. 
The calibration model was established using nine non-zero calibrators (2, 5, 10, 25, 
100, 200, 300, 400, and 500 ng/mL) over five independent runs. Calibration models were 
evaluated using the coefficient of determination (R2), standardized residual plots and the 
F-test to determine the significance of the quadratic term (α = 0.05). Interferences 
associated with the biological matrix, isotopically labeled internal standards, common 
drugs and structurally related compounds were systematically evaluated. Matrix 
interferences were evaluated using ten drug-free urine samples from independent sources 
in the absence of internal standard. Ion contributions arising from the use of stable isotope 
internal standards were evaluated by fortifying drug-free urine with internal standard (100 
ng/mL) and monitoring the signal of the target analytes. In a similar fashion, ion 
contributions associated with highest calibrator (500 ng/mL) were evaluated in the absence 
of internal standard.  
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Drug interferences were evaluated using thirty common drugs and other therapeutic 
drugs of significance. A 10 to 100-fold excess of interferent (relative to the target drug) 
was routinely employed for interference testing. The negative control consisted of drug-
free urine fortified with 1,000 ng/mL of interferent. Positive controls contained target 
analytes and interferents at 10 ng/mL and 1,000 ng/mL respectively (100X), and 50 ng/mL 
and 500 ng/mL (10X). Matrix effects were quantitatively assessed using post-extraction 
addition at two concentrations (5 ng/mL and 400 ng/mL). Ten drug-free matrices from 
independent sources (n = 2) were extracted in the absence of drug and fortified with drug 
post extraction. Ion suppression or enhancement was calculated by comparing the mean 
peak areas of drug in matrix with the drug in mobile phase (no matrix). Carryover was 
assessed by analyzing a negative control immediately following the injection of a high 
calibrator (500 ng/mL). Carryover was present if the analyte met the detectable reporting 
criteria (signal to noise ratio of 3:1 or more, retention time ± 2% and ion ratios within 20% 
of expected).  
Results and discussion 
During method development, significant emphasis was placed on the 
chromatographic separation of structural isomers (MG, SC and SG) and the elimination of 
adducts. To this end, several mobile phase systems were evaluated. 7-Hydroxymitragynine 
(m/z 415) has a tendency to form a very prominent water adduct (m/z 433), particularly 
when formic acid (0.1%) is used as a mobile phase additive (Figure 2.2). Adducts are 
relatively common in LC-MS analysis, but are known to reduce both sensitivity and 
reproducibility. Adduct formation was previously reported for Mitragyna alkaloids by 
Kikura-Hanajiri, who integrated the adduct into their method, rather than removing it (41). 
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In our study, traditional means to eliminate the adduct by modifying source conditions 
were unsuccessful. Mobile phase additives (formic acid and ammonium formate) at 
different concentrations and in combination were also evaluated without success.  In the 
fully optimized method described here, it was possible to completely eliminate the water 
adduct described in other methods using 5mM ammonium acetate. 
Figure 2.2: Prominence of water adduct (m/z 433) for 7-hydroxymitragynine (m/z 415) in 
the presence of mobile phase containing formic acid (0.1%). Mitragynine (m/z 399) is also 
shown. 
 
The chromatographic separation of structural isomers (mitragynine, speciociliatine 
and speciogynine) also presents a challenge. These compounds fragment in an identical 
fashion, producing identical MS-MS spectra (Figure 2.3). The corynantheidine-type 
compounds undergo characteristic cleavage of the quinolizine ring to yield stable indole 
(m/z 174 and 190) and piperidine derivative fragments (m/z 238, 236, 226, 224). The 238 
and 236 ions result from cleavage at C5, while 226 and 224 are formed via neutral loss of 
the methoxy indole group between C5 and nitrogen. HRMS allowed product ions to be 
structurally identified with mass accuracies within 0.5 ppm (Table 2.2). Using the 
optimized procedure, complete chromatographic resolution of the five Mitragyna alkaloids 












Table 2.2: Proposed fragmentation and mass accuracy of Mitragyna alkaloids using positive 











C23H30N2O4 399.2269 399.2278 -0.2 
C11H12NO 174.0911 174.0913 -0.1 
C12H20NO3 226.1433 226.1436 -0.1 
C13 H20NO3 238.1431 238.1438 -0.3 
7-
Hydroxymitragynine 
C23H31N2O5 415.2225 415.2227 0.0 
C11H12NO2 190.0862 190.0863 -0.1 
C12H20NO3 238.1434 238.1438 -0.2 
C13H20NO3 226.1434 226.1436 -0.1 
Speciociliatine 
C23H30N2O4 399.2270 399.2278 -0.2 
C11H12NO 174.0912 174.0913 -0.1 
C12H20NO3 226.1434 226.1436 -0.1 
C13 H20NO3 238.1432 238.1438 -0.3 
Speciogynine 
C23H30N2O4 399.2269 399.2278 -0.2 
C11H12NO 174.0909 174.0913 -0.2 
C12H20NO3 226.1431 226.1436 -0.2 
C13 H20NO3 238.1430 238.1438 -0.3 
Paynantheine 
C23H28N2O4 397.2117 397.2122 -0.1 
C11H12NO 174.0912 174.0913 -0.1 
C12H18NO3 236.1275 236.1281 -0.3 
C13 H18NO3 224.1277 224.1281 -0.2 
 
The extraction efficiency of mitragynine from urine was 96%, and 63–96% for 
remaining alkaloids (Table 2.3). It is perhaps not surprising that the compound with the 
lowest extraction efficiency was 7-hydroxymitragynine, which is known to be highly 
unstable.  Following visual, analytical, and statistical evaluation of calibration models, a 
weighted (1/x) quadratic model was selected for all analytes. The coefficients of 
determination were above 0.99 or for all models. Upon visual assessment using residual 
plots, the data appeared to be randomly dispersed when a non-linear (quadratic) model was 
used. Statistical evaluation further indicated a weighted (1/x) curve was optimal.  
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Figure 2.4: Chromatographic separation of kratom alkaloids in a representative extract 
(200 ng/mL). Speciociliatine, 1.93 min; 7-hydroxymitragynine, 2.51 min; speciogynine, 
3.31; paynantheine, 3.76 min; mitragynine,  4.61 min. 
 
Limits of detection and quantitation were all within the range of forensic interest. 
The LOD and LOQ for mitragynine was 0.25 and 0.5 ng/mL, respectively. Limits of 
detection and quantitation for remaining alkaloids were 0.5–1 ng/mL (n = 18). Bias, 
precision and signal to noise ratios at the limits of detection and quantitation are 
summarized in Table 2.4 and extracted ion chromatograms (EICs) for all compounds at 
the limit of quantitation in urine are shown in Figure 2.5. At the limit of quantitation, bias 












Figure 2.5: Extracted ion chromatograms (EICs) in urine at the limit of quantitation. 
 
Precision and bias were also evaluated at low, medium, and high concentrations in 
triplicate over five days. Intra-assay CVs were 0.5-15.1% (5 ng/mL); 0.3-7.5% (200 
ng/mL); 0.2–6.0% (400 ng/mL) (n = 3) and inter-assay CVs over the same concentration 
ranges were 5.5-8.4%, 2.4-5.3% and 1.0-4.5% (n = 15). Bias and precision at all 
concentrations tested were within acceptable ranges (±20%) and are summarized in Table 
2.5. Interferences from matrix, isotopically labeled internal standards, and other drugs were 
systematically evaluated. No interferences were present form either matrix or isotopically 
labelled internal standards. Although current validation standards in forensic toxicology 
only require potential interferences to be evaluated qualitatively (39), the potential for 




Table 2.3: Extraction efficiencies from urine (250 ng/mL). 
Analyte 
Mean Extraction Efficiency (%) 
(n=6) 
MG 96 ± 1 
7-MG-OH 63 ± 13 
SG 79 ± 16 
SC 96 ± 9 
PY 87 ± 12 
 
No qualitative interferences were present for any of the target compounds. Even in the 
presence of 100-fold higher concentrations of interferents, all compounds met reporting 
criteria.  However, a quantitative interference was observed for speciociliatine, whereby 
the concentration was not within 20% of the expected value. This interference was 
attributed to dextromethorphan, which coeluted with SC. Although the two drugs do not 
share identical transitions, the excess of dextromethorphan (relative to SC), decreases the 
ionization efficiency of the compound. Although this could be mitigated by the use of an 
isotopically labelled internal standard, none are commercially available for speciociliatine 

















Table 2.4: Limits of detection and assay performance at the limit of quantitation in urine. 



















MG 0.25 0.5 0.52 ± 0.09 276:1 4.0% 16 




SG 0.5 0.5 0.50 ± 0.05 128:1 0.0% 10 
SC 0.5 0.5 0.53 ± 0.07 1750:1 6.0% 14 

















Table 2.5: Precision and bias (n=15) in urine at low (5 ng/mL), medium (200 ng/mL), and high (400 ng/mL) concentrations. 
Alkaloid 
Intra-Assay Precision (n=3, %CV) Inter-Assay Precision (n=15, %CV) Bias (n=15, %) 
5 200 400 5 200 400 5 200  400 
MG 0.5-10.9 0.3-2.8 0.2-1.1 5.5% 2.5% 1.0% 0.9 1.4 1.0 
7-MG-OH 0.6-7.0 0.5-3.4 0.5-1.6 4.4% 2.4% 1.4% 2.2 1.5 0.1 
SG 1.8-6.0 2.6-5.3 0.5-6.0 7.6% 5.2% 4.5% -3.2 6.4 -1.7 
SC 1.4-12.8 1.1-7.5 0.4-5.3 8.4% 5.3% 3.2% -1 1.9 -0.4 
PY 1.6-15.1 0.8-3.6 0.7-1.6 7.3% 2.8% 1.8% 1.2 -0.7 -0.2 
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The potential for ion suppression or enhancement was evaluated using ten 
independently sourced urine samples. Matrix effects were evaluated quantitatively using 
the post-extraction addition technique for all five analytes and two internal standards. 
Matrix effects for MG, MG-D3, SC, SG, and PY were -4-31% at 10 ng/mL, and -8-30% at 
400 ng/mL. Ion suppression was present for both 7-MG-OH and MH-OH-D3 (-60 to -15% 
at 10 ng/mL and -53 to -25% in 400 ng/mL). However, given the instability of 7-
hydroxymitragynine, quantitative reporting is not recommended. Corresponding CVs for 
SC, SG, PY, MG, and MG-D3 were 5-7% and 5-7%, respectively. However, the 
corresponding CVs for 7-MG-OH and 7-MG-OH-D3 were 30-27% and 23-25% (Table 
2.6). Matrix effects and associated CVs for mitragynine, speciociliatine, paynantheine and 
speciogynine were well-within tolerable limits (39) . No carryover was present at 500 
ng/mL for MG, 7-MG-OH, SC, and SG. Carryover of PY was present at 500 ng/mL, 
although given the relative abundance of this alkaloid in kratom, concentrations in this 



















Table 2.6: Matrix effect (%) and associated CVs in urine (10 and 400 ng/mL). 
Alkaloid 
CV (%) n=10 Matrix Effect (%) 
10 ng/mL 400 ng/mL 10 ng/mL 400 ng/mL 
MG 6% 8% 16% 15% 
7-MG-OH 27% 23% -45% -39% 
SG 7% 8% 19% 11% 
SC 7% 5% 8% 1% 
PY 6% 8% 7% 15% 
MG-D3 
 
5% 7% 18% 19% 
MG-D3 20% 25% -41% -38% 
 
Conclusion 
Kratom is a novel psychoactive substance of natural origin that is becoming 
increasingly popular as a drug of abuse. In light of the current epidemic of opioid use in 
the United States and the tendency of users to substitute kratom for other mu receptor 
agonists, kratom is of growing concern. Increased vigilance among the clinical and forensic 
community in needed. The availability of analytical methods capable of detecting analytes 
at sufficiently low concentration will advance our understanding of both prevalence and 
trends associated with its use. The methods presented here offer distinct advantages over 
previously published work. Simultaneous identification of all five alkaloids, including 
isomers of mitragynine was achieved using solid phase extraction and LC-Q/TOF-MS 
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analysis at low to sub-ng/mL concentrations. Using deuterated internal standards, the 
method was fully validated for forensic use (39).  
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Mitragyna speciosa (Kratom) has emerged as a recreational drug and a substance of 
medicinal intrigue. Although the drug was initially used recreationally for its sedating and 
euphoric effects, more recently its use has been associated with the non-medically 
supervised treatment of opioid abstinence syndrome. Mitragynine is the principal 
pharmacologically active alkaloid in kratom. Although metabolites of mitragynine have 
been identified, the cytochrome P450 (CYP450) enzymes responsible for its 
biotransformation are still under investigation. The goal of this study was to contribute 
further knowledge regarding CYP450 activity as it relates to mitragynine. Recombinant 
cytochrome P450 enzymes (rCYPs) were used to investigate the isoforms involved in its 
metabolism.  Biotransformational products were identified using liquid chromatography-
quadrupole/time of flight-mass spectrometry (LC-Q/TOF-MS).  Four rCYP enzymes 
(2C18, 2C19, 2D6 and 3A4) were found to contribute to the metabolism of mitragynine. 
7-Hydroxymitragynine (which has an affinity for the mu opioid receptor >10-fold that of 
morphine) was produced exclusively by 3A4. 9-O-Demethylmitragynine, the most 
abundant metabolite in vitro (and the most prevalent metabolite in urine among kratom 
users) was produced by 2C19, 3A4 and 2D6. 16-Carboxymitragynine was produced by 
rCYPs 2D6, 2C19 and 2C18. 2C19 was solely responsible for the formation of 9-O-
demethyl-16-carboxymitragynine. In vitro rCYP studies were compared with phase I 
metabolites in urine from cases involving mitragynine.  




CYP450-Mediated Metabolism of Mitragynine and Investigation of Unhydrolyzed 
Phase I Metabolites in Human Urine 
Introduction 
Kratom is a psychoactive drug present in the leaves of the Korth tree (Mitragyna 
speciosa) (1). Traditionally, kratom leaves have been chewed by the natives of Thailand to 
relieve pain and as an energy stimulant (2). It has also been reported to have been used as 
an opium substitute (3). In the Western world kratom is predominately used as a 
recreational drug and more recently, for the non-medically supervised treatment of opioid 
abstinence syndrome (1, 3). In addition, since kratom is widely available for sale on the 
Internet and lacks regulatory control, usage has increased dramatically in Western Europe 
and the United States (4).  According to the National Forensic Laboratory Information 
System (NFLIS), mitragynine seizures in the U.S. have been on the rise since 2010 (5-7). 
Kratom is a controlled substance in Australia, Malaysia, Myanmar (Burma), Thailand, 
Denmark, Romania, Sweden, Poland, Latvia, Lithuania, and New Zealand, but is still 
unregulated in most countries (8).  
In August 2016, the Drug Enforcement Administration (DEA) announced its 
intention to add kratom to Schedule I of the Federal Controlled Substances Act (9). 
However, the DEA promptly withdrew the request following significant public outcry by 
users, commercial vendors and researchers, citing the need for the therapeutic effects of 
the drug to be more thoroughly explored prior to any scheduling action. In November of 
2017, the Federal Drug Administration (FDA) issued a public health advisory related to 
mounting concerns regarding the risks associated with the use of kratom (10). 
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Forty-four compounds have been isolated from the leaves of M. speciosa (1). These 
include both indole and oxindole alkaloids. Mitragynine is the predominant 
pharmacologically active compound in kratom, and accounts for 66% of the total alkaloids 
present (11).  Mitragynine’s structure was defined in 1963 and was later confirmed through 
crystallographic studies in 1965 (12, 13). It is a corynanthe-like alkaloid, structurally 
similar to yohimbine. It is comprised of an indole aromatic ring (A and B) attached to two 
piperidine rings (C and D) (Figure 3.1). The piperidine moiety is believed to be central to 
its opioid activity (1) and the methoxy-moiety at the positions C16 and the C9 have an 
open ring with substitution (14).   
Figure 3.1: Chemical structure of mitragynine.  
 
Kratom elicits both stimulant and sedative effects in a dose-dependent manner. Low 
doses of kratom are reported to produce central nervous system stimulant effects similar to 
cocaine, and high doses are reported to produce opiate-like effects (4). As such, it is 
considered an “atypical opioid” due to its activity at both opioid and non-opioid 
(monoamine transporter) receptors. Mitragynine acts as partial agonist at mu opioid 
receptors and a competitive antagonist at both kappa and delta receptors (15). The dose-
dependent effects of kratom have been well documented. Reported effects range from 
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increased energy and alertness, sociability and heightened libido at low doses, to 
drowsiness, confusion, seizures, loss of consciousness, coma and death at high doses (4, 
16-24). Regular kratom use is associated with drug dependency and withdrawal (25, 26). 
A study by Elliot et al. reported that in a series of 293 habitual kratom users, physical 
withdrawal effects included difficulty sleeping, muscle spasms, fever, watery eyes or nose 
and diarrhea (27). Psychological symptoms associated with withdrawal include 
restlessness, tension, anger, sadness and nervousness. 
There are relatively few studies detailing the metabolism of mitragynine, although 
recently there has been renewed interest in this area. An early study by Zarembo in 1974 
used Helmin-thosporum sp. to determine that oxidation and hydroxylation were the 
primary metabolic routes (28). Mitragynine is known to undergo hepatic metabolism (16). 
Philipp et al. conducted the first comprehensive in-vivo study to date (11).  Rats were 
administered a single 40 mg/kg dose of mitragynine by gastric intubation. Results were 
compared with human urine from known kratom users. They reported that phase I 
metabolism involved the hydrolysis of the methylester group at C16, demethylation of the 
methoxy groups at C9 and C17 positions, followed by oxidative and reductive 
transformations to produce carboxylic acid and alcohol derivatives. Given these 
transformative pathways, it is not surprising that mitragynine is reported to undergo 
extensive phase II metabolism to produce both glucuronide and sulfate conjugates. As 
many as seven phase I metabolites were identified in rat urine, and six in human urine 
following enzymatic hydrolysis (11). More recently a study by Lee et al. reported a 
quantitative liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure for 
the identification of mitragynine, 16-carboxymitragynine, 9-O-demethylmitragynine and 
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glucuronides in human urine. They also reported that sulfate-conjugated metabolites were 
resistant towards enzyme hydrolysis (29).  
Although some progress has been made identifying the metabolites of mitragynine 
in animal studies and in human specimens, insight regarding the specific enzymes 
responsible for its metabolism is just beginning to emerge. Most recently Kamble et al. 
used human liver microsomes (HLMs) and S9 fractions to identify metabolic pathways of 
mitragynine (30).  They concluded that the major metabolites of mitragynine included four 
oxidative species (including 7-hydroxymitragynine) and one demethylated metabolite (9-
O-demethylmitragynine). It was hypothesized that mono-oxygenation of the three 
remaining species occurred on the indolequinolizine moiety, although structural 
elucidation was not possible. Using rCYPs they concluded that CYP3A4 was the 
predominant cytochrome P450 isoform responsible for metabolism, with minor or 
negligible contributions from CYP 2D6, 2C9 and 2C19. Focusing exclusively on 7-
hydroxymitragynine, Kruegel et al. showed that this metabolite was produced using both 
human and mouse liver microsomes (31). This is important given the increased 
pharmacological activity of 7-hydroxymitragnine, reported to have a ten-fold greater 
affinity for the mu opioid receptor compared to morphine  (32). It has been suggested that 
first pass metabolism of mitragynine could explain why the drug has been shown to be 
paradoxically more potent as an analgesic when administered via oral and intraperitoneal 
routes, compared with subcutaneous injection (31). The heightened pharmacodynamic 
response of 7-hydroxmitragynine might explain why it was reported to have a high 
potential for abuse (33). Although 7-hydroxymitragynine is a minor alkaloid in Mitragyna 
speciosa, these findings suggest that routes of administration, or CYP isoform activities 
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that favor its formation, could have increased potential for addiction. Pharmacological 
activity has not been reported for other mitragynine metabolites has not been reported.   
Understanding the specific isoforms involved can provide valuable information 
regarding the potential for adverse consequences due to genetic polymorphisms or drug-
drug interactions. Published case reports suggest that multiple drug use is common among 
kratom users (Table 3.1). In addition, Anwar et al. reported that 35% of reports to poison 
centers involving kratom admitted to poly-drug use. Ethanol, botanical drugs, 
benzodiazepines, narcotics, and acetaminophen were the most commonly reported (46). In 
a recent report involving kratom from the Centers for Disease control (CDC), fentanyl and 
its analogs were the most commonly detected substances (65%) among a series of fatalities  
in twenty-seven states (47). Heroin was the second most frequently detected substance 
(33%), followed by benzodiazepines (22%), prescription opioids (20%) and cocaine 
(18%). Concomitant use of kratom with other opioids has been reported previously (1, 3). 
Given the extensive poly-drug use associated with kratom, additional studies regarding the 






Table 3.1: Poly-drug use among published kratom case reports.  
Investigation Matrix Other Compounds Detected Reference 
Hospitalization 
(n=1) 
Urine Cannabinoids (not specified); Oxycodone; Tricyclic antidepressants (not specified) (18) 
Fatality (n=1) Blood 7-Aminoclonazepam; Dextromethorphan; Diphenhydramine;  Temazepam 
 
(22) 
Fatality (n=9) Blood Alimemazine; Alprazolam; Amphetamine; Buprenorphine; Citalopram; O-
Demethyltramadol; Desmethylalimemazine; O-Desmethylvenlafaxine; Diazepam; 
Ethanol; Fluoxetine; Mirtazapine; Nordiazepam; Norfluoxetine; Olanzapine; 
Phenazon;  Pregabalin; Tetrahydrocannabinol; Venlafaxine;  Zopiclone  
(34) 
Fatality (n=1) Blood; 
Tissues 
Acetaminophen; Morphine; Promethazine; Propylhexedrine  (17) 
Fatality (n=1) Blood; 
Urine 
O-Demethylvenlafaxine; Diphenhydramine; Ethanol; Mirtazapine; Venlafaxine (35) 
Antemortem Drug 
Screen (n=1) 
Urine O-Desmethyltramadol (36) 
Fatality (n=1) Blood; 
Urine 
Bupropion; Delorazepam; 3-Methoxyphencyclidine; Paroxetine (37) 
Fatality (n=1) Blood; 
Urine 
Citalopram; Lamotrigine; Zopiclone  (38) 
Fatality (n=1) Urine Codeine (39) 
Hospitalization 
(n=1) 
Urine O-Demethyltramadol (40) 
Impaired Driver 
(n=1) 











Investigation Matrix Other Compounds Detected Reference 
Fatality (n=1) Blood; 
Urine 
Acetaminophen; Amphetamine; Codeine; Etizolam; Fluoxetine; Gamma-
Hydroxybutyric acid; Lorazepam; Methamphetamine; 3-
Methylenedioxyamphetamine; 3,4-Methlenedioxymethylamphetamine;  2-
Methylmethcathinone; 6-Monoacetylmorphine; Morphine; Olanzapine; 
Pipamperone; Pregabalin; Pseudoephedrine; Quetiapine; Triazolam  
(43) 
Fatality (n=1) Blood; 
Tissues 
Alprazolam, Etizolam; Fentanyl; Labetalol; Laudanosine; Lorazepam; Metoprolol;  
Mirtazapine; Morphine; Nicardipine; Norfentanyl; Normirtazapine; Norsertraline; 
Ofloxacine;  Sertraline; U-47700 
(44) 
Fatality (n=1) Blood Quetiapine; Valproic Acid (45) 
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A recent study by Kong et al. reported that methanolic extracts of kratom were 
potent inhibitors of 3A4 and 2D6 (48). Another study by Hanapi et al. reported that 
mitragynine inhibits 2C9, 2D6 and 3A4 (49).  Additionally, a study by Lim et al. reported 
that mitragynine was a significant in-vitro 1A2 inducer, weak 3A4 inducer, and a weak 
3A4 enzyme inhibitor (50). Studies have also shown that mitragynine and 7-
hydroxymitragynine could have potential drug-drug interactions with drugs that are P-
glycoprotein substrates and can activate the pregnane X receptor which could then lead to 
an increase in the activity of 3A4, 1A2, and P-glycoprotein (51, 52).  
In this study, recombinant CYP450 isoenzymes were used to investigate the in vitro 
metabolic pathways of mitragynine. While this approach is useful, in vitro techniques do 
not fully emulate the complexity of metabolism in a living system. Nevertheless, given the 
increase in kratom use in the United States, enhanced knowledge regarding its 
biotransformation and the disposition of active metabolites can provide insight regarding 
the pharmacological and toxicological effects of this drug.  
Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q/TOF-MS) is 
particularly useful for metabolite identification due to its mass accuracy and sensitivity 
(53).  We previously reported a quantitative assay for mitragynine and related alkaloids 
using high resolution mass spectrometry (54).  In this report, a modified assay was used to 
identify specific isoforms responsible for the metabolism of mitragynine. Several 
cytochrome P450 isoenzymes (2C8, 2C9, 2C19, 2D6, and 3A4) are known to be active in 
phase I metabolism for opioids (55-58) and other drugs. These and other recombinant 
CYPs (2C19, 3A4, 1A2, 2D6, and 2C9) were investigated as part of this study. Inhibition 
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studies were used to confirm CYP activity, and urine samples from sixteen fatalities were 
evaluated to identify metabolites of interest.  
Methods 
Chemicals and reagents  
Reference standards for mitragynine, 7-hydroxymitragynine, mitragynine-D3, 
ketoconazole, and fluvoxamine were purchased from Cerilliant in methanolic solutions 
(Round Rock, TX, USA). 7-Hydroxymitragynine, which is unstable, was purchased in 
ammoniated methanol (1% concentrated ammonium hydroxide in methanol, v/v) and 
stored at -80oC. Unless otherwise stated, solvents and inorganic reagents were LC or ACS 
grade, respectively. Acetonitrile (LC-MS grade) was obtained from Fisher Scientific (Fair 
Lawn, NJ, USA) and ammonium acetate (LC-MS grade) was obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Recombinant human cytochrome P450 (rCYP) isoenzymes 
expressed in E. coli (bactosomes) were obtained from Xenotech, LLC (Kansas City, KS, 
USA). Reduced nicotinamide adenosine di-phosphate (NADPH) regenerating system 
solution A (40 Ug/mL glucose-6-phosphate dehydrogenase in 5 mM sodium citrate), 
solution B (26 mM NADP+, 66 mM glucose-6-phosphate and 66 mM magnesium chloride 
in aqueous solution) were obtained from Corning (Glendale, AZ, USA).  All other 
chemicals and reagents (analytical grade) were obtained from VWR (Radnor, PA, USA). 
Deionized water was purified using a Millipore Direct-Q®UV Water Purification system 
(Billerica, MA, USA). Pooled drug-free urine used for the preparation of calibrators and 
controls, was preserved with 1% sodium fluoride (w/v) and PolyChrom ClinII 3 cc (35 mg) 




Nitrogen was generated using a Genius 3040 nitrogen generator (Peak Scientific, 
Billerica, MA, USA). An Agilent Technologies 6530 LC-Q/TOF-MS (Agilent 
Technologies, Santa Clara, CA, USA) equipped with an Agilent 1290 Infinity autosampler 
was used to analyze samples. Separation was achieved using an Agilent Technologies 
Series 1200 LC system equipped with an Agilent Poroshell 120 EC-C18 column (2.1 × 100 
mm, 2.7 µm) and an Agilent Poroshell 120 EC-C18 guard column (2.1 × 5 mm, 2.7 µm) 
in a thermostatically controlled column compartment (35oC). The mobile phase consisted 
of 5 mM ammonium acetate solution in deionized water (A) and acetonitrile (B). 
For the identification of metabolites, a flow rate of 0.4 mL/min was maintained 
using the gradient elution profile as follows: 10% B (0–0.5 min), 10-90% B (0.5–10 min), 
followed by re-equilibration. The total acquisition time was 12 min and the metabolites 
eluted between 1.3 min and 7.3 min. The LC-Q/TOF-MS was equipped with an ESI source 
(positive mode) with Jet Stream technology under the following conditions: drying gas 
(N2), 13 L/min; drying gas temperature, 350
oC; nebulizer, 45 psi; sheath gas temperature, 
400oC; nitrogen sheath gas flow, 12 L/min; capillary voltage, 4000 V; nozzle voltage, 0 V; 
fragmentor, 150 V; skimmer, 65 V. Data was acquired in auto MS/MS (full scan) mode 
using a preferred list of suspected metabolites based upon previously published reports 
(11). Agilent MassHunter software was used for acquisition and qualitative analysis. Mass 
spectra were generated using collision induced dissociation (CID) energies of 25 and 28 
eV. Data was acquired using a mass range of 100–1000 Da, with a MS scan rate of 8 
spectra/s and a MS/MS Scan rate of 3 spectra/s. During the selection of potential 
metabolites, fragments were structurally identified, and mass accuracies were evaluated.  
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Mitragynine was quantitatively determined using a previously validated method 
(54). Briefly, the LC-Q/TOF-MS configuration described above was used with the 
following gradient elution profile: 47% B (0–0.5 min), 47-90% B (0.5–10 min), followed 
by re-equilibration. Source conditions, flow rate and scan rates were as described above. 
Targeted MS/MS acquisition was performed for mitragynine (m/z 399.2278 > 174.0913, 
226.1438, 238.1438) using mitragynine-D3 as the internal standard. Quantitation ions are 
shown in bold and the collision energy was 30 eV.  
Identification of CYP450 isoenzyme activity 
Each rCYP isoenzyme (1A2, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6 and 3A4) was 
incubated separately to evaluate individual metabolic activity towards mitragynine.  Fully 
optimized incubations were performed at 37°C in the presence of 50 µM mitragynine and 
25 pmol/mL rCYP isoenzyme in accordance with manufacturer recommendations and 
previously published protocols (59). The incubation mixture also contained 100 mM 
potassium phosphate buffer (pH 7.4), 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 
mM magnesium citrate and 0.4 U/mL glucose-6-phosphate dehydrogenase.  Incubation 
mixtures were initially assayed at t = 0, 60, 120, 180 and 240 minutes. Each 25 µL aliquot 
was quenched using an equal volume of ice cold acetonitrile containing 5 µM internal 
standard (mitragynine-D3).  The solution was centrifuged at 10,000 g at 4°C for 3 minutes.  
The supernatant was mixed with an equal volume of a 50/50 mixture of mobile phase A/B 
and 1 µL was injected onto the LC-Q/TOF-MS. Control and blank samples were included 
in each assay. For the controls, rCYP isoenzymes were replaced with Xenotech control 
bactosomes, and for the blank (no drug) samples, mitragynine was replaced with phosphate 
buffer. Since multiple time stops were performed, a single aliquot of microsomal 
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incubation mixture was removed at 60, 120, 180 and 240 minutes. However, since 7-
hydroxymitragynine was a novel metabolite at the time of this study, additional 
experiments to confirm the activity of CYP 3A4 were performed using six replicates.  
Inhibition studies 
For the inhibition study, active rCYPs (2C18, 2C19, 2D6, and 3A4) were incubated 
side by side, in the presence and absence of inhibitor (n=4).  Conditions were identical to 
those described earlier, with the exception of the addition of the inhibitor. Ketoconazole 
(20 µM) was used for rCYPs 2C9, 2C18, 2C19 and 3A4 and fluvoxamine (20 µM) was 
used for rCYP 2D6.  Inhibitor concentrations were selected based on Ki values and 
previously published work (59). For the inhibition studies, aliquots were removed at t = 0 
and 120 minutes and samples were analyzed using LC-Q/TOF-MS. For 7-
hydroxymitragynine, 6 replicates were utilized to remain consistent with the previous 
incubation study.  
Metabolite identification 
Potential metabolites were first identified by observing changes in each rCYP 
incubation mixtures over time.  Using the optimized LC separation, the abundance of each 
potential metabolite was normalized to the internal standard (mitragynine-D3). 
Measurement of the relative peak area (RPA) minimized random errors associated with 
volumetric steps, injection volume and ionization efficiency.  The exact masses of 
predicted metabolites were monitored using a preferred list, and mass spectra of 
compounds that appeared to increase over time were further investigated over a range of 
CID voltages. Since many of these metabolites lack a certified reference standard, 




Mitragynine and potential metabolites were identified in 16 postmortem urine 
samples in accordance with an IRB-approved study (Sam Houston State University, IRB#: 
2016-05-29903). Mitragynine was quantitatively determined using a previously validated 
method (54) and metabolites, including those identified in the in vitro study, were 
investigated qualitatively.  
Mitragyna alkaloids were isolated from urine using solid phase extraction (SPE) as 
previously described (54). Briefly, internal standard solution was added to 1 mL urine to 
achieve a final concentration of 100 ng/mL. Following acidification with 2 mL of 0.1 M 
hydrochloric acid, samples were transferred to PolyChrom Clin II SPE cartridges. 
Following the addition of 1 mL deionized water and 1 mL of 1 M acetic acid, columns 
were dried for five minutes at full vacuum. Additional washes using 1 mL aliquots of 
hexane, ethyl acetate and methanol were performed prior to elution with 1 mL ethyl 
acetate/concentrated ammonium hydroxide (98:2). Extracts were evaporated to dryness 
under nitrogen at 50oC and reconstituted in 25 µL of 1:1 Mobile Phase A/B prior to 
injection (1 µL) on the LC-Q/TOF-MS. The limits of detection and quantitation for 
mitragynine were 0.25 ng/mL and 0.5 ng/mL and the calibration range of the assay was 0.5 
-500 ng/mL.  
Due to the high concentration Mitragyna alkaloids in actual case samples, specimen 
dilution was necessary. Using the previously published procedure, dilution integrity for 
urine was evaluated using 2, 10 and 100-fold dilutions of matrix in 0.1 M HCl. The total 
volume of diluted urine was 1 mL and the SPE was performed as described earlier.  The 
initial concentration of mitragynine prior to dilution was 400 ng/mL and quantitative 
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results within ±20% of the expected concentration were deemed acceptable for extracts 
analyzed in triplicate.  
Mitragynine metabolites were also investigated in postmortem urine samples using 
the extraction protocol described above. However, in order to improve the detectability of 
the metabolites identified in the in vitro study, urine was not diluted prior to extraction. 
Metabolites were acquired using the auto MS/MS LC-Q/TOF-MS assay described for 
metabolite identification above. In the absence of commercially available metabolite 
reference standards, rCYPs (3A4, 2D6, 2C19, and 2C18) were used to prepare 9-O-
demethylmitragynine, 16-carboxymitragynine, and 9-O-demethyl-16-carboxymitragynine 
in-situ for qualitative identification purposes. Retention times, MS/MS spectra and mass 
accuracy were used for identification purposes.  
Results and discussion 
In vitro metabolites 
Of the eight rCYPs investigated, metabolic activity was observed for 2C18, 2C19, 
2D6 and 3A4A. 9-O-Demethylmitragynine was produced by CYPs 2C19, 3A4 and 2D6 
and 16-carboxymitragynine was produced by 2D6 and 2C19. 9-O-Demethyl-16-
carboxymitragynine, which was identified in lower abundance, was attributed to 2C19 
alone, and 7-hydroxymitragynine was only produced by rCYP 3A4. Figure 3.2 
summarizes the CYP450 activity observed for mitragynine. The extracted ion 
chromatograms for representative incubation mixes at 120 min are shown in Figure 3.3 
and the associated MS/MS spectra are depicted in Figure 3.4. Molecular formula, retention 
times, exact and accurate masses are summarized in Table 3.2. Fragmentation of the 
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metabolites and mass accuracies of diagnostic ions shown in bold are also summarized in 
Table 3.2.   
Figure 3.2: Proposed biotransformational pathways of mitragynine.  
 
 
The mass fragmentation of mitragynine has been described in the literature (54, 
60). Loss of the piperidine moiety is responsible for the formation of m/z 174, which 
contains the relatively stable indole fragment, while the m/z 238 and 226 ions contain the 
nonaromatic portions of the molecule (Figure 3.5). The m/z 238 ion is formed from the 
cleavage at the C5 to form the dihydropyridine derivative with the loss of the methoxy 
indole moiety. The m/z 226 ion is formed by the neutral loss of the methoxy indole group 
between C5 and nitrogen in piperidine. Similar fragmentation patterns occur for the 
remaining metabolites to produce ions with m/z 174 and 160 corresponding to the loss of 
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the piperidine, and 238, 224, 226, and 212 resulting from the C-ring cleavage. Mass 
accuracies of the proposed metabolite fragments were within 5.4 ppm (Table 3.2). 
Although microsomal incubations were assayed at 60, 120, 180 and 240 minutes, no 
significant increases in metabolite were observed beyond 180 minutes and 7-
hydroxymitragynine plateaued by 60 minutes (Figure 3.6). The abundance of each 
metabolite was measured relative to the internal standard in the incubation mixture. The 
rate of metabolite formation was not estimated because in vitro rates of reaction using 
rCYPs do not necessarily reflect in vivo kinetics due to biological and environmental 






























Figure 3.3: Extracted ion chromatograms (120 min) of 9-O-demethyl-16-
carboxymitragynine (m/z 371.1965; 1.3 min, rCYP 2C19), 16-carboxymitragynine (m/z 
385.2122, 3.05 min, rCYP 2C19), 9-O-demethylmitragynine (m/z 385.2122, 4.6 min, rCYP 
2C19), 7-hydroxymitragynine (m/z 415.2227, 5.3 min, rCYP 3A4) and mitragynine (m/z 









Figure 3.4: MS/MS spectra of mitragynine, 9-O-demethylmitragynine, 16-
carboxymitragynine, 9-O-demethyl-16-carboxymitragynine and 7-hydroxymitragynine 





The relative contribution of each CYP towards the formation of each metabolite 
(determined by abundance, i.e. RPA) is shown in Figure 3.7. 9-O-Demethylmitragynine 
was the most abundant metabolite in the in vitro study and was produced by three 
isoenzymes (2C19, 3A4 and 2D6). This is in contrast to Kamble et al. who reported 
negligible activity for 2C19 and no activity for 2D6. This might be attributed to differences 
in reactivity between rCYP isoforms or experimental approaches (i.e. reduced incubation 
times). Nevertheless, it highlights the need for comparative studies and additional research.  
Not surprisingly, 9-O-demethyl-16-carboxymitragynine, which is formed in a step-wise 
fashion, was the least abundant and was produced by 2C19 alone. This metabolite was not 
reported by Kamble et al.  Although the relative abundance observed using recombinant 
isoforms may not reflect those observed in humans, it does provide important insight 
regarding the overall role of the CYP450 enzymes. No metabolites were observed in any 























Table 3.2: Molecular formula, retention time, and mass accuracies for mitragynine (MG), 
7-hydroxymitragynine (7-OH-MG), 9-O-demethylmitragynine (9-O-DM-MG), 16-
carboxy mitragynine (16-COOH-MG) and 9-O-demethyl-16-carboxymitragynine (9-O-
DM-16-COOH-MG). Precursor ions are shown in bold.  
 
Inhibition studies were performed to verify observed isoenzyme activity. The 
results of the inhibition study are shown in Table 3.3. Significant inhibition (>20%) was 
observed for 3A4, 2C19, 2C18, and 2D6 for all identified phase I metabolites.  Inhibition 
rates of 63-100% were observed, confirming all metabolic pathways proposed in Figure 
3.2. Although our results confirm the importance of CYP 3A4-mediated metabolism of 


















C23H31N2O4 399.2276 399.2278 -0.5 
C11H12NO 174.0907 174.0913 -3.4 
C12H20NO3 226.1431 226.1438 -3.1 




C22H29N2O4 385.2112 385.2122 -2.6 
C10H10NO 160.0750 160.0757 -4.4 
C12H20NO3 226.1428 226.1438 -4.4 




C22H29N2O4 385.2114 385.2122 -2.1 
C11H12NO 174.0909 174.0913 -2.3 
C11H18NO3 212.1278 212.1281 -1.4 





C21H27N2O4 371.1967 371.1965 0.5 
C10H10NO 160.0756 160.0757 -0.6 
C11H18NO3 212.1277 212.1281 -1.9 
C12H18NO3 224.1293 224.1281 5.4 
7-OH-MG 5.3 
C23H31N2O5 415.2221 415.2227 -1.4 
C11H12NO2 190.0865 190.0863 1.1 
C12H20NO3 226.1442 226.1438 1.8 
C13H20NO3 238.1439 238.1438 0.4 
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Figure 3.5: Fragmentation of mitragynine.  
 
 
Although in vitro assays using recombinant enzymes can identify possible 
pathways, they do not always mimic in vivo biotransformations in humans. Despite the 
convenience of in vitro studies, further in vivo studies are needed. A total of 16 urine 
samples from confirmed kratom users were evaluated. No hydrolysis step was performed 
prior to analysis. Therefore, the species identified represents free (unconjugated) phase I 
metabolites, or unstable phase II metabolites that might be hydrolyzed during exposure to 
acidic or basic conditions during the extraction.  The investigation of phase II metabolites 
and the efficiency of various enzymatic and chemical deconjugation was investigated, but 





Figure 3.6: 7-Hydroxymitragynine production by rCYP 3A4 (n=6). Data represents the 























































Figure 3.7: rCYP activity for 16-carboxymitragynine (16-COOH-MG), 9-O-
demethylmitragynine (9-DM-MG), 9-O-demethyl-16-carboxymitragynine (9-O-DM-16-
COOH-MG) and 7-hydroxymitragynine (7-OH-MG).  
 
Human urine samples 
Postmortem urine samples (n=16) were analyzed to determine the presence of 
mitragynine and metabolites. The concentration of mitragynine in each of the urine samples 
is shown in Table 3.4. Appropriate dilutions were performed where necessary prior to 
extraction. Evaluation of dilution integrity at 1:1, 1:10 and 1:100 produced results within 
1-16% of the expected concentration and CVs of 1.5 – 2.9% (n=3).  Drug concentrations 
in human urine ranged from 26 to 1,987 ng/mL. Interestingly, some specimens with 


























Although mitragynine was readily detected in all specimens, deconjugation of phase II 
metabolites might be necessary if metabolites are of interest.  
Table 3.3: Inhibition of mitragynine metabolism using rCYPs at t=120 mins. Results 
reflect replicate measurements (n=4) for all metabolites, with the exception of 7-
hydroxymitragynine (n=6).  
rCYP Metabolite % Inhibition 
(Mean ± SD) 
2C18 16-Carboxymitragynine 100 ± 0 
2C19 16-Carboxymitragynine 77 ± 14 
9-O-Demethylmitragynine 78 ± 10 
9-O-Demethyl-16-carboxymitragynine 100 ± 0 
2D6 16-Carboxymitragynine 63 ± 3 
9-O-Demethylmitragynine 100 ± 0 
3A4 9-O-Demethylmitragynine 100 ± 0 
7-Hydroxymitragynine 93 ± 1 
 
Metabolites were identified in 14 (88%) of the 16 postmortem urine samples tested 
(Table 3.4). The most prevalent metabolite present was 9-O-demethylmitragynine, which 
was present in 12 (75%) of the 16 case samples. 7-Hydroxymitragynine was the next most 
prevalent compound, present in 10 (63%) of the samples. However, since this alkaloid is 
also present in the plant material, its presence cannot be attributed solely to metabolism 
(62). 16-Carboxymitragynine was identified in only one sample (indicating that it may be 
a minor metabolite or highly conjugated) and 9-O-demethyl-16-carboxymitragynine was 
not detected in any of the urine samples.  
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Table 3.4: Identification of mitragynine and other metabolites in human urine. 
















1 1,987     
2 26    +1 
3 461 + +   
4 176 + +  +1 
5 1,271 + +  +1,3 
6 677 +   +1,3 
7 642  +   
8 402 + +  +1,2,3 
9 540 + +  +1,2,3 
10 938 +   +1,3 
11 258 + +  +1 
12 54 +  + +1,3 
13 254 + +  +1,3 
14 249 + +  +1,3 
15 980 + +  +1,3 
16 520     
1 m/z 387, 4.1 min; 2 m/z 387, 5.1 min; 3 m/z 387, 5.9 min;  
 
In the absence of reference materials, the presence of 9-O-demethylmitragynine, 
16-carboxymitragynine and 9-O-demethylmitragynine was confirmed using rCYP-
generated controls which were analyzed contemporaneously within the run.  Extracted ion 













Figure 3.8: Extracted ion chromatograms for mitragynine (7.2 min), 9-O-
demethylmitragynine (4.6 min), 7-hydroxymitragynine (5.4 min) and 17-O-demethyl-16-
17-dihydro metabolites (4.13, 5.15 and 5.97 min) from case #8. The tentatively identified 






Analysis of human urine from kratom users is beneficial due to the limitations of 
in vitro metabolism studies. Additional phase I metabolites that have been reported in 
literature (11) were tentatively identified in the postmortem urine samples. Notably, these 
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were not identified in vitro using the recombinant CYPs.  At least one of three compounds 
with an m/z of 387 were identified in 12 of the 16 samples, each having MS/MS spectra 
consistent with 17-O-demethyl-16, 17-dihydromitragynine (11). Speciogynine and 
speciociliatine are diastereoisomers of mitragynine and form analogous 17-O-demethyl-
16, 17-dihydro metabolites (63, 64). Due to their structural similarity, MS/MS spectra for 
all three compounds are indistinguishable and they can only be identified by retention time.  
Although it is highly likely that the intense peak at 5.9 mins is 17-O-demethyl-16,17-
dihydromitragynine, it cannot be confirmed due to the absence of a reference standard. The 
mass spectrum is depicted in Figure 3.8. The remaining peaks are likely due to 17-O-
demethyl-16,17-dihydrospeciogynine and 17-O-demethyl-16,17-dihydrospeciociliatine 
since these Mitragyna alkaloids are also present in the urine. Although 17-O-demethyl-
16,17-dihydromitragynine was only tentatively identified, mass accuracies (<5 ppm) and 
fragment assignments in a representative human urine sample are shown in Table 3.5. 
Although 17-O-demethyl-16,17-dihydromitragynine has not been produced in any of the 
in vitro studies to date, it has been identified in human urine (11, 65).  Philipp et al. 
attributed its formation to O-demethylation, carboxylation and subsequent reduction to the 
alcohol (11). This study also identified important differences in metabolism between rats 













Table 3.5: Molecular formula, retention time, and mass accuracies for 9-O-
demethylmitragynine (9-O-DM-MG), 7-hydroxymitragynine (7-OH-MG), 17-O-
demethyl-16,17-dihydromitragynine (17-O-DM-DH-MG) and mitragynine (MG) in a 




















4.6 C22H29N2O4 385.2122 385.2126 1.0 
C10H10NO 160.0757 160.0763 3.7 
C12H20NO3 226.1438 226.1441 1.3 
C13H20NO3 238.1438 238.1442 1.7 
7-MG-OH 5.4 C23H31N2O5 415.2227 415.2244 4.1 
C11H12NO 190.0863 190.0871 4.2 
C12H20NO3 226.1438 226.1444 2.7 
C13H20NO3 238.1438 238.1445 2.9 
17-O-DM-
DH-MG 
5.9 C22H31N2O4 387.2278 387.2275 -0.8 
C11H12NO 174.0913 174.0916 1.7 
C11H20NO3 214.1438 214.1436 -0.9 
C12H20NO3 226.1438 226.1437 -0.4 
MG 7.2 C23H30N2O4 399.2278 399.2273 -1.3 
C11H12NO 174.0913 174.0919 3.4 
C12H20NO3 226.1438 226.1442 1.8 
C13 H20NO3 238.1438 238.1441 1.3 
 
A comprehensive understanding of the isoenzymes involved in mitragynine’s 
metabolism is important in terms of the potential for toxicity due to genetic polymorphisms 
and drug-drug interactions. CYP450 2C19, 2D6 and 3A4 are known to metabolize many 
drugs including opiates, antidepressants, benzodiazepines and other central nervous system 
depressants (66). Existing case reports have established that poly-drug use is common 
among kratom users, notably with opioids. Despite the increase in popularity of kratom for 
recreational or self-medication purposes, the safety profile and potential for drug-drug 




CYP 3A4 mediated metabolism of mitragynine to 7-hydroxymitragynine was 
confirmed in this study.  Although the compound is known to be unstable, 
biotransformation of mitragynine to 7-hydroxymitragynine is notable because its mu 
opioid receptor activity is reported to be more than ten-fold greater than morphine (32). 
Four CYP 450 isoenzymes were involved in the metabolism of mitragynine (2C19, 3A4, 
2D6 and 2C18). 9-O-Demethylmitragynine was the most prominent phase I metabolite in 
both in vitro studies and in human urine samples. Although 9-O-demethyl and 7-hydroxy 
metabolites were readily identified in the majority of urine samples tested, the formation 
of the latter has important pharmacodynamic implications.  Due to its increased potency, 
in vivo production could explain the reported increased analgesic potency of mitragynine 
when administered orally, rather than parenterally in animals.  Differences in metabolism 
have been observed between species, and between in vitro based studies. Given increased 
kratom use, additional pharmacokinetic studies involving both mitragynine and 7-
hydroxymitragynine are warranted.   
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Mitragynine is the principal psychoactive alkaloid in kratom. The drug produces a variety 
of dose-dependent effects that appeal to recreational drug users and individuals seeking 
therapeutic benefits in the absence of medical supervision. In light of documented 
intoxications, hospitalizations and fatalities, mitragynine and other alkaloids from 
Mitragyna speciosa are of growing importance to the forensic toxicology community. 
However, the chemical stability of these compounds has not been thoroughly described. In 
this report, the stability of mitragynine (MG), 7-hydroxymitragynine (7-MG-OH), 
speciociliatine (SC), speciogynine (SG) and paynantheine (PY) are investigated. Short-
term stability of the Mitragyna alkaloids was determined over a range of pH (2-10) and 
temperature (4-80°C) over 8 h. Liquid chromatography time-of-flight mass spectrometry 
(LC-Q/TOF-MS) was used to estimate half-lives and identify degradation products where 
possible. The stability of mitragynine and other alkaloids was highly dependent on pH and 
temperature. All of the Mitragyna alkaloids studied were acid labile. Under alkaline 
conditions mitragynine undergoes chemical hydrolysis of the methyl ester to produce 16-
carboxymitragynine. 7-Hydroxymitragynine was the most unstable alkaloid studied, with 
significant drug loss at 8 hours experienced at temperatures of 40°C and above. No 
significant drug losses were observed for mitragynine in aqueous solution (pH 2-10) at 4, 
20 or 40°C. Diastereoisomers of mitragynine (speciociliatine and speciogynine) 
demonstrated even greater stability. These findings are discussed within the context of the 
identification of Mitragyna alkaloids in toxicological specimens.  




Temperature and pH-Dependent Stability of Mitragyna Alkaloids 
Introduction 
Kratom is a drug that comes from the Korth tree (Mitragyna speciosa) (1). The drug 
is widely available on the Internet and in retail outlets in the form of a leaves, powder, 
capsules, tablets, resin or concentrated extracts (2). Kratom’s physiological and 
psychological effects are known to be dose dependent, with low doses producing stimulant 
effects and high doses producing opiate like effects (3). The alkaloids of M. speciosa are 
atypical opioid receptor modulators with distinct pharmacological properties (4). The drug 
is reportedly used to treat chronic pain, intestinal infections, depression, insomnia, and 
even to improve sexual performance (3, 5-7). Kratom is also used for the non-medically 
supervised treatment of opioid abstinence syndrome (8, 9). Its rise in popularity has led to 
growing concern regarding its safety, unregulated use, and overall ease of access. In August 
2016 the Drug Enforcement Administration published its intent to place kratom alkaloids 
mitragynine and 7-hydroxymitragynine into Schedule I of the federal Controlled 
Substances Act (10). However, due to successful lobbying from kratom users, researchers 
and the dietary supplement industry, the temporary placement was rescinded and kratom’s 
legal status at the federal level is still uncertain. At the time of this report, it is illegal to 
possess or sell kratom in some states (Alabama, Arkansas, Indiana, Tennessee, Vermont, 
Wisconsin and the District of Columbia) and legislation is pending elsewhere.  
Mitragyna speciosa is the most well described species of the Mitragyna genus (11).  
The leaves are reported to contain over forty compounds, including mitragynine, 7-
hydroxymitragynine, speciociliatine, speciogynine and paynantheine. Chemical structures 
of these five alkaloids are shown in Figure 4.1. Only two alkaloids are believed to be 
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psychoactive: mitragynine and 7-hydroxymitragynine (2, 3). Mitragynine is the most 
abundant compound in kratom, comprising of about 66% of the total alkaloid content (1).  
7-Hydroxymitragynine is less abundant and accounts for only 2%, but it is considerably 
more potent than mitragynine (12). 7-Hydroxymitragynine is reported to have a 13-fold 
greater mu opioid agonist effect compared to morphine (46-fold greater than mitragynine) 
(11). In addition to its mu opioid receptor activity, mitragynine is also reported to bind to 
the α-2 adrenergic receptor (α2R), dopamine (D2) and serotonin receptors (5-HT2c and 5-
HT7) (4). Although less studied, its affinity for these receptors could explain its unique 
pharmacological and dose-dependent effects. Several published case reports have 



















Figure 4.1: Chemical structures of the Mitragyna alkaloids.  
 
Mitragynine is a basic drug (pKa 8.1) of moderate lipophilicity (log Poct/water 1.73) 
which is poorly soluble in water (28). Drug stability is an important consideration that 
influences many factors, including bioavailability and absorption, as well as analytical and 
pre-analytical factors, such as storage. Although biological specimens can be exposed to a 
wide variety of conditions before sample collection, proper handling, storage and transport 
of the specimen is critically important.  Information regarding the stability of the Mitragyna 
alkaloids is relatively sparse. Manda reported the stability of mitragynine and 7-
hydroxymitragynine in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF) 
(29). Both matrices were fortified with 5,000 ng/mL of MG and 7-MG-OH and for up to 
2.5 hours at 37°C. For mitragynine, samples in SGF (pH 1.2) were reported to be unstable 
(>26% loss) in 2 hours. Conversely, samples in SIF (pH 6.8) were stable, with a <4% loss 
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at 2.5 hours. 7-Hydroxymitragynine showed similar results with the samples being unstable 
in SGF (27% loss in 2 hours), but stable in SIF (6% loss at 2.5 hours). Interestingly, they 
reported that the decrease in 7-hydroxymitragynine concentration was accompanied by an 
increase (23%) in mitragynine, possibly attributed to the presence of enzymes. Ramanathan 
reported similar results regarding the stability of mitragynine in simulated gastric and 
intestinal fluids (28). Ramanathan also investigated the stability of mitragynine at various 
pH. Although they reported that mitragynine was stable at pH 4, 7, and 9 for 24 hours, the 
temperature of the study was not specified. A study by Fu et al indicated that both 
mitragynine and 7-hydroxymitragynine were stable at refrigerated temperature for two 
weeks, however the pH of the specimen was not indicated (30). Although methods 
describing the analysis of mitragynine have addressed stability in processed samples and 
during freeze-thaw cycles (31-34), the chemical stability of the Mitragyna alkaloids are not 
well described.  Published stability studies to date are summarized in Table 4.1. 
Table 4.1: Published literature involving Mitragyna alkaloid stability. The matrix, pH, 
temperature and concentration (if stated) are reported. 
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Vuppala explored the stability of 7-hydroxymitragynine during analytical method 
development (35). They reported that the compound was stable at various concentrations 
in rat plasma (20, 600, 3200 ng/mL), including  12 hours at 25°C, 1 month at -20°C, three 
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freeze/thaw cycles, and processed samples stored for 48 hours at 25°C. In addition to those 
published studies, certified reference materials for 7-hydroxymitragynine state that the 
compound should be stored at -80°C in strongly alkaline media (0.1N ammonia in 
methanol) due to its unstable nature (36). Fundamental knowledge of pH-dependent 
stability can provide insight from the standpoint of pharmacokinetics, analysis and 
interpretation. Based upon previously published studies and anecdotal reports, it was 
hypothesized that mitragynine and its alkaloids degrade in a pH- and temperature 
dependent manner. The stability of the Mitragyna alkaloids was investigated under 
accelerated conditions, in an effort to better understand the potential for degradation of 
these species in toxicological specimens. Use of aqueous media lends itself to tighter pH 
control and improves the possibility of identifying degradation mechanisms and products 
than more complex biological matrices. The pH and temperature-dependent stability of 
five Mitragyna alkaloids were systematically evaluated in aqueous solutions. In this short-
term stability study, half-lives for both species were determined over a wide range of pH 
(2 – 10) and temperature (4 - 80°C).  
Methods 
Chemicals and reagents 
Reference standards for mitragynine and 7-hydroxymitragynine were purchased 
from Cerilliant (Round Rock, TX USA) in methanol and ammoniated methanol, 
respectively. Paynantheine and speciociliatine were purchased from Chromadex (Irvine, 
CA, USA) in solid form. Speciogynine was provided by the National Center for Natural 
Products Research (NCNPR) at the University of Mississippi, (University, MS, USA). 
Boric acid and acetic acid were purchased from Mallinckrodt Chemicals (St. Louis, MO, 
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USA). Concentrated hydrochloric acid and sodium borate were purchased from J.T. Baker 
(Center Valley, MA, USA). Acetonitrile (LCMS grade) was purchased from Fisher 
Scientific (Fair Lawn, NJ, USA). LCMS grade formic acid, ammonium formate (10 M), 
and ammonium acetate were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Deionized water was purified in-house using a Millipore Direct-Q® UV Water Purification 
system (Billerica, MA, USA). Acetate (pH 4), formate (pH 6) and borate (pH 8 and 10) 
buffers were prepared at 10 mM from solutions of the salt and its corresponding acid. The 
aqueous pH 2 solution consisted of 10 mM hydrochloric acid.  
LC-Q/TOF-MS analysis 
An Agilent Technologies 6530 LC-Q/TOF-MS (Agilent Technologies, Santa Clara, 
CA, USA) equipped with an Agilent 1290 Infinity autosampler was used for analysis. 
Separation was achieved using an Agilent Technologies Series 1200 LC system equipped 
with an Agilent Poroshell 120 EC-C18 column (2.1 × 100 mm, 2.7 µm) and an Agilent 
Poroshell 120 EC-C18 guard column (2.1 × 5 mm, 2.7 µm) in a thermostatically controlled 
column compartment (35oC). Nitrogen was generated using a Genius 3040 nitrogen 
generator (Peak Scientific, Billerica, MA, USA).  
The LC-Q/TOF-MS conditions were based upon a previously validated method for 
MG, MH-OH, SC, SG and PY (37). The mobile phase consisted of 10 mM ammonium 
acetate solution (A) and acetonitrile (B). A flow rate of 0.4 mL/min was maintained using 
the following gradient elution profile: 10% B (0–0.5 min), 10-90% B (0.5–10 min), 
followed by a 2 minute re-equilibration. The total acquisition time was 10 min. The mobile 
phase gradient was modified from the previously validated method in order to assist with 
the identification of polar degradation products. The LC-Q/TOF-MS was equipped with an 
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ESI source (positive mode) with Jet Stream technology under the following conditions: 
nitrogen drying gas, 13 L/min; drying gas temperature, 350
oC; nebulizer, 45 psi; sheath gas 
temperature, 400oC; nitrogen sheath gas flow, 12 L/min; capillary voltage, 4000 V; nozzle 
voltage, 0 V; fragmentor, 150 V; skimmer, 65 V. Data was acquired in full scan (auto) 
mode using a preferred list that contained precursor ions for all five alkaloids. Agilent 
MassHunter software was used for data analysis. MS/MS spectra were generated using 
collision induced dissociation (CID) energies of 10-60 eV. Data was acquired using a mass 
range of 100–1000 Da, with a MS scan rate of 5 spectra/s and a MS/MS scan rate of 2 
spectra/s. Structural identification of potential degradation products was performed for 
mitragynine.  
Sampling for Stability Study 
Dilute acid (pH 2) or aqueous buffer (pH 4, 6, 8, 10) was fortified with MG, 7-MG-
OH, SG, SC or PY to achieve a final concentration of 2000 ng/mL. Aqueous samples (1.5 
mL) were sealed in tightly capped borosilicate glass tubes and protected from light. 
Solutions were maintained at 4°C, 20°C, 40°C, 60°C and 80°C. A total of twenty-five 
conditions were tested (five pHs at five temperatures) for all five Mitragyna alkaloids. Each 
compound was evaluated independently to reduce the potential for interferences caused by 
degradation products.   
Short-term stability was evaluated over a period of eight hours. Immediately 
following fortification, aliquots (50 µL, n=2) of each sample were removed and analyzed 
to establish the abundance of each alkaloid at T0 (0% loss). Sampling intervals following 
T0 were 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours.  Although the autosampler was maintained at 
4°C, T0 samples were reinjected throughout the run to verify that no changes in abundance 
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took place while samples were awaiting analysis. During each sampling interval, aliquots 
(50 µL, n=2) were removed and diluted 1:1 with the associated buffer for samples at pH 2, 
4, and 6. Due to degradation in the autosampler, samples at pH 8 and 10 were reconstituted 
1:1 with 10 mM acetate buffer (pH 4) prior to injection. Samples were then transferred to 
the refrigerated autosampler and 1 µL was injected onto the LC-Q/TOF-MS.  The analyte 
was considered unstable when the mean peak area of the precursor ion decreased by more 
than 20% (relative to T0). Assuming first-order kinetics, rate constants (k) and half-lives 
(T1/2) were estimated for alkaloids with significant decreases in abundance (>20%) over 
consecutive measurements. 
Results and discussion 
Stability of Mitragyna alkaloids 
The stability of MG, MG-OG, SC, SG and PY was evaluated under various 
conditions of pH and temperature. Changes in concentration over time are shown in Figure 
4.2.  Table 4.2   summarizes the % loss at 8 hours for each condition tested. Significant 
losses (>20%) are highlighted in bold. Data represents the mean of duplicate measurements 
at each interval. CVs <20% were achieved for all compounds tested.  As expected, both 
temperature and pH-dependent effects were observed. Mitragynine was completely stable 
for eight hours at pH 2-10 at 4, 20 and 40°C. In contrast, the drug was significantly acid 
labile at elevated temperature (60-80°C). At pH 2, 100% of the drug was lost within 6 hours 
at 80°C. Mitragynine was stable at moderate pH (4 and 6) for 8 hours, but the compound 
significantly degraded under strongly acidic conditions (pH 2) and moderate to strongly 
alkaline conditions (pH 8 and 10) at 80°C. At 60°C, significant losses were observed at the 
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most acidic and basic pH (2 and 10) (Table 2.2). These observations are consistent with 
previous studies that suggest Mitragyna alkaloids are acid labile (28).  
Figure 4.2: Short-term stability of MG, MH-OH, SC, SG and PY. 
 
In contrast to the rapid degradation of mitragynine under acidic conditions at 
elevated temperature, the drug was completely stable for eight hours at refrigerated and 
room temperature. This is consistent with studies that indicated the drug to be stable for at 
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least one month when refrigerated at 4°C (33, 34). However, it should be noted that 
mitragynine was not stable at pH 8 and 10 when placed in the autosampler for the duration 
of the run (~22 hours).  When the T0 samples were reinjected 24 hours after the initial 
injection, a >20% loss in abundance was observed at pH 8 and 10. In order to prevent 

























Table 4.2: Mean % loss of mitragynine, 7-hydroxymitragynine, speciociliatine, 
speciogynine and paynantheine at 8 hours (n=2). Significant losses (>20%) are shown in 
bold.  
Drug pH 
Mean % Loss at 8 hours 
80°C 60°C 40°C 20°C 4°C 
MG 
2 100 47 0 1 0 
4 0 0 0 1 0 
6 0 7 0 8 0 
8 31 13 20 1 0 
10 25 23 12 18 0 
7-MG-OH 
2 100 93 32 4 0 
4 93 35 7 9 0 
6 65 44 19 0 0 
8 57 32 9 0 0 
10 66 46 8 7 0 
SC 
2 58 17 12 - - 
4 0 0 0 - - 
6 0 5 11 - - 
8 20 2 11 - - 
10 20 7 6 - - 
SG 
2 43 5 6 - - 
4 0 0 0 - - 
6 0 6 11 - - 
8 11 2 11 - - 
10 15 3 4 - - 
PY 
2 37 4 6 - - 
4 0 0 0 - - 
6 0 1 9 - - 
8 5 0 7 - - 
10 8 3 2 - - 
   
In contrast, 7-hydroxymitragynine was unstable at all pHs at temperatures of 60°C 
or above. Although all samples experienced a significant loss at the highest temperatures 
(80 and 60°C) regardless of pH, degradation rates were pH dependent.  A loss of 100% 
was observed for pH 2 and a near complete loss (93% loss) was observed for pH 4 at 80°C. 
The findings are consistent with earlier studies by Manda, who reported that 7-
hydroxymitragynine was unstable in simulated gastric fluid (pH 1.2, 37°C), but stable in 
simulated intestinal fluid (pH 6.8, 37°C) after approximately 2 hours (29). Like 
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mitragynine, 7-hydroxymitragynine was observed to be unstable at elevated temperatures 
in a pH-dependent manner. Both alkaloids were significantly acid labile. However, unlike 
mitragynine, 7-hydroxymitragynine also underwent significant degradation at moderate 
pH. However, no losses were observed for 7-hydroxymitragynine at ambient or refrigerated 
temperatures, regardless of pH (Figure 4.2, Table 4.2). 
Speciociliatine, speciogynine and paynantheine demonstrated greater stability 
(Figure 4.2, Table 4.2). Significant losses at 8 hours were observed only under strongly 
acidic conditions (pH 2) at 80°C. Speciociliatine and speciogynine are both stereoisomers 
of mitragynine. SG and SC have different geometries at the C20 and C3 positions. 
Spectroscopic studies have confirmed their spatial configurations, which can greatly 
influence their chemical properties (38-40). Molecular conformation plays an important 
role in both chemical reactivity and bioactivity. Relatively small changes in spatial 
arrangements and conformational flexibility of the aliphatic regions of the rings themselves 
could impact stability. Rings A and B are aromatic and therefore planar in structure (Figure 
4.1). More conformational flexibility is possible in rings C and D however. Mitragynine 
conformers are heavily influenced by the position of the nitrogen lone pair shared by rings 
C and D, theoretically allowing it to be syn or anti to the exocyclic ethyl group at C20 (Liu, 
2010). As a result, this can place the nitrogen either above the plane of the aromatic rings, 
or below them. Interestingly, this is believed to play an important role in terms of its opioid 
receptor activity. Arrangement of the nitrogen above the rings is more stable, attributed to 
reduced steric hindrance at the CH2 group of ring C and ethyl group at C20 (41). Of the 
five alkaloids under investigation, only mitragynine and 7-hydroxymitragynine have the 
same spatial configuration at C3 and C20 (37). Ambient and refrigerated temperatures were 
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not evaluated for SC, SG or PY because these compounds did not experience any 
significant losses at 60 or 40°C.  
Half-life determination 
Half-lives (T1/2) for each alkaloid were estimated from rate constants (k) assuming 
first order decay, based upon duplicate measurements at each time interval (T1/2 = Ln2/k) 
(Table 4.3). However, these estimates were performed only if there was a significant 
decrease (>20%) over at least three consecutive measurements, with suitable linearity. Rate 
plots for MG, 7-MG-OH, SC, SG and PY are shown in Figure 4.3. A representative 
calculation for T1/2, equation of the line and coefficient of determination (R
2) is shown for 
MG. As expected, half-lives were both temperature and pH-dependent. The half-life for 
mitragynine under strongly acidic conditions (pH 2) ranged from 0.8h to 9.5h at 80 and 
60°C, respectively. In contrast, in moderate to strongly basic conditions (pH 8 and 10), 
half-lives were >12h, even at extremely elevated temperature (80°C). However, at pH 4-6 
half-lives could not be estimated due to overall stability.  
Table 4.3: Estimated half-lives of mitragynine and 7-hydroxymitragynine, speciociliatine, 





2 0.8 9.5 
8 15 - 
10 18 - 
7-MG-OH 
2 0.6 2.1 
4 2.0 12 
6 7.5 12 
8 6.8 14 
10 5.6 9.2 
SC 2 6.9 - 
SG 2 11 - 




7-Hydroxymitragynine was less stable than mitragynine and degraded significantly 
over the entire pH range at 60°C and above. However, like mitragynine, significant pH 
dependence was also observed. Half-lives ranged from 0.6 to 7.5h at pH 2 and 6 at 80°C. 
At 60°C, half-lives ranged from 2.1 to 14 hours. Although there was a significant loss of 
7-MG-OH under strongly acidic conditions at 40°C, it was not possible to reliably estimate 
a half-life due to an insufficient number of measurements. Half-lives for SC, SG and PY 
were approximately 7-13h under strongly alkaline conditions at 80°C. Notably, the 
diastereoisomers of MG were notably more stable than the principal alkaloid itself. Half-
lives under acidic conditions were more than ten-fold higher than mitragynine, and no 




















Identification of degradation products 
Samples were analyzed using auto scan mode to facilitate the identification of 
potential mitragynine degradation products. Two degradation products were observed for 
mitragynine (7.9 min) at 4.2 and 5.6 min, corresponding with [M+H]+ m/z 385 and 397, 
respectively. Extracted ion chromatograms for the parent drug and degradation compounds 
are shown in Figure 4.4. The decrease in abundance of mitragynine over time was 
accompanied by an increase in the abundance of both species. Figure 4.5 depicts this 
graphically for the m/z 397 breakdown product at pH 2 at 80°C.  Although the m/z 385 
species also increased in abundance over 8h, the shift was not as dramatic because the 
degradation rate of mitragynine under alkaline conditions occurs at a much slower rate.  
Figure 4.4: Extracted ion chromatograms of mitragynine ([M+H]+ 399) and degradation 
products under acidic conditions ([M+H]+ 397, pH 2, 80°C, 8h) and alkaline conditions 




MS/MS spectra and structural assignments for mitragynine and the two major 
degradation products are shown in Figure 4.6. The degradation product with m/z 385 was 
identified as 16-carboxymitragynine. This was produced only at pH 8 and 10, consistent 
with the alkaline hydrolysis of the methyl ester. In the absence of a commercially available 
reference standard, the MS/MS spectrum was used for identification purposes. The mass 
error of the molecular ion and its fragments was within 2 ppm for all structural assignments 
(Table 4.4). In addition to being present as a chemical breakdown product, 16-
carboxymitragynine is also a known metabolite of mitragynine (42, 43).  
Figure 4.5: Formation of the acidic degradation product [M+H]+ 397 at pH2 and 80°C. 
 
The degradation product corresponding with the m/z 397 precursor ion might be 
attributed to dehydrogenated mitragynine (-2 Da). Although the mass error associated with 
a dehydrogenated species (C23H29N2O4) was 7.1 ppm (Table 4.4), structural identification 
of this compound was not conclusive. Kamble reported a dehydrogenated species bearing 
an almost identical mass spectrum (44). They attributed the dehydrogenation to occur on 
the quinolizidine moiety of the mitragynine. Although the MS/MS spectrum of the acid 





















identification was not possible. 3-Dehydromitragynine has been reported in the literature 
and is reported to be present in leaves of M. speciosa (11).  Houghton was the first to 
identify it in plant material (45). MS/MS spectra were evaluated over a range of CID 
voltages (Figure 4.6) and m/z 397 was confirmed as the M+H molecular ion. The formation 
of the acidic breakdown product was investigated in the absence of oxygen. However, its 




















Figure 4.6: MS/MS spectra of mitragynine ([M+H]+ 399; CE 20), 16-carboxymitragynine 
([M+H]+ 385; CE 20) and acidic degradation product ([M+H]+ 397; CE 20 and 40).  
 
Mitragynine is a corynanthe-type alkaloid consisting of a conjugated pentacyclic 
skeleton with an open E ring. The mass fragmentation of Mitragyna alkaloids was 
described by Avula (46). Mitragynine and related alkaloids undergo characteristic loss of 
piperidine derivatives to form a methyl substituted indole fragment (m/z 174), cleavage at 
the C5 of the C ring to form m/z 238, and neutral loss of the methoxyindole and cleavage 
of the C5 and N to produce the m/z 226 piperidine species. The notable absence of the m/z 
174 indole fragment suggests that either the structural modification occurs on this group, 
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or that the modification influences the formation of this stable fragment. The acidic 
degradation product produced prominent ions at m/z 381, 281 and 227 (Figure 4.6). The 
MS/MS spectrum suggests the M-16 to be attributed to loss of methane (7.9 ppm) rather 
than loss of oxygen (-89.6 ppm). Further, loss of C5H8O3 (cleavage at C15) corresponds 
with the m/z 281 (7 ppm) and m/z 227 could be attributed to the piperidine fragment 
(C14H15N2O), with an associated mass shift of 7 ppm. Although mass assignments for a 
dehydromitragynine derivative were within acceptable limits and consistent with 
previously reported literature (42), the chemistry of the Mitragyna alkaloids is complex 
and other species are possible.  
Table 4.4: Chemical formula, retention time, exact mass, accurate mass, and mass error 
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Kratom is a drug of concern that has been associated with numerous intoxications, 
hospitalizations and fatalities. In this report, we describe the chemical stability of the 
principal Mitragyna alkaloids over a wide range of pH and temperature. Although stability 
in biological matrices is of concern in forensic toxicology investigations, stability studies 
in aqueous media lends itself to the investigation of extreme pH and is more conducive to 
the identification of chemical breakdown product because of the simplicity of the matrix. 
Furthermore, accelerated stability studies can help identify potential degradation pathways 
or products that may not be evident otherwise. Drugs can be exposed to a wide range of 
pH throughout the body, ranging from strongly acidic (in the stomach) to alkaline (in the 
intestines and in urine). Urinary pH can also change during long-term storage, especially 
when exposed to heat. Although toxicological specimens should not be exposed to the 
elevated temperatures used in this study, the results provide valuable insight regarding the 
stability of these alkaloids, and their potential use as biomarkers of kratom use. Exposure 
to elevated temperatures is relevant if kratom tea is ingested, and during toxicological 
analysis (particularly during derivatization, chemical hydrolysis of phase II metabolites, or 
evaporation steps following extraction).  
 While MG and 7-MG-OH both demonstrated chemical instability under acidic and 
basic conditions, both compounds were considerably more acid labile than base-labile. 
Under alkaline conditions, mitragynine undergoes hydrolysis to form 16-
carboxymitragynine, a known metabolite. Degradation under acidic conditions produced a 
species with a 2Da loss, possibly corresponding with a dehydrogenation product.  While 
mitragynine was more stable than 7-hydroxymitragynine, elevated temperature and 
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extreme pH should still be avoided. Although the drug was stable at 4, 20 and 40°C, only 
short-term stability was evaluated over 8 hours. The results of this study suggest that 
degradation in biological matrices should be considered, particularly for strongly acidic or 
basic matrices (e.g. stomach contents, or alkaline urine), particularly if it is exposed to 
elevated temperatures during the postmortem interval or during transport. An 
understanding of the chemical stability of these alkaloids also provides valuable 
information from the standpoint of method development and quantitative analytical 
procedures. Extreme pH (during solid phase extraction) and temperatures during analytical 
processing are unlikely to impact stability, with the exception of 7-hydroxymitragynine. 
Differences in stability between mitragynine and its diastereoisomers, speciogynine and 
speciociliatine, highlight the importance of stereochemistry on drug stability.  Mitragynine 
is a basic drug with limited water solubility and poor gastrointestinal permeability (47). 
Ramanathan reported the oral bioavailability in rats was only 3% (28). The results if this 
study suggest that in addition to its relatively poor solubility, the low oral bioavailability 
might also be attributed to its tendency to be acid labile. 
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Mitragyna speciosa (kratom) is a drug that is increasingly used recreationally and 
“therapeutically”, in the absence of medical supervision. Its use has been associated with a 
growing number of fatalities, and although its medicinal properties as an atypical opioid 
require further study, there are legitimate concerns regarding its unregulated use. 
Mitragynine is a prominent alkaloid within the plant. However, more than forty other 
alkaloids have been reported, including 7-hydroxymitragynine which is a potent opioid 
receptor agonist with increased abuse liability. In this report, biomarkers for mitragynine 
were investigated using liquid chromatography-quadrupole/time of flight mass 
spectrometry (LC-Q/TOF-MS). Speciociliatine and speciogynine were identified as 
alternative biomarkers, often exceeding the concentration of mitragynine in unhydrolyzed 
urine.  9-O-Demethylmitragynine and 7-hydroxymitragynine were identified in 
unhydrolyzed urine in 75% and 63% of the cases. Deconjugation of phase II metabolites 
using chemical hydrolysis was not suitable due to degradation of the Mitragyna alkaloids. 
Enzymatic hydrolysis was evaluated using three traditional glucuronidases, four sulfatases 
and four recombinant enzymes. Although enzymatic hydrolysis increased the 
concentration of 16-carboxymitragynine, it had nominal benefit for other metabolites. 
Deconjugation of urine was not necessary due to the abundance of parent drug 
(mitragynine), its diastereoisomers (speciociliatine and speciogynine) or metabolites (9-O-
demethylmitragynine and 7-hydroxymitragynine).  





Identification of Metabolites and Potential Biomarkers of Kratom in Urine 
Introduction 
Mitragynine is an “atypical opioid” that is present in the leaves of Mitragyna 
speciosa (kratom). Although it was initially encountered as a recreational drug in the 
United States, more recently there has been considerable interest in its potential therapeutic 
use (1). Kratom’s effects are mediated by both opioid and non-opioid receptor interactions, 
which can produce stimulant and opiate-like effects in a dose-dependent fashion (2). Most 
recently, it has attracted attention due to its use for the non-medically supervised treatment 
of opioid abstinence syndrome (3). Kratom is legal in many states and is not currently 
scheduled at the federal level, which leads to potential misuse as opioid users seek out 
kratom as a legal opiate replacement (4).  Even in states where regulation is present, kratom 
is relatively easy to obtain through retail outlets and online vendors (3). Drug Enforcement 
Administration (DEA) surveillance data from the National Forensic Laboratory 
Information System (NFLIS) indicates that seizures involving mitragynine or kratom have 
increased since 2010 (5-7). There are also several published case reports detailing adverse 
side effects including seizures, coma and hepatotoxicity (8-12). In addition, several 
fatalities associated with kratom use have also been reported (13-22). Recently, a report 
from the Centers for Disease Control and Protection (CDC) detailed 152 fatalities 
involving kratom from 27 states (23). In addition to concerns regarding increased use, 
together with a common perception and vendor labeling that indicate the drug is “safe”, the 
report also confirmed that kratom is frequently encountered among the opioid-abusing 
population. Among reported fatalities, fentanyl (or its analogs) (65%) and heroin (33%) 
were the most commonly encountered drugs in kratom-positive cases.  Kratom use may be 
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underreported due to the scope of toxicological screening in  biological matrices (23). 
Although confirmatory methods to identify Mitragyna alkaloids have been reported, many 
analytical methods used to identify kratom use target mitragynine alone (Table 5.1). Since 
kratom’s primary route of administration is oral consumption (24), it is possible that other 



























Urine 1 mL SPE 0.25-1 0.5-1 2-500 
MG, 7-MG-OH, 






Urine 0.2 mL LLE - 1 1-500 MG, 7-MG-OH Mitraphylline LC-MS/MS (38) 
Urine 3 mL SPE 100 - - MG, PY, SC, SG - GC-MS (33) 
































1 mL or 1 
g 
LLE 0.25 1 1-10 MG Proadifen LC-MS/MS (15) 
Urine 2 mL LLE 0.02 0.1 0.01-5 MG Ajmalicine LC-MS/MS (40) 




1 mL SPE 30 50 50-1000 MG MG-D3 GC-MS (16) 
Plasma 0.1 mL LLE 2 10 10-4000 7-MG-OH Tryptoline LC-MS (42) 
BAµE, bar adsorptive microextraction; GC-MS, gas chromatography-mass spectrometry; LC-DAD, liquid chromatography-diode 
array detector; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LC-Q/TOF-MS, liquid chromatography-quadrupole 
time-of-flight-mass spectrometry; LLE, liquid-liquid extraction; SPE, solid phase extraction. 
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The Mitragyna genus includes four species native to Africa and six species native 
to South and Southeast Asia (25). Mitragyna speciosa is distributed throughout the 
Malesian floristic region, including Thailand, Malay Peninsula, Sumatra, Borneo, the 
Philippines, and New Guinea. It is also cultivated in Southern Vietnam and Burma 
(Myanmar). More than forty kratom alkaloids have been reported in the literature and 
account for approximately 0.5 to 1.5% of the dried leaf material by weight, although there 
are variations based on location, age, and season (3). The two most commonly targeted 
Mitragyna alkaloids in published methods, mitragynine (MG) and 7-hydroxymitragynine 
(7-MG-OH), are reported to account for >60 and 2% of the overall alkaloid composition, 
respectively (1, 26, 27). Three minor Mitragyna alkaloids (speciociliatine, speciogynine, 
and paynantheine) have been reported to account for 9, 7, and 10% of the total alkaloid 
content, respectively (1, 26). However, US-grown M. speciosa has a different chemotype 
from Asian-African plants and is reported to be richer in oxindole alkaloids  (25).  In 
addition to these geographic and age-related variants, alkaloid content also varies within 
the plant. Speciogynine was identified as the principal alkaloid in leaves from young Thai 
plants, while speciociliatine was the major alkaloid in the fruits of Malaysian plants (25, 
28). These findings suggest that additional biomarkers of kratom use should be 
investigated.  
Chemical structures of these alkaloids are shown in Figure 5.1. Although studies 
detailing the metabolism of paynantheine (PY), speciogynine (SG), and speciociliatine 
(SC) have been reported (29-31), very few analytical methods to date have targeted these 
alkaloids or attempted to identify their prevalence following kratom use  (32). One study 
by Philipp et al. detailed the qualitative analysis of mitragynine, speciociliatine, 
164 
 
speciogynine, and paynantheine metabolites in human urine following suspected kratom 
or Krypton (kratom and O-desmethyltramadol) use (33). Although speciociliatine, 
speciogynine, and paynantheine were not routinely identified, the limit of detection of the 
gas chromatograph-mass spectrometry (GC-MS) assay was very high (100 ng/mL). 
Following enzymatic deconjugation and chemical derivatization, metabolites of these 
species were identified. Speciociliatine and speciogynine are diastereoisomers of 
mitragynine. Although they can be separated chromatographically, there are considerable 
challenges associated with their detection. We previously reported the use of liquid 
chromatography-quadrupole/time of flight-mass spectrometry (LC-Q/TOF-MS) for the 
simultaneous identification of MG, 7-MG-OH, PY, SC and SG in urine (32). Arndt et al. 
identified paynantheine, speciociliatine, speciogynine and mitraciliatine in a living subject 
receiving treatment for opioid withdrawal (34). Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) was used for analysis and the limit of detection was 2 ng/mL. 
Notably, speciociliatine was reported to be the most prevalent alkaloid present. Although 
these other compounds might not be psychoactive (2, 3), they could be valuable biomarkers 
of kratom use, especially given recent research that suggests that they are more stable than 
mitragynine and 7-hydroxymitragynine (35).  
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Figure 5.1: Selected indole Alkaloids in Mitragyna speciosa associated with kratom use. 
 
The metabolism of mitragynine was first described by Philipp et al. (36, 37). 
Glucuronidation and sulfation of hydroxylated and carboxylated phase I metabolites was 
reported. The primary locations for conjugation were the 16, 17, and 9 positions (Figure 
5.1). The parent drug however does not undergo such reactions due to its functionality.   
166 
 
The hydrolysis of conjugated species is typically performed either chemically or 
enzymatically. Strong acids and bases (usually combined with high temperatures) and 
enzymatic reagents (β-glucuronidase and sulfatase) can be used for this purpose. Chemical 
hydrolysis is less costly, faster, and more efficient but can degrade unstable species (38). 
Enzymatic hydrolysis, which is performed using moderate conditions of temperature and 
pH is often preferred. However, the efficiency varies significantly based on the type of 
enzyme and the drug itself (39). In addition, longer incubation times are often necessary, 
bioreagents have shorter shelf-lives, and there are increased costs (40, 41); factors that are 
often undesirable for high throughput laboratories. 
To date, two studies have addressed the necessity for deconjugation of phase II 
metabolites of mitragynine. The first study by Le et al, evaluated the efficiency of E. coli 
β-glucuronidase for the deconjugation of urine samples (n=12) from kratom users. 
Ultimately, they determined that deconjugation did not improve urine analysis and was not 
necessary for interpretation (42). The other study by Lee et al. compared the efficiency of 
E. coli β-glucuronidase and H. pomatia β-glucuronidase/sulfatase deconjugation using 
human urine (n=10). They reported that while they were able to successfully hydrolyze 
glucuronidated metabolites in order to improve analysis of the phase I metabolites, they 
were not able to hydrolyze the sulfated conjugates (43). Given increased vigilance 
regarding kratom use, and the widespread use of urine as a toxicological specimen, further 
investigation is warranted.  
In this report we describe the efficiency of chemical and enzymatic deconjugation 
techniques and discus potential biomarkers of kratom use.  Chemical hydrolysis using 
acidic and basic conditions, and eleven enzymatic reagents, including both traditional and 
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recombinant preparations (IMCSzyme™, BGTurbo™, BGS™, ASPC™, E. coli β-
glucuronidase, H. pomatia β-glucuronidase, P. vulgata β-glucuronidase, A. aerogenes 
sulfatase, abalone entrails, H. pomatia sulfatase and P. vulgata sulfatase) are described. 
Using postmortem urine samples (n=16) from kratom users, the relative merits of 
hydrolysis are discussed within the overall context of drug detection.  
Experimental 
Chemicals and reagents 
 Mitragynine and mitragynine-D3 were purchased in methanolic solution from 
Cayman Chemical Company (Ann Arbor, MI, USA). Reference standards for 7-
hydroxymitragynine and 7-hydroxymitragynine-D3 were purchased from Cerilliant Corp. 
(Round Rock, TX USA) in an ammoniated solution (1% concentrated ammonium 
hydroxide in methanol, v/v) and stored at -80oC as per the manufacturer’s 
recommendations.  Paynantheine and speciociliatine reference standards were purchased 
from Chromadex (Irvine, CA, USA) in powdered form, and speciogynine (powder) was 
kindly provided by the National Center for Natural Products Research (NCNPR) at the 
University of Mississippi (University, MS, USA). All solvents and inorganic reagents were 
LC or ACS grade, unless stated otherwise. Concentrated ammonium hydroxide was 
purchased from Macron Fine Chemicals (Center Valley, MA, USA), and ethyl acetate, 
hexane, concentrated hydrochloric acid, and methanol were obtained from J.T. Baker 
(Center Valley, MA, USA).  Acetonitrile and sodium hydroxide (solid) was obtained from 
Fisher Scientific (Fair Lawn, NJ, USA) and glacial acetic acid was obtained from 
Mallinckrodt Chemicals (St. Louis, MO, USA). 
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 Ammonium acetate, potassium phosphate (monobasic and dibasic),  ammonium 
acetate, β-glucuronidase from Escherichia coli (Type IX-A, lyophilized powder, 
1,000,000-5,000,000 units/g), β-glucuronidase from (Type H-1, partially purified powder, 
≥300,000 units/g), β-glucuronidase from Patella vulgata (Type L-II, lyophilized powder, 
1,000,000-3,000,000 units/g), sulfatase from Helix pomatia (Type H-1, sulfatase ≥10,000 
units/g), sulfatase from abalone entrails (Type VIII, lyophilized powder, 20-40 units/mg), 
sulfatase from Aerobacter aerogenes (Type VI, buffered aqueous glycerol solution, 2-5 
units/mg protein, 10-20 units/mL) and sulfatase from Patella vulgata (Type IV, essentially 
salt-free, lyophilized powder, ≥10 units/mg solid) were obtained from Sigma-Aldrich (St. 
Louis, MO, USA). IMCSzyme™ (genetically modified β-glucuronidase, purified solution, 
>50,000 units/mL) and its proprietary Rapid Hydrolysis Buffer were obtained from 
Integrated Micro-Chromatography Systems, LLC (Irma, South Carolina, USA).  
BGTurbo™ (genetically enhanced β-glucuronidase solution, ~1 mg/mL, >90% purity, 
>200,000 units/mL), BGS™ (genetically enhanced β-glucuronidase and sulfatase solution, 
~1 mg/mL (β-glucuronidase), ≥ 200,000 units/ml (β-glucuronidase), ~4.0 mg/ml 
(sulfatase), ≥ 37,000 units/ml (sulfatase)),  ASPC™  (genetically enhanced sulfatase 
solution, ~1 mg/mL, ≥ 200,000 units/ml), and Proprietary Buffer 1 and 2 were obtained 
from Kura Biotec® (La Piedra Biotecnología, Puerto-Varas, Chile). Recombinant human 
cytochrome P450 (rCYP) isoenzymes expressed in E. coli (bactosomes) were obtained 
from Xenotech, LLC (Kansas City, Kansas) and reduced nicotinamide adenosine di-
phosphate (NADPH) regenerating system solution A (40 Ug/mL glucose-6-phosphate 
dehydrogenase in 5 mM sodium citrate), solution B (26 mM NADP+, 66 mM glucose-6-
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phosphate and 66 mM magnesium chloride in aqueous solution) were obtained from 
Corning (Glendale, Arizona). 
 All other chemicals and reagents were obtained from VWR International (Radnor, 
Pennsylvania). Deionized water was purified in house using a Millipore Direct-Q®UV 
Water Purification system (Billerica, MA, USA). Pooled drug-free urine preserved with 
1% sodium fluoride (w/v) was used for the preparation of calibrators and controls. Samples 
were extracted using PolyChrom ClinII 3 cc (35 mg) solid phase extraction (SPE) columns 
that were obtained from SPEware (Baldwin Park, CA, USA). 
Postmortem specimens 
Unhydrolyzed postmortem specimens (n=16) were analyzed to determine the 
presence of Mitragyna alkaloids (speciociliatine, speciogynine, paynantheine, 
mitragynine, and 7-hydroxymitragynine) and phase I metabolites in accordance with an 
IRB-approved study. Concentrations of MG, MH-OH, SC, SG and PY were quantitatively 
determined using a previously validated method (32). 7-Hydroxymitragynine, and the 
metabolites identified during a previous in-vitro study were investigated qualitatively (36). 
Internal standard solution containing mitragynine-D3 and 7-hydroxymitragynine-D3 was 
added to 1.0 mL of urine to achieve a final concentration of 100 ng/mL. Samples were then 
acidified with 2 mL of 0.1 M hydrochloric acid and transferred to PolyChrom Clin II SPE 
cartridges. Deionized water and 1 M acetic acid was then added to each SPE cartridge in 1 
mL aliquots. The columns were then dried for five minutes at full vacuum, followed by 
additional washes of hexane, ethyl acetate, and methanol (1 mL).  The compounds were 
then eluted with 1 mL of ethyl acetate/concentrated ammonium hydroxide (98:2) and 
evaporated to dryness under nitrogen at 50°C. The samples were then reconstituted in 25 
170 
 
µL of 1:1 mobile phase A/B prior to injection (1 µL) on the LC-Q/TOF-MS. The limit of 
quantitation (LOQ) for mitragynine, speciociliatine and speciogynine was 0.5 ng/mL. The 
LOQ for paynantheine and 7-hydroxymitragynine was 1 ng/mL, and the typical calibration 
range of the assay was 2-500 ng/mL  (32).  Due to the high concentrations of alkaloids in 
human urine, dilution integrity was also evaluated.  Mitragyna alkaloids were 
quantitatively determined using 2, 10 and 100-fold dilutions of urine in 0.1 M HCl. 
Mitragynine-D3 was used as the internal standards for MG, SC, SH and PY. 7-
Hydroxymitragynine-D3 was used as the internal standard for 7-OH-MG in accordance 
with Table 5.1.  
In addition to the five targeted alkaloids (MG, MH-OH, SC, SG and PY), 
qualitative identification of metabolites in urine (1 mL) was also performed using 
untargeted acquisition and a modified mobile phase gradient (36).   In the absence of 
commercially available reference standards, rCYPs (3A4, 2D6, 2C19, and 2C18) were used 
to prepare 9-O-demethylmitragynine, 16-carboxymitragynine, and 9-O-demethyl-16-
carboxymitragynine in-situ for qualitative identification purposes. Retention times, 
MS/MS spectra and mass accuracy were used for identification purposes.  
Chemical hydrolysis 
Pooled postmortem urine (n=5) from kratom-positive fatalities was used to evaluate 
chemical hydrolysis. In order to evaluate multiple reaction conditions and accommodate 
duplicate analysis, the specimen volume was decreased to 100 µL. Pooled human urine 
(100 µL) was added to deionized water (400 µL) to achieve a final volume of 500 µL. An 
equal volume (500 µL) of concentrated hydrochloric acid (12M) or sodium hydroxide (1M) 
was added, and samples were incubated at 20, 60, and 80°C for 60 minutes (n=2). Upon 
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cooling, samples were extracted with the SPE protocol described above. Extracts were then 
reconstituted in 25 µL of 1:1 mobile phase A/B and 2 µL was injected onto the LC-Q/TOF-
MS for analysis. A blank (n=2) consisting of pooled drug-free urine (100 µL) diluted with 
deionized water (900 µL) was extracted contemporaneously in each run.  
Enzyme hydrolysis  
The same pooled postmortem urine (n=5) was also used to evaluate enzymatic 
hydrolysis. Each hydrolysis reaction was performed in duplicate. Recombinant enzymes 
and traditional sulfatase and glucuronidase preparations were also evaluated.  Enzymatic 
stock solutions (where applicable) and buffers were prepared in accordance with 
manufacturer’s recommendations, when provided. Aqueous internal standard (2 µg/mL) 
was added to urine (100 µL) before sufficient deionized water and/or buffer was used to 
bring the total reaction volume to 1000 µL. The final concentration of IS in each sample 
was 100 ng/mL. Following hydrolysis, all samples were extracted as described above. 
Samples were then reconstituted in 25 µL of 1:1 mobile phase A/B and 2 µL was injected 
onto the LC-Q/TOF-MS for analysis.  Hydrolysis conditions using traditional and 







Table 5.3: Optimal and challenging conditions for enzymatic hydrolysis using pooled urine (n=5). 
Enzyme 
Total Units 
per mL  
Buffer Urine Volume (µL) Incubation Temperature (°C) Incubation Time (min) 
IMCSzyme™ 5,000 Proprietary 
100 53-55 
30 
BGTurbo™ 8,000 Proprietary 10 
BGS™ 20,000 Proprietary 30 
30 ASPC™ 20,000 Proprietary 
E. coli 2,000 0.1 M phosphate (pH 6.8) 
100 
37 
37 180 H. pomatia 2,000 0.1 M acetate (pH 5.0) 
0.1 M acetate (pH 5.0) P. vulgata 2,000 55 
A. aerogenes 1 





Abalone Entrails 20 
H. pomatia 200 




An Agilent Technologies 6530 LC-Q/TOF-MS (Agilent Technologies, Santa Clara, 
CA, USA) equipped with an Agilent 1290 Infinity autosampler was used for analysis. 
Nitrogen was generated using a Genius 3040 nitrogen generator (Peak Scientific, Billerica, 
MA, USA). Separation was achieved using an Agilent Technologies Series 1200 LC 
system with a thermostatically controlled column compartment (35oC), an Agilent 
Poroshell 120 EC-C18 column (2.1 × 100 mm, 2.7 µm) and an Agilent Poroshell 120 EC-
C18 guard column (2.1 × 5 mm, 2.7 µm). The mobile phases used for analysis consisted of 
5 mM ammonium acetate solution in deionized water (A) and acetonitrile (B).  
Mitragyna alkaloids (MG, 7-MG-OH, SC, SG, and PY) were identified using a 
previously published method that was validated in accordance with published 
recommendations (32, 44). Briefly, in addition to the LC-Q/TOF-MS configuration 
described above, a flow rate of 0.4 mL/min was maintained using the gradient elution 
profile as follows: 47% B (0–0.5 min), 47-90% B (0.5–10 min), followed by re-
equilibration (2 min). The total acquisition time was 12 min and the target compounds 
eluted between 1.9 mins and 5 mins. The LC-Q/TOF-MS was equipped with an 
electrospray ionization source (positive mode) under the following conditions: nebulizer, 
45 psi; sheath gas temperature, 400oC; nitrogen sheath gas flow, 12 L/min; drying gas (N2), 
13 L/min; drying gas temperature, 350oC; capillary voltage, 4000 V; nozzle voltage, 0 V; 
fragmentor, 150 V;  and skimmer, 65 V. Data was acquired in targeted mode using a mass 
range of 100–1000 Da, with a MS scan rate of 8 spectra/s and a MS/MS Scan rate of 3 
spectra/s. Agilent MassHunter software was used for acquisition, qualitative and 
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quantitative analysis. Precursor and product ions, collision energies, retention times and 
the internal standard for each alkaloid are summarized in Table 5.3. 
Table 5.4: Product and precursor ions, collision energies (CE), retention time (RT), and 
internal standard (IS) selection for the targeted analysis of Mitragyna alkaloids and selected 
phase I metabolites, including 9-O-demethylmitragynine (9-ODM-MG) and 16-carboxy-
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For the identification of metabolites in case samples and following deconjugation, 
the same LC-Q/TOF-MS configuration, source conditions, flow rate and scan rates were 
utilized. However, the mobile phase gradient was modified as follows to accommodate 
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more polar species: 10% B (0–0.5 min), 10-90% B (0.5–10 min), followed by re-
equilibration (2 min). The total acquisition time was 12 min and the metabolites eluted 
between 1.2 min and 8.0 min. Data was acquired in auto MS/MS (full scan) mode using a 
preferred list of suspected metabolites based upon a previously published study (36).  
Results and discussion 
Analysis of postmortem specimens 
Mitragynine, 7-hydroxymitragynine, speciociliatine, speciogynine and 
paynantheine were identified in urine samples from kratom users. The time of use, quantity, 
and form of the drug (e.g. tea, capsules, extract, powder) were not known. The results are 
summarized in Table 5.4. Despite acceptable precision and bias during method validation, 
7-hydroxymitragynine should be considered semi-quantitative due to higher than 
acceptable matrix effects being observed for this analyte (and the deuterated IS) during the 
validation (32).  Appropriate dilutions of specimen were performed to achieve quantitative 
results within the calibration range (2-500 ng/mL). Using this procedure, dilution integrity 














Table 5.4: Concentrations of mitragynine, speciociliatine, speciogynine, paynantheine and 













A 1,987 3,309 1,684 317 ND 
B 26 161 59 2 ND 
C 461 2,161 910 103 204 
D 176 23 96 15 14 
E 1,271 150 388 65 83 
F 677 97 278 48 ND 
G 642 1,293 517 88 295 
H 402 283 338 32 63 
I 540 1,138 850 59 192 
J 938 1,396 1,499 144 ND 
K 258 1,197 272 23 129 
L 54 306 99 6 ND 
M 254 916 411 49 119 
N 249 1,103 332 34 60 
O 980 1,516 1,159 88 123 
P 520 1,637 877 72 ND 
ND, Not detected; 
 
Concentrations of Mitragyna alkaloids in urine ranged from 2 ng/mL to >3,000 
ng/mL, highlighting the wide range of forensic interest. Interestingly, the concentration of 
speciociliatine (23-3,309 ng/mL) and speciogynine (59-1,684 ng/mL) exceeded that of 
mitragynine (26-1,987 ng/mL) in 75% and 63% of cases, respectively. This finding could 
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be attributed to the increased stability of these isomers compared to mitragynine (35) or 
the use of kratom products with significant SC or SG alkaloid content as described earlier. 
Nevertheless, it suggests that both SC and SG could serve as useful biomarkers for kratom 
use. In contrast, paynantheine (2-317 ng/mL) was always present at a lower concentration 
than mitragynine, although it was detectable in all sixteen cases. Although literature 
regarding these other alkaloids is limited, our findings our consistent with those of Arndt 
et al. who reported that speciociliatine was the most prominent alkaloid in an single 
antemortem urine specimen obtained from an individual undergoing treatment for opioid 
withdrawal (34). Finally, 7-hydroxymitragynine (60-295 ng/mL) was detected in only 9 of 
the 16 cases (56%), albeit at much lower concentrations than mitragynine. This might be 
explained by its decreased stability relative to mitragynine or extensive phase II 
conjugation. Mean, median and concentration ranges for all five targeted alkaloids are 
summarized in Table 5.5 and Figure 5.2 depicts extracted ion chromatograms for a 
representative extract (Sample G). Appropriate dilutions were performed to achieve 









Figure 5.2: Extracted ion chromatograms for a representative urine extract (Case Sample 
G) containing speciociliatine (1,293 ng/mL), speciogynine (517 ng/mL), paynantheine (88 
ng/mL), mitragynine (642 ng/mL) and 7-hydroxymitragynine (295 ng/mL). Appropriate 
dilutions were performed to achieve quantitative results within the calibration range (2–

























MG 100 590 (n=16) 491 26-1,987 
7-MG-OH 63 128 (n=10) 121 14-295 
SC 100 1,043 (n=16) 1,121 23-3,309 
SG 100 611 (n=16) 400 59-1,684 
PY 100 72 (n=16) 54 2-317 
 
Metabolites of mitragynine were identified in 14 (88%) of the 16 samples tested. 
The most prevalent metabolites detected in unhydrolyzed samples were 9-O-
demethylmitragynine (n=12, 75%) and 7-hydroxymitragynine (n=10, 63%). 16-
Carboxymitragyine was only identified in two urine samples. Due to the absence of 
reference materials, the presence of these metabolites was confirmed using rCYP-
generated controls analyzed contemporaneously within the run. The abundance of these 
metabolites in hydrolyzed urine is discussed later. Extracted ion chromatograms for 
mitragynine, 7-hdroxymitragynine, 9-O-demethylmitragynine and 16-carboxymitragynine 
in a representative extract (Case K) are shown in Figure 5.3. Associated MS/MS spectra 






Figure 5.3: Extracted ion chromatograms for mitragynine, m/z 399 (7.2 min), 7-
hydroxymitragynine, m/z 415 (5.4 min), 9-O-demethylmitragynine, m/z 385 (4.5 min) and 

















Figure 5.4: MS/MS spectra of mitragynine, 7-hydroxymitragynine, 9-O-











The hydrolysis of conjugated species can be accomplished by non-specific 
chemical cleavage, or enzymatic hydrolysis (39). β-Glucurionidases sourced from E. coli, 
H. pomatia, and P. vulgata are commonly used for this purpose in forensic toxicology. 
Sulfatases, although less widely used, were also investigated here. More recently, 
recombinant sulfatase and glucuronidase reagents have become available, which are 
capable of hydrolyzing phase II metabolites within minutes, rather than hours (45). Since 
hydrolysis methods for conjugated mitragynine metabolites have not been fully explored, 
three traditional β-glucuronidase systems (E. coli, H. pomatia, and P. vulgata), four 
traditional sulfatases (A. aerogenes, abalone entrails, H. pomatia, and P. vulgata) and four 
recombinant enzymes (IMCSzymeTM, BGTurbo™, BGS™, and ASPC™) were evaluated. 
Deconjugation efficiency was evaluated by comparing the mean peak area of hydrolyzed 
(n=2) and unhydrolyzed (n=2) species.  
Chemical hydrolysis 
Acid and alkaline hydrolysis was unsuitable for the deconjugation of phase II metabolites 
of mitragynine. Changes in metabolite abundance (relative to no hydrolysis) for 7-
hydroxymitragynine and 9-demethylmitragynine are shown in Figure 5.5. Under most 
conditions, the abundance of metabolite actually decreased. This indicated that chemical 
hydrolysis was not only ineffective, but it also degraded free (unconjugated) metabolite in 
the urine. This is consistent with previously published literature that suggests that 
mitragynine is acid labile, and to a lesser extent alkaline-labile under some conditions (35, 
46, 47). Alkaline hydrolysis at 60°C and 20°C were the only conditions that increased the 
abundance of 7-OH-MG (229% and 154%, respectively). However, under these same 
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conditions 9-O-demethylmitragynine decreased significantly (degraded). Figure 5.5 also 
highlights the acid lability of both metabolites. Interestingly, no 16-carboxymitragynine 
was identified in the pooled urine (n=5), even after hydrolysis. This is consistent with our 
previous results which suggested that this was a relatively minor metabolite (36). Although 
chemical hydrolysis is clearly unsuitable for Mitragyna alkaloids, it highlights important 
considerations regarding the stability of metabolites during sample preparation and 
isolation from biological matrices in general.  
Figure 5.5: Chemical hydrolysis of 7-hydroxymitragynine and 9-O-demethylmitragynine 
in pooled urine (n=5). 
 
Enzymatic hydrolysis 
7-Hydroxymitragynine and 9-O-demethylmitragynine were the major metabolites 
identified in either non-hydrolyzed or hydrolyzed pooled urine (n=5). Figure 5.6 depicts 
changes in abundance for 7-hydroxymitragynine following enzymatic treatment. 







































glucuronidases. A statistically significant but only nominal increase was observed for 
BGSTM, one of the recombinant enzymes that contained both sulfatase and glucuronidase. 
However, increases in abundance following hydrolysis were nominal at best. No significant 
increases were observed for 9-O-demethylmitragynine. Small decreases in abundance were 
observed, again suggesting that this metabolite actually decreased in concentration during 
the sample preparation step. Since no 16-carboxymitragynine was observed in the pooled 
urine (n=5), it was necessary to investigate the individual specimens. For this evaluation a 
larger volume of urine (500 µL) was utilized. Figure 5.7 depicts the increase in 16-
carboxymitragynine concentration following hydrolysis with a traditional glucuronidase 
(H. pomatia) and dual (glucuronidase/sulfatase) recombinant enzyme (BGSTM) as 
described in Table 5.2. 16-Carboxymitragynine was identified in 12 additional specimens 
following hydrolysis. Ten of the twelve specimens had no detectable free 16-
carboxymitragynine, suggesting that this metabolite was extensively conjugated. Both H. 
pomatia and the recombinant glucuronidase/sulfatase were effective for the deconjugation 
of 16-carboxymitragynine. Figure 5.8 depicts a side-by-side comparison of both 
recombinant enzymes (BGSTM and BGTurboTM) for Case Sample P (n=2). Significant 
increases in abundance were observed using both recombinant enzymes. However, 
differences between BGSTM and BGTurboTM were not significant (α=0.05), suggesting that 
no sulfates were present and the metabolite is principally glucuronidated. More importantly 
however, increases in 7-hydroxymitragynine and 9-O-demethylmitragynine were not 






Figure 5.6: Enzymatic hydrolysis of 7-hydroxymitragynine in pooled urine (n=5). 
 
Although E. coli and H. pomatia systems have been utilized in previously published 
methods, the efficiency of the hydrolysis was not reported (42, 43). Philipp identified both 
sulfate and glucuronide conjugates of 9-O-demethylmitragynine using linear ion trap mass 
spectrometry (37). 16-Carboxymitragynine-glucuronide was identified, but no associated 
sulfate metabolite. This is consistent with our results, which suggest that use of sulfatase 
did not increase the abundance of this metabolite. Other phase II metabolites were 
identified at low abundance, but notably no 7-hydroxymitragynine was reported. Although 
enzymatic deconjugation has been employed for the determination of mitragynine 
metabolites in urine (33, 37), our results show that it has nominal benefit in terms of overall 






















Figure 5.7: Enzymatic hydrolysis of 16-carboxymitragynine in human urine (n=16) using 
H. pomatia and BGSTM. 
 
Figure 5.8: Enzymatic hydrolysis of 16-carboxymitragynine (Case Sample P) using 
BGSTM and BGTurboTM (n=2). 
 
Conclusions 
Using a series of postmortem urine specimens from known drug users, 
speciociliatine and speciogynine were identified as important biomarkers of kratom in 
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speciociliatine and speciogynine are prominent alkaloids in young plants and fruits from 
some geographical regions. Parent drug was identified in all samples tested, ranging in 
concentration from approximately 20 to almost 2,000 ng/mL. 9-O-demethylmitragynine 
and 7-hydroxymitragynine were the most prevalent metabolites, detected in 75% and 63% 
of urine samples without hydrolysis. 16-Carboxymitragynine was infrequently detected in 
untreated urine, but hydrolysis increased its prevalence from 13% to 75%. Due to 
significant quantities of free mitragynine, its diastereoisomers (speciociliatine and 
speciogynine), and phase I metabolites (9-O-demethylmitragynine and 7-
hydroxymitragynine) in untreated urine, enzymatic hydrolysis was not necessary.  
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Purpose: Kratom is a botanical drug with psychoactive properties that is increasingly being 
used recreationally and “therapeutically” in a non-medically supervised setting. Analytical 
methods for the detection of kratom use in biological matrices are limited in scope. 
Prevalence of these alkaloids and their metabolites in forensic specimens is not well 
understood. The purpose of this study develop and validate a procedure to identify five 
Mitragyna alkaloids in blood and tissues using liquid chromatography quadrupole time-of-
flight mass spectrometry (LC-Q/TOF-MS).   
Methods: Mitragynine (MG), speciociliatine (SC), paynantheine (PY), speciogynine (SG) 
and 7-hydroxymitragynine (7-MG-OH) were identified in postmortem blood (n=40) and 
liver specimens (n=20). Mitragyna alkaloids were determined quantitatively using targeted 
acquisition and metabolites were identified qualitatively using full scan (untargeted) 
acquisition.  
Results and conclusions: The analytical procedure was validated in accordance with 
published recommendations. Limits of quantitation were 0.5-2 ng/ml for the five targeted 
alkaloids. Precision, bias, and matrix effects were all within acceptable thresholds. 
Concentrations of mitragynine in central and peripheral blood were 1-422 ng/mL and 1-
412 ng/mL. 7-Hydroxymitragynine was confirmed in blood in at least 95% of the cases. 
Liver concentrations ranged from <4 to 1,454 ng/g. In addition to 7-hydroxymitragynine, 
9-O-demethylmitragynine and 16-carboxymitragynine were also identified in postmortem 
blood. Notably however, speciociliatine was frequently identified at concentration in 
excess of mitragynine, therefore serving as an alternative biomarker of kratom use.  
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Identification of Five Mitragyna Alkaloids in Blood and Tissues using Liquid 
Chromatography-Quadrupole/Time of Flight Mass Spectrometry 
Introduction 
Kratom (Mitragyna speciosa) is a psychoactive botanical substance that presents a 
variety of analytical challenges (1). Mitragyna alkaloids can produce dose-dependent 
effects. Stimulant-like effects predominate at low dose, while higher dosages produce 
opiate-like effects (2). In the United States, the drug is used recreationally and for non-
medically approved purposes as an “atypical opioid” (3). Mitragynine, one of the principal 
alkaloids in the plant, mediates its effects via mu opioid receptors, in addition to 
serotonergic and adrenergic receptors (4, 5). Kratom is often labeled by users as a “safe” 
alternative to opioids and as an effective way to treat afflictions such as chronic pain, opioid 
addiction, depression, diarrhea, insomnia, diabetes and impotence (2, 6-9). However, the 
drug is not currently approved for medical use in the United States. Multiple reports 
describing the unintended effects associated with the drug, including fatalities, have raised 
concerns regarding its unregulated use (2, 10-26). 
Kratom is legal throughout most of the United States and is not scheduled federally 
(27). The drug is readily available via the Internet and in retail outlets (28). Kratom’s 
pharmacodynamic profile, lack of regulation, and wide availability have led to an increase 
in its use. The National Forensic Laboratory Information System (NFLIS) reports an 
increase in mitragynine seizures since 2010 (29-31) and the Drug Enforcement Agency 
(DEA) has labeled kratom as a “drug of concern” (32). Recently, the Center for Disease 
Control and Protection (CDC) released a report detailing 152 deaths involving kratom from 
27 states that occurred between July 2016 and December 2017 (27). This report has further 
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raised concerns regarding the increased use of a drug that is considered by many to be 
“natural” or “safe”. 
The 2019 CDC report also suggested that kratom use may be underreported due to 
difficulties with analytical detection. More than forty compounds have been isolated from 
the leaves of Mitragyna speciosa (33). Chemical structures for selected alkaloids are shown 
in Figure 6.1. The major psychoactive constituent is reported to be mitragynine which, 
according to one study can account for 60-66% of the total alkaloid content in plant 
material (34). However, the alkaloid content varies considerably based on age, species, and 
environmental factors (35). For example, Takayama et al. reported that mitragynine 
content in a Thai specimen was 66% higher than a Malaysian specimen (36). Interestingly, 
some specimens grown in other locations have been reported to contain different alkaloid 
contents, including specimens where the predominant alkaloid was not mitragynine (35).  
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Figure 6.1: Indole alkaloids in Mitragyna speciosa. 
 
A limited number of analytical methods for blood and plasma have been published 
in the literature, but they have almost exclusively focused on the detection of mitragynine 
(Table 6.1). Analysis is challenging due to the large number of related compounds, 
including structural isomers and diastereoisomers of mitragynine, some of which share 
identical molecular weights and in some cases mass spectral fragmentation (1). In this 
study, five Mitragyna alkaloids were targeted in whole blood using liquid chromatography-
quadrupole/time of flight-mass spectrometry (LC-Q/TOF-MS). Target compounds include 
the two mu mu agonists mitragynine (MG) and 7-hydroxymitragynine (7-MG-OH), two 




Although there are several case reports detailing fatalities associated with kratom 
use (20, 21, 27, 37), there is limited information regarding its overall prevalence in forensic 
casework. Philipp et al. described the alkaloid content in the urine of 120 suspected kratom 
users, but attempts to identify paynantheine, speciociliatine and speciogynine consistently 
in specimens were hampered by detection limits of 100 ng/mL (38). Another study by 
Arndt et al. described the analysis of mitragynine, speciociliatine, speciogynine, and 
paynantheine in an antemortem urine sample using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) (39). While this was only a qualitative method and had a small 
sample size (n=1), they reported that speciociliatine was the most prevalent alkaloid. In a 
series of sixteen postmortem cases MG, 7-MG-OH, SC, SG and PY were identified in urine 
using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q/TOF-
MS) (40). Speciociliatine and speciogynine were present in all of the mitragynine-positive 
case samples, frequently at concentrations that exceeded MG, consistent with Arndt et al.  
(39). 7-Hydroxymitragnyine and 9-O-demethylmitragynine were also reported in the 


























Blood 1 mL LLE 0.25 1 1-10 MG Proadifen LC-MS/MS (26) 
Plasma 0.1 mL LLE 0.2 1 1-5000 MG Amitriptyline LC-MS (41) 
Blood 1 mL SPE 30 50 50-1000 MG MG-D3 GC-MS (20) 
Plasma 0.1 mL LLE 2 10 10-4000 7-MG-OH Tryptoline LC-MS (42) 
Blood 0.5 mL LLE 0.16 - 5-500 MG MG-D3 LC-MS/MS (1) 
Plasma 0.5 mL LLE 0.2 0.2 0.2-1000 MG Amitriptyline LC-MS/MS (43) 
Plasma 0.1 mL SPE 25 50 50-10,000 MG Mefloquine LC-UV-DAD (44) 
GC-MS, gas chromatography-mass spectrometry; LC-UV-DAD, liquid chromatography-UV-VIS -diode array detector; LC-MS, 
liquid chromatography-mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LLE, liquid-liquid 
extraction; SPE, solid phase extraction. 
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In this study, we describe a validated analytical method using LC-Q/TOF-MS that 
was used to identify five Mitragyna alkaloids (MG, 7-MG-OH, SC, SG, and PY) in blood 
and tissues. We also describe the prevalence of these five alkaloids and the phase I 
metabolites of mitragynine in 60 postmortem specimens.  
Materials and methods 
Chemicals and reagents 
 All solvents and inorganic reagents were LC or ACS grade, unless stated otherwise. 
Mitragynine and mitragynine-D3 were purchased in methanolic solutions from Cayman 
Chemical Company (Ann Arbor, MI, USA). Reference standards for 7-
hydroxymitragynine and 7-hydroxymitragynine-D3 were purchased from Cerilliant Corp. 
in ammoniated methanol (1% concentrated ammonium hydroxide in methanol) (Round 
Rock, TX USA). Drugs used in the interference study were also purchased from Cerilliant 
Corp. Paynantheine (solid) and speciociliatine (solid) reference standards were purchased 
from Chromadex (Irvine, CA, USA) and Speciogynine (solid) was provided by the 
National Center for Natural Products Research (NCNPR) at the University of Mississippi, 
(University, MS, USA). Paynantheine, speciogynine, and speciociliatine were 
reconstituted and stored as methanolic solutions. Ethyl acetate, hexane, concentrated 
hydrochloric acid, and methanol were obtained from J.T. Baker (Center Valley, MA, 
USA).  Concentrated ammonium hydroxide was purchased from Macron Fine Chemicals 
(Center Valley, MA, USA) and glacial acetic acid was obtained from Mallinckrodt 
Chemicals (St. Louis, MO, USA). Acetonitrile was obtained from Fisher Scientific (Fair 
Lawn, NJ, USA). Ammonium acetate (solid) and potassium phosphate (monobasic and 
dibasic) (solid) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Recombinant 
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human cytochrome P450 (rCYP) isoenzymes expressed in E. coli (bactosomes) were 
obtained from Xenotech, LLC (Kansas City, Kansas) and reduced nicotinamide adenosine 
diphosphate (NADPH) regenerating system solution A (40 Ug/mL glucose-6-phosphate 
dehydrogenase in 5 mM sodium citrate), solution B (26 mM NADP+, 66 mM glucose-6-
phosphate and 66 mM magnesium chloride in aqueous solution) were obtained from 
Corning (Glendale, Arizona). All other miscellaneous chemicals and reagents were 
obtained from VWR International (Radnor, Pennsylvania).  
 Deionized water was purified in house using a Millipore Direct-Q®UV Water 
Purification system (Billerica, MA, USA). Samples were extracted using PolyChrom 
ClinII 3 cc (35 mg) solid phase extraction (SPE) columns that were obtained from SPEware 
(Baldwin Park, CA, USA). Bovine blood containing 1% sodium fluoride and 0.2% 
potassium oxalate was purchased from Quad Five (Ryegate, MT, USA). Drug-free human 
liver was provided by the Applied Anatomical Research Center at Sam Houston State 
University. Postmortem blood (n=40) and liver (n=20) samples were received from the 
North Carolina Office of the Chief Medical Examiner in accordance with an Institutional 
Review Board (IRB)-approved study. 
Instrumentation 
An Agilent Technologies 6530 LC-Q/TOF-MS (Agilent Technologies, Santa Clara, 
CA, USA) equipped with an Agilent 1290 Infinity autosampler was used to analyze 
processed samples. Nitrogen was generated using a Genius 3040 nitrogen generator (Peak 
Scientific, Billerica, MA, USA). Separation was achieved using an Agilent Technologies 
Series 1200 LC system, an Agilent Poroshell 120 EC-C18 column (2.1 × 100 mm, 2.7 µm) 
and an Agilent Poroshell 120 EC-C18 guard column (2.1 × 5 mm, 2.7 µm). The column 
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was stored in a thermostatically controlled column compartment (35oC) and the 
autosampler was maintained at 4ºC. The mobile phase systems consisted of 5 mM 
ammonium acetate solution in deionized water (A) and acetonitrile (B).  
LC-Q/TOF-MS analysis was performed using a flow rate of 0.4 mL/min with a 
gradient elution profile was as follows: 47% B (0–0.5 min), to 90% B (0.5–10 min). The 
LC-Q/TOF-MS was equipped with an electrospray ionization (ESI) source operated in the 
positive mode under the following conditions: drying gas (N2), 13 L/min; drying gas 
temperature, 350oC; nebulizer, 45 psi; sheath gas temperature, 400oC; nitrogen sheath gas 
flow, 12 L/min; capillary voltage, 4000 V; nozzle voltage, 0 V; fragmentor, 150 V; 
skimmer, 65 V. Agilent MassHunter software was used for qualitative and quantitative 
analysis. Precursor ions were selected using a 1 Da window and a minimum of two 
transition ions for each alkaloid were selected for targeted MS/MS acquisition. Data was 
acquired using a mass range of 100–1000 Da, with a MS scan rate of 8 spectra/s and a 
MS/MS scan rate of 3 spectra/s.  
For the identification of metabolites in case samples, the same LC-Q/TOF-MS 
configuration, source conditions, flow rate and scan rates were used as described above. 
The mobile phase elution gradient was modified as follows: 10% B (0–0.5 min), 10-90% 
B (0.5–10 min). Data was acquired in auto MS/MS (full scan) mode using a preferred list 
of identified metabolites based upon a previously published study (45). Agilent 
MassHunter software was used for qualitative analysis. Retention times, MS/MS spectra 
and mass accuracy were used for identification of these metabolites. Precursor and product 
ions, collision energies, acquisition mode, retention times and the internal standard for each 
drug and metabolite are summarized in Table 6.2. 
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Table 6.6: Molecular formula, product and precursor ions, collision energies (CE), 
retention time (RT), acquisition mode, and internal standard (IS) selection for Mitragyna 
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25 1.3 Full Scan MG-D3 
16-COOH-MG, 16-carboxymitragynine; 9-O-DM-16-COOH-MG, 9-O-demethyl-16-
carboxymitragynine; 9-O-DM-MG, 9-O-demethylmitragynine; MG, mitragynine; MG-D3, 
mitragynine-D3; 7-MG-OH, 7-hydroxymitragynine; 7-MG-OH-D3, 7-
hydroxymitragynine-D3;  PY, paynantheine; SC, speciociliatine; SG; speciogynine. 
 
Preparation of standards and reagents 
Working standards containing SC, SG, PY, MG-D3, and MG were prepared in 
methanol whereas standards containing 7-MG-OH and 7-MG-OH-D3 were prepared in 
ammoniated methanol (described earlier).  Working standards for the five target 
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compounds were prepared at 10, 5, 1, 0.5, 0.1, 0.05, and 0.01 µg/mL for calibration and 
validation purposes. Internal standard working solutions were prepared at 2 µg/mL. In the 
absence of commercially available reference standards, rCYPs (3A4, 2D6, 2C19, and 
2C18) were used to prepare 9-O-demethylmitragynine, 16-carboxymitragynine, and 9-O-
demethyl-16-carboxymitragynine in-situ for qualitative identification purposes as 
described previously  (40). The SPE elution solvent which was prepared before each 
extraction, consisted of concentrated ammonium hydroxide in ethyl acetate (2%, v/v).  
Blood extraction 
Bovine blood (1.0 mL) was fortified with the targeted compounds at various 
concentrations using the working standard solutions. Internal standard solution (50 µL) 
was added to achieve a final concentration of 100 ng/mL for MG-D3 and 7-MG-OH-D3. 
All targeted analytes and internal standards were added to the blood while continuously 
vortexing. Proteins were precipitated with 2 mL of cold acetonitrile while vortex mixing. 
Samples were then centrifuged at 4000 RPM for 10 minutes, and the supernatant was 
decanted into new disposable culture tubes. Blood was then acidified with 2 mL of 0.1 M 
hydrochloric acid and briefly vortexed before being transferred to SPE columns and 
allowed to flow through under gravity or sufficient vacuum in order to maintain a constant 
flow of approximately 1 mL/min. Columns were rinsed with 1 mL deionized water 
followed by 1 mL of 1 M acetic acid before being allowed to dry at full vacuum for five 
minutes. After drying, samples were washed with 1 mL aliquots of hexane, ethyl acetate 
and methanol. All compounds were eluted using 2 mL of elution solvent and then were 
evaporated to dryness under nitrogen at 50ºC. Extracts were reconstituted in 25 µL of a 
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50:50 mixture of Mobile Phase A/B, briefly vortexed, and then centrifuged at 2500 rpm for 
10 mins before ultimately being injected (1 µL) onto the LC-Q/TOF-MS for analysis. 
Assay validation 
Assay performance was evaluated in terms of extraction efficiency, calibration 
model, precision, bias, limit of detection (LOD), limit of quantification (LOQ), ion 
suppression, interference, dilution integrity, processed sample stability, and carryover in 
accordance with published recommendations (46). Extraction efficiency in blood was 
determined at 250 ng/mL by direct comparison of extracted and non-extracted samples. 
Samples containing internal standard were extracted in the presence and absence of the 
target compounds. Samples extracted without target compounds were fortified post-
extraction (prior to evaporation and reconstitution)  with 250 ng analyte. Analytical 
recovery was calculated by comparing the relative peak area (drug/IS) for extracted 
samples (n=4) with the mean relative peak area for the non-extracted samples (n=4).  
Limits of detection and quantitation were established using drug-free bovine blood 
fortified with target analytes. Three independent sources of blood were analyzed in 
duplicate over three independent runs. The LOD was the lowest concentration of drug that 
produced a reportable result (signal to noise (S/N) ratio of 3:1 or more; retention time ± 
2% of the standard; ion ratios ± 20%). The LOQ was determined contemporaneously and 
was defined as the lowest concentration of drug to produce a quantitative value within 20% 
of the expected value, a S/N ratio of 10:1 or more, retention time ± 2 % of the standard, 
ion ratios within 20%, and a concentration within 20% of the expected value.  
Precision and bias was evaluated at 5, 200 and 400 ng/mL using pooled fortified 
matrix (in triplicate), at three concentrations (low, medium, high), over five runs. Within-
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run precision was calculated for each concentration (n=3) over each of the five assays. 
Between-run precision was calculated for each concentration over all five days (n=15). 
Bias was evaluated contemporaneously with precision using the same concentrations over 
five days. The acceptable range for bias and precision was ± 20%. 
The calibration model was established using nine non-zero calibrators (2, 5, 10, 25, 
100, 200, 300, 400 and 500 ng/mL) over five independent runs. Calibration models were 
evaluated using the coefficient of determination (R2) and standardized residual plots. 
Interferences associated with the biological matrix, isotopically labeled internal standards, 
common drugs and structurally related compounds were systematically evaluated. Matrix 
interferences and ion suppression/emhancement were evaluated using ten different blood 
samples that were extracted in the absence of internal standard and the targeted compounds. 
Ion contributions arising from the use of stable isotope internal standards were evaluated 
by fortifying blood with internal standard (100 ng/mL) and monitoring the signal of the 
target analytes.  
Interferences from the matrix, isotopocally labeleld internal standards and common 
drugs were assessed in accordance with published recommendatons (46). Drug 
interferences were evaluated using more then seventy common drugs and other therapeutic 
drugs of significance  using a 100-fold excess of interferent (relative to the target drug) in 
triplicate. Ion suppression and enhancement were quantitatively assessed using post-
extraction addition at two concentrations (20 ng/mL and 400 ng/mL). Samples from 10 
drug-free matrices were extracted (n=2) in the absence of drug and fortified with drug post 
extraction. Ion suppression/enhancement was calculated by comparing the mean peak areas 
of drug in matrix with the drug in mobile phase (no matrix). Carryover was assessed by 
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analyzing a negative control immediately following the injection of the highest calibrator 
(500 ng/mL). Carryover was present if the reporting criteria for the targeted analytes was 
achieved (signal to noise ratio of 3:1 or more, retention time ± 2% and ion ratios within 
20% of expected).  
The influence of sample dilution was evaluated using fortified blood diluted ten-
fold in deionized water prior to extraction. Quantitative results were evaluated and 
concentrations within ±20% of the expected concentration were deemed acceptable. The 
stability of processed samples was evaluated by extracting samples (100 ng/mL) in 
triplicate and analyzing them over a period of up to 48 hours. The samples were considered 
stabled if the bias remained within ± 20% of the expected quantitative value. 
Tissue extraction 
Liver homogenates were prepared using a Bead Ruptor 12 (OMNI International, 
Kennesaw, GA, USA) and a reinforced sample tube (7 mL) containing one part tissue (1 
g) with 3 parts deionized water. Full homogenization was achieved using three 30-s pulses 
at the highest speed setting. The samples vials were pre-filled with five 2.8 mm and ten 1.4 
mm ceramic beads (OMNI International). Liver homogenate (0.5 mL) was transferred to a 
culture tube, and internal standard solution was added while vortex mixing. If the liver 
homogenate was being used as a control, then targeted compounds were also added. The 
samples were then precipitated and extracted using the SPE procedure for blood described 
above. Quantitative liver determinations were performed using whole blood calibrators and 
matrix-matched (liver) controls. Blank liver homogenate (0.5 mL) was fortified in triplicate 
with 25 ng drug, thus reflecting final liver concentrations of 200 ng/g. If the targeted 
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compounds met the acceptance criteria for bias (± 20%), then the quantitative value was 
reported. 
Postmortem specimens 
A total of 20 kratom-positive cases were identified and a total of 60 specimens were 
included in this study. These specimens comprised of liver (n=20), central blood (n=21), 
and peripheral blood (n=19). Central blood was identified as aortic blood (n=18) and vena 
cava blood (n=3), Peripheral blood was identified as femoral blood (n=9) and iliac blood 
(n=10).  Due to the long-term storage of specimens prior to quantification, inferences 
regarding postmortem redistribution and central to peripheral drug concentrations ratios 
were not deemed appropriate.  In addition to the five targeted Mitragyna alkaloids, blood 
specimens (n=32) were also reanalyzed qualitatively to determine the presence of 
metabolites known metabolites (e.g., 9-O-demethylmitragynine, 16-carboxymitragynine, 
9-O-demethyl-16-carboxymitragynine) (47).  
Results and discussion 
Blood validation 
Significant emphasis was placed on chromatographic separation during method 
development due to the structural and stereoisomers involved. Figure 6.2 presents an 
overlaid extracted ion chromatogram (EIC) that depicts the chromatographic separation of 
all five Mitragyna alkaloids in blood at 100 ng/mL.  These alkaloids are known to produce 
characteristic fragmentation patterns when exposed to ESI resulting in near identical 
MS/MS spectra (48, 49)  (Figure 6.3). Briefly, Mitragyna alkaloids undergo the cleavage 
of the quinolizine ring to yield both indole (m/z 174 and 190) and piperidine derivative 
fragments (m/z 238, 236, 226, 224).  Ultimately, complete chromatographic resolution for 
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the five Mitragyna alkaloids was achieved (Figure 6.2) using the previously published LC-
Q/TOF-MS conditions (49).    
Figure 6.2: Chromatographic separation of Mitragyna alkaloids in a representative blood 
extract (100 ng/mL). Speciociliatine, 2.06 min; 7-hydroxymitragynine, 2.53 min; 
speciogynine, 3.34 min; paynantheine, 3.82 min; and mitragynine,  4.62 min. 
 
Figure 6.3: MS-MS spectra of speciociliatine, 7-hydroxymitragynine, speciogynine, 








The extraction efficiency of mitragynine using the extraction protocol described 
above, was 80%, with 82-87% for speciociliatine, speciogynine, and paynantheine (Table 
6.3). Despite the very low extraction efficiency of 7-hydroxymitragynine, the limit of 
quantitation was still sufficiently low (2 ng/mL), with quantitative bias of -2% and a CV 





Table 6.3: Extraction efficiencies for Mitragyna alkaloids in blood (250 ng/mL, n=4). 
Alkaloid 
Extraction Efficiency (%) 
Mean ± SD (n=4) 
MG 80 ± 7 
SC 85 ± 8 
SC 87 ± 11 
7-MG-OH 16 ± 1 
PY 82 ± 7 
 
Table 6.4: Limits of detection (LOD), limits of quantitation (LOQ), and assay performance 
at the limit of quantitation (n=18). Signal to noise ratio (S/N) is presented as the mean value 















MG 0.5 0.5 0.47 ± 0.04 551:1 -6 10 
7-MG-
OH 
2 2 1.97 ± 0.21 108:1 -2 11 
SC 1 2 2.18 ± 0.25 2612:1 6 12 
SG 2 2 2.14 ± 0.17 564:1 9 8 
PY 1 1 0.86 ± 0.08 2548:1 -14 9 
 
Following visual, analytical, and statistical evaluation of various calibration 
models, a weighted (1/x) quadratic model was selected for speciociliatine, speciogynine, 
mitragynine, and 7-hydroxymitragynine to minimize heteroscedasticity. Paynantheine 
produced homoscedastic data using an unweighted quadratic model. The coefficients of 
determination were above 0.99 for all models and when residual plots underwent visual 
assessment, the data appeared to be randomly dispersed for each model. Statistical 
evaluation also indicated that calibration curve selection for these compounds was optimal.   
Extracted ion chromatograms for all targeted Mitragyna alkaloids at the LOQ are shown 
in Figure 6.4.  The LOD and LOQ for MG, 7-MG-OH, SC, SG and PY ranged from 0.5-
2 ng/mL and was within the range of forensic interest. At the limit of quantitation, bias and 
precision ranged from -9-14% and 8-12%, respectively. Precision and bias were also 
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evaluated at low, medium, and high concentrations in triplicate over five days (Table 6.5). 
Intra-assay CVs were 1-18% (5 ng/mL); 1-16% (200 ng/mL); 1-19% (400 ng/mL) (n = 3) 
and inter-assay CVs (over the same concentration range) were 2-6%, 1-6% and 1-3% (n = 
15). Bias for all three concentrations (5, 200, and 400 ng/mL) ranged from -3-6% for all 
five alkaloids. Overall, bias and precision were within acceptable ranges (±20%) for all 
compounds. In addition, there was also no carryover present after the injection of the 























Figure 6.4: Extracted ion chromatograms at the limit of quantitation for targeted alkaloids 










Table 6.5: Precision and bias (n=15) at low (5 ng/mL), medium (200 ng/mL), and high 
(400 ng/mL) concentrations. 
Analyte 
Intra-Assay CV (%) 
(n=3) 






















MG 2-7 1-8 1-12 2 1 2 6 0 3 
7-MG-
OH 
1-12 2-14 1-8 2 2 3 4 3 0 
SC 4-17 1-16 1-19 6 4 1 5 2 3 
SG 3-18 2-13 2-18 4 2 3 5 5 3 
PY 2-7 2-8 1-10 6 6 1 3 -3 2 
 
No interferences were present from either matrix, isotopically labelled internal 
standards, and no qualitative interferences from other drugs were present for any of the 
target compounds. Ion suppression or enhancement was evaluated quantitatively using the 
post-extraction addition technique for all five analytes and two internal standards with ten 
independently sourced bovine blood samples. Matrix effects were measured at both low 
and high concentrations (20 and 400 ng/mL). Matrix effects for all five Mitragyna alkaloids 
ranged from -18 to 20% at 20 ng/mL, and -4 to 4% at 400 ng/mL. Corresponding CVs for 
all five compounds were 9-17% and 2-6%, respectively (Table 6.6). Dilution integrity was 
evaluated using ten-fold dilutions of matrix at 400 ng/mL in triplicate. Bias ranged from -
14.3% to 13.4% using diluted specimens, which was within acceptable tolerance. Finally, 
processed samples were stable in the refrigerated autosampler (4ºC) for 48 hours at 100 
ng/mL. Quantitative measurements for all analytes produced concentrations within 7% of 
the expected value at 48h and absolute peak areas for target compounds or their internal 




Table 6.6: Matrix effect (%) and associated CVs (%) at 20 and 400 ng/mL. 
Analyte 
CV (%) n=10 Matrix Effect (%) 
20 ng/mL 400 ng/mL 20 ng/mL 400 ng/mL 
MG -18 15 0 3 
7-MG-OH -17 16 -2 3 
PY 9 15 -2 2 
SC 10 17 0 3 
SG 20 17 -4 3 
MG-D3 12 11 0 4 
7-MG-OH-D3 -8 9 4 6 
 
Identification of Mitragyna alkaloids and metabolites in postmortem specimens 
A total of 60 specimens (liver (n=20); central blood (n=21); peripheral blood 
(n=19)) from 20 kratom-positive cases were analyzed using the validated method described 
above.  Postmortem findings for all specimens are summarized in Table 6.7 and extracted 
ion chromatograms of the Mitragyna alkaloids from a representative case specimen are 
shown in Figure 6.5. Concentrations in blood ranged from 1-422 ng/mL (mitragynine), 
<2-1,574 ng/mL (speciociliatine), <2-386 ng/mL (speciogynine), <1-67 ng/mL 
(paynantheine), and 3-434 ng/mL (7-hydroxymitragynine). In order to quantitatively assess 
the liver samples, precision and bias were measured using liver controls (0.5 mL of 
homogenate) fortified with drug at 200 ng/g (n=3). Liver controls were analyzed 
concurrently with blood calibrators and controls.  All compounds with the exception of 
speciociliatine, were within ± 20% of the expected value using 0.5 mL of liver homogenate. 
Negative bias for speciociliatine in liver was attributed to matrix effects; attempts to reduce 
the quantity of matrix (0.1 mL liver homogenate) did not resolve the issue, so 
speciociliatine (the earliest eluting compound) was reported only qualitatively in liver. 
Concentrations in liver ranged from 7-1,454 ng/mL (mitragynine), 17-1,642 ng/mL 
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(speciogynine), <8-422 ng/mL (paynantheine), and <4-920 ng/mL (7-
hydroxymitragynine).  














































































































In addition to the five Mitragyna alkaloids, blood samples (n=32) were also 
reanalyzed qualitatively to determine the presence of phase I metabolites (Table 6.8) as 
described previously (45). Metabolites of mitragynine were identified in 31 (97%) of the 
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32 blood samples tested. The most prevalent metabolite in all 32 case samples was 7-
hydroxymitragnine (97%). However, because 7-hydroxymitragynine is an alkaloid present 
in the plant and also a metabolite, its presence cannot be attributed solely to 
biotransformation (50). The phase I metabolites identified in blood were 9-O-
demethylmitragynine (28%) and 16-carboxymitragyine (25%). The minor phase I 
metabolite, 9-O-demethyl-16-carboxymitragynine, was not detected in any of the blood 
samples. Interestingly, three known metabolites with an m/z 387 were also identified in 28 
(88%) of the 32 authentic specimens. As reported previously with the urine specimens from 
the same case samples (45) these compounds produce MS/MS spectra consistent with 17-
O-demethyl-16,17-dihydromitragynine reported by Philipp et al. (47).  However, because 
speciogynine and speciociliatine form analogous 17-O-demethyl-16, 17-dihydro 
metabolites (51, 52), the MS/MS spectra for all three compounds are indistinguishable. 
Due to the absence of reference materials for these compounds, further differentiation was 
not possible. Extracted ion chromatograms and MS/MS spectra for the phase I metabolites 


















Figure 6.5: Extracted ion chromatograms for a representative blood (aortic) extract 
containing speciociliatine (1,574 ng/mL), speciogynine (386 ng/mL), paynantheine (67 
ng/mL), mitragynine (285 ng/mL) and 7-hydroxymitragynine (349 ng/mL). Appropriate 
dilutions were performed to achieve quantitative results within the calibration range (2–















Table 6.8:  Identification of mitragynine and other metabolites in blood (n=32). 
Identification of 17-O-demethyl-16, 17-dihydro (17-O-DM-16,17-DH) metabolites was 



















Aortic Blood 2  + + +1 
Femoral Blood ND  + +  
2 
Aortic Blood ND  +   




ND     
Iliac Blood ND  +   
4 
Aortic Blood 79  +  +1 
Femoral Blood 33 + +  +1,2 
5 
Aortic Blood 27  +  +1 
Iliac Blood ND  +  +1 
6 
Aortic Blood 65  +  +1 
Iliac Blood 2  +  +1 
7 
Aortic Blood 54  + + +1,3 
Iliac Blood ND  +  +1 
8 
Aortic Blood 159  +  +1 
Femoral Blood 55 + + + +1,3 
9 
Aortic Blood 1  +  +1,3 




75 + +  +3 





















Aortic Blood 422 + + + +1,3 
Iliac Blood 4 + + + +1,3 
12 
Aortic Blood 7  +  +1,2,3 
Iliac Blood 108 + + + +1,3 
13 
Aortic Blood 1  +  +1 
Iliac Blood 1  +  +1 
14 Femoral Blood 1  + + +1,3 
15 
Aortic Blood 1  +  +1 
Femoral Blood 21 + +  +1,3 
17 Aortic Blood 4  +  +1,3 
19 Aortic Blood 1  +  +1 
20 Aortic Blood 285 + +  +1,2 





















Figure 6.6: Extracted ion chromatograms depicting mitragynine metabolites in a 
representative postmortem blood extract: 7-hydroxymitragynine, m/z 415 (5.3 min), 9-O-
demethylmitragynine, m/z 385 (4.5 min), 16-carboxymitragynine m/z 385 (3.0 min) and 







Figure 6.7: MS/MS spectra depicting mitragynine metabolites in a representative 
postmortem blood extract: 16-carboxymitragynine, 9-O-demethylmitragynine, 7-







Kratom is a psychoactive substance that presents many challenges from the 
standpoint of toxicological analysis. In addition to structural isomers that must be 
chromatographically resolved, there are concerns regarding its stability, and its prevalence 
may be under-reported during routine investigations. In this report five Mitragyna alkaloids 
were identified in postmortem blood (n=40) and liver specimens (n=20). The results 
confirm earlier reports in urine that suggest that additional biomarkers of kratom use exist, 
particularly speciociliatine, which may exceed the concentration of mitragynine. It is not 
known if this observation is due to the increased overall stability of this alkaloid relative to 
mitragynine, or due to the use of kratom products with high speciociliatine content. 
Mitragynine metabolites were also identified in 32 unhydrolyzed blood samples (97%). In 
addition to 7-hydroxymitragynine (a potent mu opioid receptor agonist), 9-O-
demethylmitragynine, 16-carboxymitragyine and 17-O-demethyl-16-17-dihydro-
metabolites were also identified.  
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Significant advances were made in terms of the identification of Mitragyna 
alkaloids in biological matrices. LC-Q/TOF-MS was used to identify mitragynine, 
speciociliatine, speciogynine, paynantheine and 7-hydroxymitragynine in blood, urine and 
postmortem tissue. The deuterated compounds, mitragynine-D3 and 7-
hydroxymitragynine-D3, were used as internal standards. Extraction efficiencies were 63-
96% for urine and 16-87% for blood, which was an improvement on existing methods in 
the literature. Limits of detection and quantitation were 0.25-1 ng/mL in urine and 0.5-2 
ng/mL in blood. Using weighted (1/x) and unweighted quadratic models, the routine 
calibration range for each assay was 2-500 ng/mL, which is well within the range of 
forensic interest. Precision (both intra- and inter-assay CV) and bias were well within 
accepted standards for both matrices (±20%) and no carryover was observed, except for 
extremely elevated concentrations of paynantheine in urine. No qualitative interferences 
were seen for any of the five targeted alkaloids. Ion suppression was within tolerable limits 
(<±20%) for all targeted compounds in both matrices with one exception. 7-
Hydroxymitragynine experienced significant ion suppression (>40%) in urine. These 
validated methods for blood and urine are the first in published literature to simultaneously 
analyze the five Mitragyna alkaloids and quantify the diastereoisomers in specimens of 
forensic interest.  
The metabolism of mitragynine was investigated using recombinant CYPs. Four 
phase I metabolites were identified in the initial investigation: 9-O-demethylmitragynine, 
16-carboxymitragynine, 9-O-demethyl-16-carboxymitragynine, and 7-
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hydroxymitragynine. 7-Hydroxymitragynine is a notable metabolite because of its 
pronounced pharmacological effect, relative to the parent drug. Four CYPs were found to 
contribute to mitragynine’s metabolism (CYP3A4, CYP2D6, CYP2C18 and CYP2C19). 
9-O-Demethylmitragynine was the most abundant metabolite in the in vitro study and was 
produced by three isoenzymes (2C19, 3A4 and 2D6). 16-Carboxymitragynine was 
produced by rCYPs 2C19, 2C18 and 2D6, while 7-hydroxymitragynine was produced 
exclusively by CYP 3A4. 9-O-Demethyl-16-carboxymitragynine, a very minor metabolite, 
was attributed to 2C19. Using a series of kratom-related fatalities, 9-O-
demethylmitragynine was the most prominent phase I metabolite and other alkaloids were 
identified as potential biomarkers. The involvement of the various CYP450 isoforms 
provides valuable insight into potential adverse drug reactions and drug-drug interactions 
that may result from poly drug use.  
The short-term stability of mitragynine, 7-hydroxymitragynine, paynantheine, 
speciogynine and speciociliatine was investigated under accelerated conditions. Five 
temperatures (4°C, 20°C, 40°C, 60°C, and 80°C) and pH (2, 4, 6, 8, and 10) were 
investigated over an 8 hour period. All Mitragyna alkaloids were significantly acid labile, 
exhibiting losses >20% loss at pH 2 when exposed to high temperatures. Mitragynine and 
7-hydroxymitragynine were also base-labile, though to a lesser degree.  Interestingly, 
speciociliatine, speciogynine and paynantheine were more stable than mitragynine and 7-
hydroxymitragynine, even when exposed to highly unfavorable conditions. Degradation 
products were also investigated for mitragynine. Under alkaline conditions, mitragynine 
underwent hydrolysis of the methylester to form 16-carboxymitragynine. Only tentative 
identification of the acidic degradation product was possible. These findings highlight the 
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need to further investigate the short- and long-term stability of the Mitragyna alkaloids in 
biological samples.  
Phase II metabolites of mitragynine were investigated using urine from kratom 
users. The efficiency of both chemical and enzymatic deconjugation methods were 
explored. Chemical hydrolysis was unsuitable due to stability issues and the extreme pH 
required for deconjugation. Enzymatic hydrolysis was explored using both traditional (β-
glucuronidase:  Escherichia coli, Patella vulgata, and Helix pomatia; sulfatase abalone 
entrails, Aerobacter aerogenes. Patella vulgata, and Helix pomatia) and recombinant 
systems (BGTurbo™, BGS™, ASPC™ , and IMCSzyme). Enzymatic hydrolysis was 
deemed unnecessary for 7-hydroxymitragynine and 9-O-demethylmitragynine, since these 
metabolites were present at sufficient quantity in free (unconjugated) form. However, 
enzymatic hydrolysis did improve the detection of 16-carboxymitragynine. This was the 
first study to explore the efficiency of the deconjugation, or the necessity to perform this 
additional sample preparation step, for kratom-positive specimens. 
Finally, postmortem tissue, blood and urine specimens were investigated to 
determine the presence of Mitragyna alkaloids and phase I metabolites. Overall, 76 
specimens (urine (n=16), blood (n=40) and liver (n=20)) from 20 fatalities were analyzed. 
Speciocilatine and speciogynine (diastereoisomers of mitragynine) were identified as 
potential biomarkers of kratom use. Concentration of these alkaloids, particularly 
speciociliatine often exceeded the concentration of mitragynine. These findings could be 
attributed to its enhanced stability, or the use of kratom products with high speciociliatine 
content. 9-O-Demethylmitragynine and 7-hydroxymitragynine were identified in the 
majority of blood and urine specimens. Since most analytical methods used to detect 
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kratom focus on mitragynine alone, identification of these biomarkers may encourage 
forensic laboratories to expand their scope of testing, therefore enhancing their ability to 
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